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A area
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BMI body mass index
BSA body surface area
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H head
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PASI Psoriasis Area and Severity Index
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1
general introduction and outline of this thesis
1.1 Pediatric psoriasis
Psoriasis is a common, chronic, inflammatory skin disorder1, with an estimated prevalence 
in western countries between 2-4%.2-5 Disease onset can be at any age, but more than 
one third of the patients developed psoriasis during childhood.6-9 Different prevalence 
rates of pediatric psoriasis are described, varying between 0% (Taiwan) to 2.1% (Italy).2,5,7,10-15 
In three studies from respectively Germany10,14 and the United Kingdom5, the prevalence 
of psoriasis in children in the first decade (0-9 years) was estimated between 0.18%-0.55%, 
whereas in the second decade (10-19 years) a prevalence rate of 0.83%-1.37% was reported. 
A Dutch study described a prevalence rate of 0.37% in children aged 0-10 years and 1.09% 
in patients aged 11-19 years.7 In some studies on the epidemiology of pediatric psoriasis, an 
approximately linear increase in prevalence was suggested during the first 18 years.10,14 
Whereas in some studies girls were found to be much more often affected than boys16-19, 
in others the reported gender distribution was approximately equal.14,20-24 In a population- 
based study on the incidence of psoriasis in children in the United States, a more than 
two-fold increase in incidence was reported during a 30-year time period from 1970 to 
2000.24 The overall annual incidence rate (age- and sex-adjusted) in this study was 40.8 
per 100.000 person-years.2,24,25
 The most common clinical subtype of psoriasis in the pediatric population is plaque 
psoriasis (also referred to as psoriasis vulgaris)19-24,26-32, followed by guttate psoriasis.22-24,32 
Other psoriasis subtypes e.g. pustular psoriasis, palmoplantar psoriasis, inverse psoriasis 
and erytrodermic psoriasis occur less frequently in children and adolescents.21,23,26,29 
Typical psoriatic lesions are characterized by well-defined, sharply demarcated erythemato-
squamous papules and plaques of variable size which are scattered in a usually symmetrically 
distribution on the body.33,34 In pediatric patients, lesions are usually smaller, thinner and 
less scaly than in adult patients.21,27,29,30 Predilection sites of psoriasis are the extensor 
surface of elbow and knee, scalp, lumbosacral region and umbilicus.33,34 In children and 
adolescents, the scalp is commonly affected18-20,24,28,30 and involvement of the face and 
flexural areas is more common than in adult patients.27,29 Involvement of the nails (nail 
plate and/or nail bed) appears in up to 40% of the pediatric patients16,18-20,29,35, primarily 
nail pitting.20,25,29 Other clinical manifestations of nail involvement include onycholysis, 
oil drop discoloration, subungual hyperkeratosis, splinter hemorrhages, red spots in the 
lunula, crumbling, leukonychia and beau’s lines.29,36-38
1.2 Treatments in pediatric psoriasis
The treatment of psoriasis in the pediatric population poses some challenges.27,29,30,39 
First, there is only limited evidence on the efficacy and safety of treatments in children and 
adolescents with psoriasis.40 In addition, most treatments are not licensed for use in 
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children.29,30,39 In daily practice, therapeutic decision making is influenced by several 
factors, considering for example: age, disease severity, location and type of psoriasis, 
previous treatments, psychosocial impact, presence of comorbidities, practicality of the 
regimen, tolerability and safety, accessibility, costs and patient preferences.25,27-30,41 
To support caregivers in their treatment choices, evidence based data on the efficacy and 
safety of treatments in pediatric psoriasis are essential. As psoriasis is a chronic disease 
which currently cannot be cured28,29, and treatments are given to children with a life-time 
ahead, particularly long-term safety data are indispensible.41,42 
 In this introduction the treatments which are commonly prescribed in pediatric 
psoriasis will be discussed. These comprise topical treatments (corticosteroids, vitamin D3 
analogues, calcineurin inhibitors, keratolytics, coal tar and dithranol), phototherapy, 
conventional systemic treatments (methotrexate, cyclosporine, retinoids, fumaric acid 
esters) and biologics. The evidence that was available at the start of this thesis will be 
described, and the lack of evidence or need for more information will be addressed. As our 
group published a systematic review on the efficacy and safety of treatments in pediatric 
psoriasis in 201040, much of the evidence described below, is revealed from that review. 
Topical treatments
Corticosteroids
Corticosteroids have anti-inflammatory, anti-pruritic and anti-proliferative properties28,43-
45 and are the most commonly prescribed treatment in pediatric psoriasis.32,46 There are 
numerous distinct topical steroids available, which differ from each other in their potency 
and the used vehicle.32,47 In the Netherlands, four potency classes are distinguished.47 In 
general, possible side effects of topical steroids can be distinguished in local cutaneous 
and/or systemic side effects.44,47 Local cutaneous side effects include skin atrophy, 
periorificial dermatitis, striae distensae, telangiectasia, acne, folliculitis and purpura.44,47 
Possible systemic side effects encompass Cushing’s syndrome, suppression of the hypo-
thalamic-pituitary-adrenal (HPA) axis, osteoporosis, osteonecrosis, growth retardation, 
glaucoma and cataracts.44,47 In younger children care should be taken to their higher 
body surface area to body weight ratio and consequently the increased risk on both 
cutaneous and systemic side effects.42,44 To reduce the potential side effects of topical 
corticosteroids, it is recommended to use steroids intermittently and alternately with 
other nonsteroidal agents.28,32,44 In addition, it is recommended to switch to lower-potency 
steroids when remission has been achieved.44 
 The evidence on the use of topical steroids in children and adolescents with psoriasis 
was found to be limited and of low level.40 The majority of evidence is derived from two 
studies reporting the efficacy of halobetasol propionate 0.05% cream and ointment48 
and clobetasol propionate emulsion formulation foam 0.05%49 respectively in a total of 
20 patients for a treatment period of two weeks.40 Reported side effects were relatively 
mild and include skin atrophy, erythema, depigmentation and burning.40,48,49
503687-L-bw-van Geel
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Vitamin D3 analogues
The therapeutic effect of the vitamin D3 analogues calcitriol (1,25-dihydroxyvitamin D3) 
and calcipotriol (also called calcipotriene, a synthetic form of vitamin D3)45 is based on the 
inhibition of keratinocyte proliferation and deoxyribonucleic acid (DNA) synthesis and the 
promotion of keratinocyte differentiation.28,31,44 From September 2011, monotherapy with 
calcipotriol is no longer available in the Netherlands43, but calcitriol ointment is still available. 
Although calcitriol and calcipotriol are not registered for use in children and adolescents43, 
vitamin D3 analogues are considered to be important in the treatment of pediatric psoriasis.40,43 
Rotational therapy with mild-to-moderate topical corticosteroids is recommended40,43 
because of their synergistic and corticosteroid-sparing effect.28,32 Most frequently occurring 
local side effects are skin irritation and pruritus.40,43 Vitamin D3 analogues are considered 
to be an effective and reasonably well-tolerated treatment option for pediatric psoriasis.40,43 
 Over recent years, a combination product including calcipotriol 50 µg g-1 and a 
potent corticosteroid (betamethasone dipropionate 0.5 mg g-1) in ointment and gel 
vehicle has become available for the treatment of adult psoriasis.43,50-53 In adults, both 
formulations have shown to be an effective and well-tolerated treatment option for 
psoriasis.43,53 At the start of this PhD-project, data on the use of the two-compound 
ointment in pediatric psoriasis were lacking. Therefore, the effectiveness, safety and 
influence on the quality of life (QoL) of calcipotriol/betamethasone dipropionate ointment 
in pediatric psoriasis will be described in this thesis. 
Calcineurin inhibitors
Tacrolimus ointment (0.03% and 0.1%) and pimecrolimus cream (1%) are calcineurin 
inhibitors. Their mechanism of action is based on the inhibition of the enzyme calcineurin, 
resulting in a decreased T-cell activation and proliferation and a decreased production of 
interleukin (IL)-2.28,30,43 Topical tacrolimus 0.03% ointment and pimecrolimus 1% cream 
are approved for the treatment of atopic dermatitis in patients aged 2 years and above.44,54 
Tacrolimus 0.1% ointment is registered for atopic dermatitis patients aged ≥16 years.54 
After application burning, stinging or pruritus can occur.28,32,43,44 In (pediatric) psoriasis 
calcineurin inhibitors are prescribed off-label.28,43 Evidence on their use in pediatric 
psoriasis is scarce.40 For short-term treatment of facial and intertriginous pediatric psoriasis, 
tacrolimus 0.1% ointment seemed to be effective and safe.40 
Keratolytics
Keratolytics like topical salicylic acid, lactic acid and urea, are nonsteroidal agents which 
decrease hyperkeratosis and scaling by reducing intercellulair cohesion of keratinocyts.28 
They are generally used in conjunction with other topical agents.28,32,44 Keratolytics 
containing salicylic acid should be prescribed with caution in young children because 
of the increased risk on salicylate intoxication.28,30,32 To our knowledge, data on the 
effectiveness and safety of keratolytics in pediatric psoriasis are lacking. 
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Coal tar
Coal tar is a distillation product from coal which contains a huge number of different 
compounds including phenols, polycyclic aromatic hydrocarbons and heterocyclic 
compounds.28,44 It is a well-known treatment option for inflammatory disorders including 
psoriasis because of its anti-pruritic and anti-proliferative effects.28 The mechanism of 
action has recently been unraveled by van den Boogaard et al.55 The use of coal tar can be 
limited because of its odor and staining of skin and clothes.28,32,43,44 Potential side effects 
include folliculitis, irritant contact dermatitis and photosensitivity.28,32,44 The use of topical 
and bath form coal tar in combination with phototherapy (Goeckermann regimen) in 
pediatric psoriasis is described in some studies.28,56-58 However, to our knowledge, 
evidence on the use of coal tar as monotherapy in children and adolescents with psoriasis 
does not exist.
Dithranol 
Dithranol (anthralin) therapy is a synthetic nonsteroidal agent which acts by its anti- 
proliferative and anti-inflammatory properties28,32, although the exact pathogenic 
mechanism is not fully unraveled.32,44 Two ways of application of dithranol are described: 
short-contact therapy (application during 10-30 minutes) versus classic 24-hours 
application.43 Application is preferably in day care setting with frequent follow-up 
visits.59,60 Potential side effects include local skin irritation and staining of skin and 
clothes.25,28,30,44 Application should be avoided in erytrodermic, pustular, facial and 
intertriginous psoriasis.28,30 In pediatric psoriasis, dithranol is considered to be an effective 
and safe treatment option40,59,61, and is proposed when treatment with topical agents 
(calcipotriol, whether or not combined with mild-to-moderate topical corticosteroids) is 
ineffective or psoriasis is moderate-to-severe.40
Phototherapy and photochemotherapy
The spectrum of ultraviolet (UV) radiation can be distinguished in UVA (320-400 nm) 
which encompasses UVA-I (340-400 nm) and UVA-II (320-340 nm), UVB (290-320 nm) and 
UVC (200-290 nm).62 For the treatment of psoriasis, phototherapy with UVB and UVA is 
generally used43, whereby UVB only reaches the epidermis due to its shorter wavelength, 
while UVA gets access to both epidermis and dermis.62 The therapeutic effect of 
photo therapy is based on a broad range of anti-inflammatory, anti-proliferative and 
 immunosuppressant modalities.43,62 Photochemotherapy is the combined use of 
phototherapy (generally UVA) and a (topical or systemic) photosensitizer like psoralens 
(PUVA).43,62 In the Netherlands, treatment with PUVA in pediatric psoriasis is contra- 
indicated because of the risk of carcinogenesis.43,63 The use of phototherapy as a treatment 
option in children and adolescents with psoriasis has been described in several 
publications, mostly reporting on narrow band UVB (NB-UVB, 311-313 nm).28,62 In these 
studies NB-UVB showed beneficial effects on plaque and guttate pediatric psoriasis.25,40,62 
503687-L-bw-van Geel
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Short-term side effects from phototherapy are usually mild and include in general xerosis, 
erythema, pruritus, blistering and photoactivation of herpes virus.62,64 While premature 
photoaging and carcinogenesis are reported long-term side effects in adults treated with 
PUVA, the potential long-term carcinogenic risk of NB-UVB treatment is still subject of 
debate.28,43,65-70 Furthermore, an increased number of sunburns during all life-periods has 
reported to be associated with an increased risk of melanoma.71 To our knowledge, in 
children and adolescents with psoriasis long-term safety data in large studies on the use 
of NB-UVB treatment are not clearly reported so far.40,43,62,72 Although there is a need for 
long-term safety data on phototherapy73 in the pediatric psoriasis population, this will not 
be addressed in this thesis. In pediatric patients, especially anxiety, but also time 
commitment for patient and families and inconvenience could be problematic when 
using phototherapy.40,62,74 According to the Dutch guideline, short-term NB-UVB could 
be considered in adolescents with psoriasis but has to be used carefully whereby special 
caution should be taken to those with fair skin.40,43,63
Systemic treatments
Methotrexate
Methotrexate (MTX) is a folic acid antagonist reversibly inhibiting the enzyme dihydrofolate 
reductase. It consequently inhibits thymidylate and purine synthesis resulting in decreased 
DNA and ribonucleic acid (RNA) synthesis and decreased repair and replication of T-and 
B-lymphocytes.28,30,41,43 It has been used for the treatment of psoriasis since 1958.43,75 
Potential side effects include nausea, vomiting, fatigue, stomatitis, loss of appetite, bone 
marrow suppression, pulmonary toxicity, renal insufficiency, photosensitivity and 
hepatotoxicity including liver fibrosis.28,30,41 In children and adolescents, MTX has not 
been approved for the treatment of psoriasis, but is used off-label.41 Evidence on the 
efficacy and safety of MTX in children and adolescents is limited and only retrospectively 
collected.40 The majority of evidence comes from three retrospective case series with a 
total of 32 children.76-78 Based on this evidence, MTX was concluded to be an effective 
treatment option in moderate-to-severe pediatric psoriasis and it was proposed to be the 
first-line systemic treatment option in pediatric psoriasis.40 Because of the lack of 
(prospective) evidence on the effectiveness and safety of MTX in pediatric psoriasis, we 
performed a prospective study on the effectiveness, safety and impact on QoL of MTX in 
pediatric psoriasis patients in daily clinical practice during this PhD-project which is 
described in this thesis. 
Cyclosporine
Cyclosporine is an immunosuppressant drug, that binds to the intracellular protein 
cyclophilin and therefore selectively inhibits calcineurin resulting in a reversibly inhibitory 
effect on T-lymphocytes and suppression of IL-2 and interferon-y.28,30,41,75 Clinical 
improvement can occur within 2-4 weeks after start.28 Possible side effects include 
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nephrotoxicity, hypertension, nausea, vomiting, diarrhea, myalgias, arthralgias, headache, 
gingival hyperplasia, paresthesia, hypertrichosis and immunosuppression thereby 
increasing the risk of lymphoproliferative disorders and other malignancies and 
infections.28,30,41,43,64,75 In pediatric psoriasis, cyclosporine is not approved for use.30,41 
The use of cyclosporine in pediatric psoriasis has only sparsely been described in case 
series and case reports.40 Although there was a need for more evidence on cyclosporine 
in pediatric psoriasis, we did not address this question in this thesis. However, in the 
discussion the newest evidence will be presented. 
Retinoids
Retinoids are vitamin A derivates which affect the cellular metabolism, epidermal differen-
tiation, and apoptosis by binding to the nuclear receptors in keratinocytes.28,30,64 Most of 
the evidence in pediatric psoriasis was found on etretinate40, which is no longer 
available.43,75 Evidence on acitretin in pediatric psoriasis is scarce.40 Potential side effects 
include cheilitis, xerosis, epistaxis, skin fragility, ocular toxicities and hair thinning.25,30,64 
Skeletal changes are described in children using long-term retinoid treatment.30,40,64,79 In 
infants and male adolescents with pustular and erytrodermic psoriasis, short-term 
treatment with retinoids can be considered.40 Cause for concern includes the high 
teratogenic risk of retinoids.30,64,79 Therefore, in females and women of child-bearing 
potential effective contraceptive measures are obligatory during and up to at least two 
years after discontinuation of therapy.43,63,75
Fumaric acid esters
The immunomodulatory effects of fumaric acid esters (FAE) are diverse and primarily 
based on the active ingredient dimethylfumarate (DMF).43,75,80 Although FAE are described 
in the European guideline75, they are not registered in the Netherlands.43,63 In the 
Netherlands different FAE formulations are available, including monotherapy with DMF as 
well as mixtures of DMF and three salts of ethyl hydrogen fumarate.43,75 Despite the fact 
that FAE are not approved, they are widely used in adults with psoriasis. The majority of 
evidence on the use of FAE in pediatric psoriasis comes from a Dutch retrospective case 
series of 14 children in which FAE seemed to be effective and safe.81 Gastrointestinal 
complaints, flushing, temporary shifts in leukocytes, increased liver enzymes, proteinuria 
and elevated serum creatinine levels were reported as side effects in this retrospective 
case series.81 In this thesis, a prospective case series on FAE in recalcitrant pediatric 
plaque-type psoriasis is described. 
Biologics
Biologics, or biologicals, are recombinant proteins which selectively interfere with specific 
components of the inflammatory cascade in the pathogenesis of psoriasis.28,30,64,82 At the 
beginning of this PhD-project, etanercept (Enbrel®), a fully human soluble tumour necrosis 
503687-L-bw-van Geel
17
1
general introduction and outline of this thesis
factor (TNF)-receptor fusion protein that competitively inhibits the binding of endogenous 
TNF-α to its receptor30,41,75, was the only biological which was approved by the European 
Medicines Agency (EMA) for the treatment of chronic severe pediatric plaque-type 
psoriasis (age ≥ 6 years) in case of ineffectiveness or intolerance to other systemic 
treatments or phototherapy.83,84 Very recently, the first data on the use of two other 
biologics in pediatric psoriasis have become available: adalimumab and ustekinumab. 
These data will be described in the discussion of this thesis. 
Psychosocial support
Another additional treatment modality to medical treatments in pediatric psoriasis 
includes patient education and psychosocial support.28,30,31 To our knowledge, the 
evidence on training programmes in children and adolescents with psoriasis is limited to 
one inpatient education programme performed in Germany.85 In this particular study an 
inpatient treatment group (n = 34) was compared to a control group of 21 children and 
adolescents with former inpatient rehabilitation, but without education, resulting in 
improved skills of disease management, long-term self-estimated skin condition and 
psychosocial impairment.85 In 2011, our group developed an outpatient multidisciplinary 
training programme for children and adolescents with psoriasis and their parents.86 In a 
case-study, its development and design was illustrated.86 In this thesis, the efficacy of this 
multidisciplinary outpatient training programme is evaluated in a pilot study. 
1.3  Assessment measures on disease severity and 
psychosocial impact 
Psoriasis severity 
It is important to assess psoriasis severity as precisely as possible for optimal therapeutic 
decision-making. In addition, it allows caregivers to monitor changes induced by 
treatment. Therefore, valid and reliable measures to assess psoriasis severity are 
indispensable.87-89 To the best of our knowledge, validated psoriasis severity measures in 
children and adolescents are lacking. In adult psoriasis patients, a wide variety of psoriasis 
severity measures exist87-91, which are summarized in two systematic reviews from 
2010.87,89 Nowadays, the most widely used psoriasis severity measure for scientific 
evaluation is the Psoriasis Area and Severity Index (PASI).75,87,89,92 
 PASI has originally been developed in 1978.75,93 To calculate the PASI score, four body 
regions (Head, H; Upper extremities, U; Trunk, T; Lower extremities, L) are separately 
assessed for severity of the lesions and percentage of the involved area in a body region. 
These four body regions (Head, Upper extremities, Trunk and Lower extremities) account 
for 10%, 20%, 30% and 40% of the total body surface area respectively. In each body 
region, disease severity is measured by assessing erythema (E), infiltration (I) and 
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desquamation (D) on a five-point scale (range 0-4; 0, no involvement; 1, slight; 2, moderate; 
3, marked; 4, very marked). In addition, the percentage of involved body surface area per 
body region (A) is assessed using a seven-point scale (0, no involvement; 1,<10%; 2, 
10<30%; 3, 30<50%; 4, 50<70%; 5, 70<90%; 6, 90–100%).88,94,95 PASI is calculated by the 
following formula: 
PASI = 0.1Ah (Eh + Ih +Dh) + 0.2Au (Eu + Iu + Du)+ 0.3At (Et +It + Dt)+ 0.4Al (El + Il + Dl). PASI 
ranges from 0 to 72 with higher scores indicating more severe psoriasis.88 
 PASI is reported to be the most extensively studied psoriasis severity measure and 
is recommended to assess psoriasis severity in a research setting.87 PASI is also often used 
as a reference standard for the validation of new severity measures.89,92 Furthermore, PASI 
has been incorporated in the established European treatment goals for moderate-to- 
severe psoriasis.96 In these treatment goals and also in the European guideline for the 
treatment of psoriasis, an improvement in PASI of 75% or more (PASI 75) is defined as a 
clinically meaningful endpoint.75,91,96 PASI, however, has been criticized by having a 
number of shortcomings.87,89,91,92 A frequently reported limitation encompasses PASI 
being not able to assess small affected areas in a body region.89,91,97-99 Because of this 
need to assess small affected areas in a body region (<10% of a body region) as precisely 
as possible, we aimed to develop a refined PASI score for psoriasis patients with small 
affected areas (Low PASI), which is described in this thesis. 
 Two other frequently used psoriasis severity measures are the percentage of the 
affected body surface area (BSA) and the Physician’s Global Assessment (PGA).75,100 The 
BSA can be assessed by counting the involved body area by the number of patients’ 
handprints.89 One handprint of the patient (palm plus 5 digits) is approximately equivalent 
to 1% of the total BSA in children and <1% of the total BSA in adults.101,102 Another way to 
estimate BSA is using the ‘rule of nines’, dividing the total body area in several smaller areas 
each counting for 9% of the total BSA, with 1% leaving for the genital area.89,103 The other 
commonly used severity measure is the PGA.75,89,100,104 The PGA assesses the overall 
psoriasis severity using an ordinal rating scale. Several PGA scales are available, varying in 
the number of ratings. The assessment can be done static (at one moment in time) or 
dynamic (compared to baseline severity).89 
Psychosocial impact 
To assess the impact of psoriasis on the physical, social and psychological functioning of 
those affected, patient-reported outcome (PRO) measures can be used.105 Their approach 
can be generic, dermatology-specific or psoriasis- specific.75,105,106 A major construct in PRO 
measures is health-related quality of life.107 As quality of life (QoL) can be affected by many 
factors other than health, the more restricted term ‘health-related QoL’ is used when 
evaluating the effects of health status including disease and treatment on physical, 
psychological and social functioning and well-being of the patient.108 The impact of 
psoriasis on the QoL in children and adolescents can be profound.109-115 
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 To the best of our knowledge, psoriasis-specific QoL questionnaires designed for use 
in children and adolescents do not exist116, apart from the Scalpdex which has been 
validated for children (aged 6-18 years) with scalp psoriasis.117 To assess QoL in pediatric 
psoriasis, a dermatology-specific questionnaire can be used. There are some validated 
 dermatology-specific questionnaires available for use in children and adolescents (e.g. 
the Children’s Dermatology Life Quality Index (CDLQI)118, the Skindex-Teen119 and the 
Teenagers’ Quality of Life (T-QoL©) Index.120 As a comprehensive review of all available 
measures to assess psychosocial impact (including generic) in children and adolescents is 
out of the scope of this thesis, only the assessment measures which are used in this thesis, 
will be described below. 
Children’s Dermatology Life Quality Index
In children with psoriasis the CDLQI is a widely used dermatology-specific QoL instrument.118 
The CDLQI has been validated in children with different skin diseases aged 4 to 16 years.118 
It consists of ten questions concerning itch/pain, embarrassment, friendships, clothing, 
going out/playing/doing hobbies, swimming/sports, school/holiday, teasing/bullying/
asking questions/avoiding, sleep and treatment.118 These questions (Q) encompass six 
headings on symptoms and feelings (Q1-2), leisure (Q4-6), school or holidays (Q7), personal 
relationships (Q3,8), sleep (Q9) and treatment (Q10).121 The CDLQI evaluates patients’ 
perceptions from the last week. Each question is scored on a four-point Likert scale (0, not 
at all; 1, only a little; 2, quite a lot, 3, very much) resulting in a total score ranging from 0 to 
30. More impairment of QoL is indicated by higher scores.118,121,122 In 2003 Holme et al. 
validated a cartoon version of the CDLQI, which was faster and easier for children to use.123
Dermatology Life Quality Index
In patients aged 16 years and above, the Dermatology Life Quality Index (DLQI)124 is a 
commonly used dermatology-specific questionnaire to assess QoL. The DLQI was developed 
and validated in 1994 to assess QoL in patients (≥16 years) with various skin conditions.124 
Just like the CDLQI, the DLQI encompasses ten questions using a four-point Likert scale (0, 
not at all/not relevant; 3, very much; range 0-30) and more impact on QoL is indicated by 
higher scores.124-126 The ten questions of the DLQI concern itch/pain, embarrassment, 
shopping/looking after home or garden, clothing, social or leisure activities, sports, work/
study, problems with partners/close friends/relatives, sexual difficulties and treatment.124 
These questions encompass the following headings: symptoms and feelings (Q1-2), daily 
activities (Q3-4), leisure (Q5-6), work or school (Q7), personal relationships (Q8-9), and 
treatment (Q10).125,126 The questions concern patients’ perception during last week.124 
Impact of Chronic Skin Disease on Daily Life
The Impact of Chronic Skin Disease on Daily Life (ISDL) is a dermatology-specific and generic 
health instrument.127 In the dermatology-specific part of this multidimensional health 
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status inventory, dimensions of physical functioning (skin status; physical symptoms of 
itch, pain and fatigue; scratching responses) and disease-related stressors including 
stigmatization are assessed. In the generic part of this inventory dimensions of psychological 
functioning, disease-related impact, illness cognitions and social support are concerned. 
The ISDL has been validated in adult patients with psoriasis and atopic dermatitis.127 
Stein Impact on Family Scale
The Stein Impact on Family Scale (SIFS) is a generic questionnaire which measures the 
perceived reactions of a family member of the effects of the child’s ongoing health 
condition on family life. For our study we used the revised version in which 15 items are 
used to calculate the Total Impact on Family Score.128,129 Each item is scored using a 
four-point scale (1, strongly agree; 4, strongly disagree).128 The total score therefore ranges 
from 15 to 60 with lower scores indicating more impact on family life.129 
Dermatitis Family Impact questionnaire
The Dermatitis Family Impact (DFI) questionnaire was developed by Lawson et al. to assess 
the impact of childhood atopic dermatitis on family life.130,131 The DFI has to be filled out 
by the parent or caregiver and consists of a ten-item questionnaire concerning the impact on 
housework, food, sleep, leisure, time shopping, expenditure, tiredness and/or exhaustion, 
emotional distress, relationships and treatment.130 The questions regard the impact from 
the last week. Each question is scored on a four-point scale ranging from 0 to 3 (0, not at 
all; 1, a little; 2, a lot; 3, very much). This results in a total score ranging from 0 to 30.130,131 
Composite measure – the Simplified Psoriasis Index
The measures as mentioned before in this introduction, assess either disease severity or 
psychosocial impact. In 2013 a new summary measure was published: the Simplified 
Psoriasis Index (SPI).92 The SPI is a composite assessment measure which is derived from 
the Salford Psoriasis Index.92,132 The SPI consists of three separate components: first a 
disease severity component (SPI-s), second a psychosocial impact (SPI-p) component and 
third a historical course and response to therapeutic interventions component (SPI-i).92 
There are two versions available which are complementary and can be completed by a 
health professional (proSPI) or by patient self-assessment (saSPI).92 
 The first domain of the SPI (SPI-s) (Figure 1, part 1) encompasses a composite severity 
score in which disease extent is multiplied by an overall disease severity score. To assess the 
extent of psoriasis, ten unequal areas of the body are measured using a three-point scale 
(0, absent or minimal; 0.5, noticeable; 1, extensive) resulting in a total score ranging from 
0-10. The ten areas which are assessed are: 1) scalp and hairline; 2) face, neck and ears; 3) 
arms and armpits; 4) hands, fingers and fingernails; 5) chest and abdomen (stomach); 6) 
back and shoulders; 7) genital area and/or around the anus (back passage); 8) buttocks 
and thighs; 9) knees, lower legs, and ankles; 10) feet, toes, and toenails. The scores for 
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Figure 1  Dutch version of the self-assessment Simplified Psoriasis Index (saSPI). 
(adjusted from: Chularojanamontri L, Griffiths CE, Chalmers RJ. The Simplified Psoriasis Index (SPI): a practical 
tool for assessing psoriasis. J Invest Dermatol 2013; 133: 1956-62).92
saSPI 301212                                                                                                                                    
 
Bedankt voor het invullen van deze vragenlijst. Deze vragenlijst helpt ons om een indruk te 
krijgen hoe ernstig de psoriasis is. Je mag de vragenlijst ook samen met (een van) je ouders 
invullen. De vragen bestaan uit 3 gedeelten en vertellen ons een beetje hoe (ernstig) je 
psoriasis nu is, hoe vervelend jij je huid vond en hoe de psoriasis vroeger was. Als je vragen 
hebt over deze vragenlijst, vraag dit dan aan de verpleegkundige of de onderzoeker. 
Simplified Psoriasis Index         
Zelfrapportage vragenlijst 
 
 
 
  
 
 
 
 
 
 
 
Hieronder mag je aangeven waar je nu psoriasis hebt.  
 
DEEL 1A Hieronder staan 10 gebieden van het lichaam.  
Omcirkel voor elk gebied 1 keuze die het beste je 
psoriasis vandaag beschrijft.  
 
 
Geen plekken of zo weinig dat het nauwelijks opvalt  (0) 
Duidelijk aanwezig, maar nog steeds veel normale huid aanwezig(0.5) 
Wijdverspreid over een groot gedeelte van het gebied (1.0) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DEEL 1B  Omcirkel welk van onderstaande keuzes de psoriasis plekken  
die je vandaag hebt het beste beschrijft. Geef een score voor het 
gemiddelde van je psoriasisplekken, scoor dus niet alleen de plekken die het 
meest ernstig zijn. Om je te helpen bij het scoren van je psoriasis mag je 
de voorbeeldfoto’s gebruiken. 
Geen roodheid of alleen lichte roodheid of verkleuring   
Milde roodheid of schilfering met een klein beetje verdikking  
Duidelijke roodheid, schilfering of verdikking 
Matig ernstig met duidelijk meer roodheid, schilfering of verdikking 
Zeer rood en geïrriteerd, veel schilfering of verdikking  
Hevig geïrriteerde huid met of zonder puistjes (plekjes met pus)     Zie achterkant                       
0 ±  
0 
± 
+ 
1  Behaarde hoofdhuid & haargrens  0 ± + 
2  Gezicht, nek & oren 0 ± + 
3  Armen & oksels 0 ± + 
4  Handen, vingers & vingernagels*  0 ± + 
5  Borst & buik   0 ± + 
6  Rug & schouders  0 ± + 
7  Schaamstreek en/of rond de anus (bilspleet)  0 ± + 
8  Billen & bovenbenen  0 ± + 
9  Knieen, onderbenen & enkels  0 ± + 
10  Voeten, tenen & teennagels*  0 ± + 
 
*PSORIASIS VAN DE NAGELS: Als minstens 2 nagels ernstige 
psoriasis hebben (bijvoorbeeld: putjes én witte vlekjes of rode 
vlekjes of afbrokkelen van de nagelplaat of loslating of verdikking 
van het nagelbed), mag je ± omcirkelen, zelfs als er geen 
psoriasis zit op de huid van je handen of voeten. Bij 6 vinger of 
teennagels mag je + omcirkelen.  
SOM 
 
 
0 
1 
2 
3 
4 
5 
+ 
 
PRODUCT 1A X 1B 
Datum:  
Registratienummer of sticker: 
Geslacht:  
 
Voornaam: 
Achternaam: 
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Figure 1  Continued.
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DEEL 2   Zet een streepje op de lijn hieronder dat het beste aangeeft hoe vervelend jij je huid 
vandaag vindt en hoeveel last je ervan hebt (bijvoorbeeld: last van een pijnlijke, jeukende of 
stekende huid; jezelf schamen of niet prettig voelen over je huid; bij het omgaan met vrienden/ 
vriendinnen; verwisselen van kleren/ schoenen; bij uitgaan, spelen of hobby’s; bij zwemmen of 
andere sporten; op school of op vakantie; ben je gepest of uitgescholden of hebben mensen 
aan je gevraagd wat je had; bij het slapen; problemen met de behandeling).  
 
 
 
 0 1 2 3 4 5 6 7 8 9 10 
 
Score:  0 = ik heb helemaal geen last van mijn psoriasis; ik kan alles doen wat ik wil 
  5 = door mijn huid heb ik (best) veel moeite om de dingen te doen die ik zou willen doen  
          10 = ik heb heel veel last van mijn psoriasis (ik kan me niet voorstellen dat het nog erger 
kan zijn) 
 
 
 DEEL 3   Hieronder staan een aantal beweringen. Kruis het hokje achter de zin aan als je denkt dat de bewering voor jou klopt. Laat het hokje leeg als je niet zeker bent 
of als je de behandeling niet kent.  
 
Punt  
 
Over je psoriasis 
Ik heb al meer dan 10 jaar psoriasis   
De psoriasis is voor mijn 10e jaar ontstaan  
Ik heb een zeer geïrriteerde psoriasis gehad van mijn hele huid (mijn hele huid was 
rood en/of mijn huid was geïrriteerd met puistjes) 
 
Ik ben opgenomen in het ziekenhuis voor mijn psoriasis.   
Over je psoriasis behandeling 
Ik heb minstens 1x lichttherapie gehad (UV-B of PUVA)   
Ik ben behandeld met methotrexaat (nu of in het verleden)   
Ik ben behandeld met acitretine (Neotigason, etretinaat) (nu of in het verleden)   
Ik ben behandeld met ciclosporine (Neoral) (nu of in het verleden)  
Ik ben behandeld met een “biological” gegeven door een injectie of infuus (nu of in 
het verleden) 
         Biologicals zijn Remicade/infliximab; Enbrel/etanercept;  
        Raptiva/efalizumab; Humira/adalimumab; Stelara/ustekinumab  
 
Ik ben behandeld met een ander tablet/ injectie behandeling voor mijn psoriasis (nu 
of in het verleden). Als dat zo is, kan je de naam van de behandeling nog 
herinneren? 
 
Naam van de behandeling: ………………………………………………………….  
 
 
Wil je nakijken of je alle vragen hebt beantwoord. Dank voor je medewerking.  SUM 
PART 2 
P 
PART 3 
I Deel 1 
S 
Deel 2 
P 
Deel 3 
I 
Dit wordt ingevuld door de arts of verpleegkundige 
    
 Deel 1 
S 
   
 Deel 2 
P 
    
 Deel 3 
I 
 
  
       SEVERITY (0-50)                  PSYCHOSOCIAAL (0-10)            INTERVENTIE (0-10) 
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hands en feet include the possibility to score nail disease (0.5 if severe psoriasis of at least 
two and 1 for six or more finger or toenails affected). The overall psoriasis severity is scored 
using a six-point average plaque severity score resulting from 0 to 5. The SPI-s is derived 
by the multiplication of the psoriasis extent score (0-10) and the overall severity score (0-5) 
resulting in a maximum score of 50.92 
 The second domain of the SPI (SPI-p) (Figure 1, part 2) consists of a 10-cm visual 
analogue scale line which is converted to the nearest integer, resulting in a score ranging 
from 0 to 10.92 The third domain of the SPI (Figure 1, part 3) includes a historical course and 
intervention score (SPI-i). The SPI-i incorporates four questions about historical course and 
six questions about therapeutic interventions, resulting in a score ranging from 0 to 10.92 
The total score of the SPI is presented as three separate scores for SPI-s (0-50), SPI-p (0-10) 
and SPI-i (0-10).92 The validation and reliability of the SPI have already been shown in adult 
psoriasis patients.92 In pediatric psoriasis, data on the validation of the SPI do not exist. 
1.4 Daily clinical practice registry
The Child-CAPTURE registry (Continuous Assessment of Psoriasis Treatment Use Registry) 
is a prospective, longitudinal, long-term, single center pediatric psoriasis registry which 
was set up in 2008 at the department of Dermatology at the Radboud university medical 
center. In this registry daily clinical practice data on the effectiveness, safety and impact on 
QoL of all children and adolescents with psoriasis visiting the outpatient clinic are 
collected. At the moment, 340 children are included and inclusion of patients is still 
ongoing. The prospective data described in this thesis, are mainly extracted from the 
Child-CAPTURE registry. 
1.5 Aims and outline of this thesis
This thesis on children and adolescents with psoriasis focuses on treatments and assessment 
measures.
The first part of this thesis (Chapter 2) concentrates on therapeutic interventions in 
children and adolescents with psoriasis. As mentioned before, at the beginning of this 
PhD-project, evidence on the effectiveness and safety of treatments in pediatric psoriasis 
was limited. In addition, most evidence was of low level.40 In 2010, our group proposed an 
evidence-based treatment algorithm for pediatric psoriasis based on a systematic review 
of the literature on efficacy and safety of treatments in this patient group.40 Over recent 
years however, more evidence has become available, and in addition, this thesis aimed to 
add evidence to the existing literature. First of all, we aimed to investigate the effectiveness, 
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safety and influence on the QoL of calcipotriol/ betamethasone dipropionate ointment 
in a prospective, daily clinical practice cohort of pediatric psoriasis patients (Chapter 2.1). 
A two-compound formulation containing calcipotriol 50 µg g-1 and a potent corticosteroid 
(betamethasone dipropionate 0.5 mg g-1) in ointment and gel vehicle has become available 
for adults.43,50-53 However, evidence on the use of this two-compound formulation in 
ointment vehicle in pediatric psoriasis does not exist. As topical treatments are first-line 
and used in the majority of the pediatric psoriasis population28,40,42,46, we considered it 
very important to investigate the effectiveness, safety and influence on QoL of this 
two-compound ointment in pediatric psoriasis. 
 Second, we aimed to provide a systematic overview on the efficacy and safety of 
systemic treatments in children and adolescents with psoriasis (Chapter 2.2) as recently, 
several overview articles on systemic treatments in pediatric psoriasis have been 
published27,28,31,39,41,42,64,133,134 and in this vulnerable patient group, evidence-based data 
on efficacy and safety of systemics are indispensable to support clinical therapeutic 
decision making. 
 Based upon the conclusions from the previous publication from 201040 and the 
newly retrieved evidence in this systematic update, two conventional systemic treatments 
with limited and only retrospectively collected evidence, were further investigated in this 
thesis. The conventional systemic treatments of interest in this thesis were MTX and FAE. 
The effectiveness of MTX in pediatric plaque-type psoriasis in daily clinical practice was 
investigated prospectively in Chapter 2.3. Data were extracted from the Child-CAPTURE 
registry. Furthermore, the safety, influence on the QoL, 48- and 96-week drug survival, and 
the influence of body mass index (BMI) and waist circumference (WC) on the effectiveness 
of MTX were described. Chapter 2.4 includes a prospective, daily clinical practice case 
series on the effectiveness, influence on QoL and safety of FAE in recalcitrant pediatric 
psoriasis.
 However, treatment of pediatric psoriasis encompasses more than the prescription of 
medicinal products. In children and adolescents psychological well-being can be 
negatively affected by their psoriasis.109-115 Therefore, an important additional treatment 
intervention includes patient education and psychosocial support.25,28,30,31 As the 
evidence on educational training programmes in pediatric psoriasis was rare85, in 2011 a 
multidisciplinary training programme for children and adolescents with psoriasis and their 
parents was developed in our center.86 Its development and design are already described 
in a case-study suggesting that it could be a promising addition to regular treatment.86 
However, its efficacy has not been evaluated. In Chapter 2.5 the effects of this multidisci-
plinary training programme on patient and parent satisfaction, QoL, itch and scratch 
responses, illness cognitions and impact on family life are presented. 
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The second part of this thesis (Chapter 3) focuses on assessment measures on psoriasis 
severity and psychosocial impact. To evaluate treatment response as precisely as 
possible, valid and reliable psoriasis severity measures are very important. In the adult 
literature, PASI93 is the most commonly used and the most extensively studied psoriasis 
severity measure.75,87,89 However, PASI has been criticized by having some 
shortcomings.87,89,91,92 A major and commonly reported limitation addresses PASI being 
not able to assess small affected areas in a body region.89,91,97-99 To monitor differences in 
psoriasis severity before- and after treatment in patients with minimal involvement (lower 
than 10% of a body region), accurate assessment of these small affected areas in a body 
region is essential. Therefore, we developed a refined PASI score for psoriasis patients with 
small affected areas, called Low PASI. In Chapter 3.1 the Low PASI score is presented and 
compared with the classic PASI. Furthermore, the interobserver agreement of the classic 
PASI and the Low PASI was evaluated and the two scores were compared within both 
investigators.
 In addition to the monitoring of psoriasis severity as described before, it is also 
important to assess the impact of psoriasis on the physical, social and psychological 
functioning of those affected.75,135-137 In pediatric psoriasis, the CDLQI118 is a commonly 
used dermatology-specific measure to assess QoL, whereas in patients aged 16 years and 
older, the DLQI124 is widely used. In psoriasis patients aged 16-17 years, it is not known 
whether DLQI and CDLQI reflect QoL in the same way. Therefore, we aimed to examine 
and compare the DLQI and CDLQI scores in adolescents aged 16-17 years with psoriasis 
(Chapter 3.2). 
 Abovementioned assessment measures encompass either only disease severity or 
only QoL. Recently, a new psoriasis assessment measure has been developed which 
includes both aspects: the SPI.92 The SPI can be assessed by the health professional 
(proSPI) or by patient self-assessment (saSPI) and has recently been validated in adults 
with psoriasis.92 In children and adolescents, data on the SPI do not exist. To our knowledge, 
evidence on composite measures to assess both disease severity and QoL in pediatric 
psoriasis in general are missing. Therefore, we aimed to validate the severity (SPI-s) and 
psychosocial impact (SPI-p) domains of the professional and patient self-assessment SPI in 
children and adolescents with psoriasis (Chapter 3.3).
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In summary, the following aims were defined: 
Treatments
1. To investigate prospectively the effectiveness, safety and influence on quality of life 
of calcipotriol/betamethasone dipropionate ointment in pediatric psoriasis in daily 
clinical practice.
2. To present a systematic overview on the efficacy and safety of systemic treatments in 
pediatric psoriasis. 
3. To investigate prospectively the effectiveness, safety and the influence on quality of 
life of methotrexate in pediatric psoriasis in daily clinical practice. 
4. To study prospectively the effectiveness, influence on quality of life and safety of 
fumaric acid esters in pediatric psoriasis in daily clinical practice. 
5. To explore the efficacy of an outpatient multidisciplinary training programme for 
children and adolescents with psoriasis and their parents. 
Assessment measures on disease severity and psychosocial impact
6. To develop a refined PASI score for patients with small affected areas (Low PASI).
7. To compare DLQI and CDLQI scores in psoriasis patients aged 16-17 years. 
8. To investigate the criterion validity, construct validity, and response distribution of the 
severity (SPI-s) and psychosocial impact (SPI-p) domains of the professional and 
self-assessment versions of SPI in children and adolescents with psoriasis. 
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Abstract
Background: Psoriasis in children has a significant negative impact on the quality of life 
(QoL) and effective treatment can improve this. The two-compound ointment calcipotriol 
50 μg g-1 and betamethasone dipropionate 0.5 mg g-1 is an effective treatment option for 
moderate-to-severe psoriasis in adults. 
Objectives: To study prospectively the effectiveness and safety of calcipotriol/beta- 
methasone dipropionate ointment in pediatric patients with mild-to-moderate plaque 
psoriasis in daily clinical practice and to investigate the influence on QoL. 
Methods: Data were obtained from a prospective, longitudinal pediatric psoriasis registry, 
called Child-CAPTURE. Severity was assessed using the Psoriasis Area and Severity Index 
(PASI) and body surface area (BSA). The Children’s Dermatology Life Quality Index (CDLQI) 
was used to assess QoL and visual analogue scores (VAS) for pain and itch were collected. 
For safety data the number of (serious) adverse events was recorded.
Results: Seventy-three patients (mean age 10.8 years, range 3-18) were treated for a 
median time of 35.0 weeks (range 1.0-176.0). At week 12, mean PASI decreased 15.4% (from 
5.2 to 4.4), BSA barely changed, and median CDLQI decreased significantly from 5.5 to 
4.0. VAS scores for pain and itch declined. At week 24, mean PASI decreased to 4.3 (17.3%). 
No related serious adverse events were observed. 
Conclusions: In this daily clinical practice study in pediatric psoriasis, calcipotriol/
betamethasone dipropionate ointment initially improved mild-to-moderate psoriasis and 
then maintained its effect. In addition, it improved QoL, with few adverse events. 
503687-L-bw-van Geel
39
2
treatments
Introduction
Psoriasis is a chronic, inflammatory skin disease that affects 2-3% of the general population. 
In approximately 30% of patients first symptoms appear during childhood.1, 2 Psoriasis 
may have a significant negative impact on the quality of life in children and effective 
treatment can improve this quality of life.3 Therefore, knowledge about therapeutic 
options in pediatric psoriasis is important, but so far, evidence is limited. 
 Currently, there is no cure for psoriasis and therapy is aimed at suppressing psoriatic 
lesions and relieving associated symptoms.4 de Jager et al.5 concluded in their systematic 
review that the treatment of choice in mild or moderate pediatric psoriasis should be 
topical treatment with calcipotriol, if necessary, combined with mild-to-moderate topical 
corticosteroids. 
 Recently, a two-compound ointment containing calcipotriol 50 μg g-1 and beta- 
metha sone dipropionate 0.5 mg g-1 has been developed in order to avoid separate 
applications and to improve patient compliance.6 Several studies in adults have already 
demonstrated that this combination of calcipotriol and betamethasone dipropionate is 
more effective than either of the individual components and is well tolerated in short-term 
follow-up.6-10 However, to date, evidence on the effectiveness and safety of calcipotriol/
betamethasone dipropionate ointment in pediatric psoriasis is lacking. In addition, there 
are no data on the daily clinical management of unselected pediatric patients with 
psoriasis, nor on long-term effectiveness and safety of this therapy in children. 
 In this study we aimed to evaluate the effectiveness and safety of calcipotriol/ 
betamethasone dipropionate ointment therapy in a prospective longitudinal cohort 
of pediatric patients with mild-to-moderate plaque psoriasis in daily clinical practice. 
In addition, we investigated the influence of this two-compound treatment option on the 
quality of life of those affected. 
Patients and methods
Study design
This study was a descriptive, single-group, prospective observational daily clinical practice 
study enrolling children with psoriasis treated with calcipotriol/betamethasone dipropionate 
ointment. This study was carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent.
Study population 
All children with psoriasis receiving calcipotriol/betamethasone dipropionate ointment at 
our medical center between September 2008 and June 2013 were enrolled in this study. 
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 Data were obtained from a prospective longitudinal pediatric psoriasis registry, called 
Child-CAPTURE (Continuous Assessment of Psoriasis Treatment Use Registry). The 
Child-CAPTURE was set up in September 2008 to monitor the effectiveness, safety and 
quality of life in all pediatric patients with psoriasis (age ≤ 18 years) who visited our 
outpatient clinic at the Radboud University Medical Center.3
 Exclusion criteria were: current use of calcipotriol/betamethasone dipropionate 
ointment prior to enrolment; use of systemic antipsoriatic treatment (and therefore 
patients with severe psoriasis and psoriatic arthritis), phototherapy, or dithranol therapy 
within 6 weeks before the start or during calcipotriol/betamethasone dipropionate 
ointment treatment; or absence of any follow-up visit. 
Study procedures 
At baseline patient characteristics were recorded, including age, sex, age at onset, family 
history, medical history, presence of psoriatic arthritis, present and previous antipsoriatic 
treatments on all areas of the body and concomitant medication. At each visit disease 
severity scores [Psoriasis Area and Severity Index (PASI), physician’s global assessment 
(PGA), body surface area (BSA), visual analogues scores (VAS) on itch and pain], concomitant 
therapies, a quality of life score [Children’s Dermatology Life Quality Index (CDLQI)] and 
the occurrence of (serious) adverse events were recorded. 
 In a daily clinical practice setting, patients were provided with the best treatment and 
care according to the physician’s opinion, but only two different treatment regimens were 
used dependent on the severity of psoriasis. In the more intensive treatment regimen 
patients were prescribed the ointment for once-daily use for 4 weeks, followed by 
prescription once daily four times per week. In the less intensive regimen patients were 
assigned to once-daily application four times per week directly from the start of treatment 
and thereafter. Appointments and the need for a new visit were made in dialogue with 
patient and parents; consequently follow-up was highly variable due to the daily clinical 
practice design.
 Use of topical treatments other than calcipotriol/betamethasone dipropionate ointment 
on the scalp, face, folds and genital areas was allowed. 
Outcome measures
The extent and the severity of the disease were assessed by a physician using the PASI 
(range 0–72).11 A six-point scale PGA was used by the physician as an overall assessment 
of the severity of psoriasis graded from 0 to 5 (‘clear’, ‘minimal’, ‘mild’, ‘moderate’, ‘severe’ or 
‘very severe’). Also, the percentage of the total body surface (BSA) affected by psoriasis 
was recorded. VAS (range 0-100) scores were recorded as a measure for severity of itch and 
pain resulting from psoriatic lesions. 
 To quantify the impact of psoriasis on the children’s quality of life, a validated Dutch 
version of the CDLQI was used (10 items; range 0–30).12, 13 Higher scores indicate more 
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impairment in quality of life. All adverse events noted by the investigator or addressed by 
the patient (or parents) were recorded. 
 The primary objective of this study was the change in PASI score compared with 
baseline. Secondary objectives included changes in BSA, PGA and VAS, improvement in 
quality of life and safety data on (serious) adverse events.
Statistical analysis
PASI scores were interpolated to obtain outcome measures at weeks 2, 4, 8, 12, 24 and 48 
after the start of treatment as time to follow-up in our cohort was variable due to the daily 
clinical setting. Analysis was made according to an as-treated principle (analysing 
continuing patients only according to follow-up). Subgroup analyses on PASI scores were 
performed on two groups with different treatment regimens.
 The secondary outcomes (PGA, BSA, VAS and CDLQI) were analysed at visits at 12 
weeks (window ± 4 weeks) using the Wilcoxon signed-rank test. If patients had multiple 
treatment episodes with the two-compound ointment, only the first episode was 
analysed, in order to avoid selection bias. All serious adverse events were recorded and 
the relationship with the use of study medication was described.
 P-values < 0.05 (two-sided) were considered statistically significant. The statistical 
analyses were performed using SPSS software 20.0 (IBM Corp., Armonk, NY, U.S.A.) and 
Microsoft Office Excel 2007 SP3 MSO (Microsoft Corporation, Redmond, WA, USA).
Results
Patients 
From September 2008, 147 children with psoriasis were prospectively treated with 
calcipotriol/ bethamethasone dipropionate ointment. A total of 73 patients were included 
in this study (Figure 1). Fifty-six per cent of the patients were female; the mean age at 
the start of calcipotriol/betamethasone dipropionate ointment was 10.8 years (Table 1).
 No significant differences were found between the patients in the two different 
treatment regimens with respect to age, sex, age at first diagnosis or duration in weeks 
of the two-compound ointment use. 
 The median duration of calcipotriol/betamethasone dipropionate assignment until 
data lock was 35 weeks (range 1-176). At the time of analysis, calcipotriol/betamethasone 
dipropionate ointment was prescribed to 34 patients (47%). In 17 patients (23%), the 
calcipotriol/betamethasone dipropionate ointment did not yield a sufficient response 
and was ceased, whereas in 12 patients (16%) in their opinion the ointment became 
redundant because of a successful response. Six patients (8%) admitted stopping the 
treatment because they were not motivated to apply the ointment. Two patients (3%) 
only used calcipotriol/betamethasone dipropionate ointment to tide them over a period 
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until the start of dithranol (anthralin) treatment. Two patients (3%) were lost to follow-up 
(Figure 1). 
 The median duration of calcipotriol/betamethasone dipropionate ointment use in the 
39 patients who stopped using the ointment was 22 weeks (range 1-141). Of the 17 patients 
who yielded an insufficient response, 11 switched to dithranol (anthralin) treatment, three to 
phototherapy and one to methotrexate. One patient tried another topical corticosteroid 
(mometasone furoate) with additional calcipotriol ointment and one patient switched to 
a two-compound ointment containing betamethasone dipropionate and salicylic acid. 
Table 1  Patient characteristics for the total study population (n = 73).
Characteristic
Sex, male, n (%) 32 (43.8)
Age at diagnosis (years), mean (range) 7.8 (1-16)
Age at starting use of ointment (years), mean (range) 10.8 (3-18)
Duration of calcipotriol/betamethasone dipropionate 
ointment use (weeks), median (range) 35.0 (1.0-176.0)
Calcipotriol/betamethasone dipropionate ointment 
discontinued, n (%)
No
Yes
34 (46.6)
39 (53.4)
Treatment regimen, n (%)
Starting once daily seven times per week during 4 weeks, 
followed by prescription once daily four times weekly
Starting once daily four times weekly and thereafter
50 (68.5)
23 (31.5)
With/without concomitant vitamin D ointment treatment 
3 days a week, n (%)
Without
With
26 (35.6)
47 (64.4)
Previous calcipotriol/betamethasone dipropionate 
ointment use, n (%)
No
Yes
40 (54.8)
33 (45.2)
Concomitant therapies on specific areas of the body, n (%)
Scalp
Face
Genital area
Folds 
Ears
64 (87.7)
41 (56.2)
16 (21.9)
3 (4.1)
20 (27.4)
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Primary outcomes 
The mean PASI score before treatment with calcipotriol/betamethasone dipropionate 
ointment was 5.2 (range 0-11.5). The mean PASI scores for the total population (n = 73) at 
weeks 2, 4, 8, 12, 24 and 48 are displayed in Figure 2. At 12 weeks, patients who were still 
treated (n = 61) achieved a decrease in mean PASI score of 15.4% (from 5.2 to 4.4). After 24 
weeks the mean PASI score was slightly decreased to 4.3 (range 0.3-8.9), which was a 
decrease from baseline of 17.3%. After 48 weeks the mean PASI score was 3.4 (range 0-7.3), 
which was a 34.6% improvement compared with baseline. However, at 48 weeks the PASI 
score was based on the data of only 25 patients. 
Figure 1   Flow chart on inclusion and exclusion of patients using calcipotriol/
betamethasone dipropionate ointment.
CAPTURE, Continuous Assessment of Psoriasis Treatment Use Registry; PASI, Psoriasis Area and Severity Index.
Calcipotriol/betamethasone dipropionate 
ointment treatment in the 
Child- CAPTURE registry
n = 147 patients
Patients included n = 73
Excluded:
No baseline PASI-score (e.g. phone contact), n = 5
No follow-up visit, n = 14 
Already on two-compound ointment prior to enrolment, n = 15
On systemic therapy, n = 12
No washout period after systemic therapy, n = 1 
On dithranol therapy, n = 5
No washout period after dithranol therapy, n = 16
Phototherapy, n = 2
No washout period after phototherapy, n = 4
74 patients excluded
At data lock, the two-compound ointment 
was stopped, n = 39
• Insufficient response, n = 17
• Redundant (patient´opinion), n = 12
• No motivation to apply, n = 6
• Use of the two-compound ointment to tide over a period 
until start dithranol, n = 2
• Lost to follow-up, n = 2
At data lock, the two-compound ointment 
was still prescribed, n = 34
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 In Figure 2 different lines are plotted for the total population and split for two different 
treatment regimens. Fifty patients (68%) were prescribed the more intensive treatment 
regimen starting with application of the ointment once daily for 4 weeks. Twenty-three 
patients (32%) were assigned to once-daily application four times per week directly from 
the start of treatment. As depicted in Figure 2, patients who were prescribed the more 
intensive treatment regimen had significant higher baseline PASI scores (mean PASI 6.1 vs. 
3.3). In this intensive treatment regimen group the mean PASI score decreased from 6.1 
(range 2.6-11.5) at baseline to 4.9 (1.9-8.9) after 24 weeks, which was a decrease of 19.7%. 
In the group with the less intensive treatment regimen the mean PASI score remained 
stable from 3.3 (0-8.7) at baseline to 3.3 (0.3-8.1) at 24 weeks. Of the earlier described 
17 patients who did not yield a sufficient response, two patients were prescribed the less 
intensive treatment regimen.
Secondary outcomes 
At baseline the median CDLQI score was 5.5 [interquartile range (IQR) 3.0-9.0] compared 
with a median CDLQI score of 4.0 (IQR 2.3-7.8) after 12 weeks (Table 2). This included 
an absolute improvement of 1.5 points, which was statistically significant (Table 2). The 
distribution of the PGA scores was not statistically different at 12 weeks treatment compared 
with baseline.
Figure 2   Psoriasis Area and Severity Index (PASI) score in time (as-treated analysis).
Treatment regimen A, starting once daily seven times per week for 4 weeks, followed by prescription once daily 
four times weekly; treatment regimen B, starting once daily four times weekly.
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 All children included in the study had < 30% of body involvement. The affected BSA 
barely differed before and after treatment. The median VAS on pain decreased from 2.0 
(IQR 0-15.5) to 0 (IQR 0-4.5) after 12 weeks, which was statistically significant. The median 
VAS on itch decreased from 33.0 (IQR 15.0-60.0) to 15.0 (IQR 3.5-43.0). Thirty-two patients 
reported both a CDLQI and a VAS itch at baseline and at week 12. At week 12, 50% of 
patients achieved CDLQI 0-1 and/or VAS itch ≤ 10 compared with 25% at baseline.
Safety
In total, five patients (7%) reported, or were observed to have, possible treatment-related 
adverse events. Four patients had striation of the skin: a 12-year-old girl had striations on 
the medial side of the upper legs after gaining weight in puberty; a 13-year-old girl had 
vertical striations on the upper legs and horizontal striations on the mammae and flanks; 
a 17-year-old boy had striations on the elbows and abdomen after gaining 10 kg in weight; 
and a 15-year-old boy had horizontal striations on the upper legs, arm pits and buttocks 
after a fast increase in body length. One girl experienced pain when applying the ointment 
at the location of a scar after surgery. No serious adverse events were reported.
Discussion
In this study we present a large, prospective, daily clinical practice cohort of pediatric 
patients with psoriasis with long-term follow-up. Several studies on calcipotriol/
betamethasone dipropionate ointment have been performed on adults, but nearly all of 
these focus on induction therapy only.6-10 Because of the chronic nature of the disease,14 
data on long-term effectiveness and safety are essential. Especially for children with 
mild-to-moderate psoriasis, more evidence on topical treatments is needed, as most of 
these children are primarily treated with topical treatment. 
Table 2  Secondary outcome measures for total population after 12 weeks of treatment.
Outcome 
measure 
n Median  
baseline score  
(IQR)
Median score  
after 12 weeks 
(IQR)
Absolute 
change in 
score 
P-valuea 
CDLQI 36 5.5 (3.0-9.0) 4.0 (2.3-7.8) -1.5 0.02*
PGA 41 2.0 (2.0-3.0) 2.0 (1.0-2.5) 0 0.68
BSA 41 4.5 (3.0-7.6) 4.9 (2.0-7.0) +0.4 0.72
VAS pain 33 2.0 (0-15.5) 0.0 (0-4.5) -2.0 0.04*
VAS itch 33 33.0 (15.0-60.0) 15.0 (3.5-43.0) -18.0 0.05
BSA, body surface area; CDLQI, Children’s Dermatology Life Quality Index; IQR, interquartile range; PGA, physician’s 
global assessment; VAS, visual analogue score; a Wilcoxon signed-rank test. * P < 0.05. 
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We found a decrease in mean PASI score of 15.4% and 17.3% at weeks 12 and 24, respectively, 
compared with baseline. This is less than observed in previous trials in which adults were 
treated with calcipotriol/betamethasone dipropionate ointment. 6-10 In these randomized 
controlled trials (RCTs), adult patients were treated for only 4-12 weeks and baseline PASI 
scores were mostly around 10. In these studies, 68.2-74.4% improvement from the baseline 
PASI score was found.6-10 As our study comprised children with mostly mild psoriasis,15 
the mean baseline PASI score was 5.2. With a PASI score near 3, the percentage of each 
segment affected with psoriasis is usually < 10%. Consequently, reductions in the area 
affected with psoriasis are usually not associated with improvements in PASI.7 Therefore, 
when scores are low, PASI may be a less precise tool for measuring the severity of psoriasis 
and effectiveness of a treatment.7,16 In addition, most of the studies in adults were clinical 
trials with a washout period not only for systemic, but also for topical treatments. As this 
is a daily clinical practice study, a washout period for topical corticosteroids was not 
performed.
 As stated before, the adult RCTs were performed over a relatively short period of 
time, with an active treatment period of only 4-12 weeks.6-10 In these studies, a rapid 
improvement of psoriasis was seen, even as soon as after 1 week of treatment.7-10 We also 
found that calcipotriol/ betamethasone dipropionate ointment seems to yield most of its 
effect in pediatric psoriasis in the first 12 weeks after the start of treatment. This may 
indicate that the largest effect of calcipotriol/ betamethasone dipropionate ointment is 
achieved in the first weeks. When used over a longer period as maintenance therapy it 
seems to stabilize psoriasis. In only one study, adult patients were followed for 52-weeks.17 
However, the main interest of that study was safety data; effectiveness was a secondary 
objective and only measured using PGA. The time between visits is a critical factor 
affecting adherence and outcomes.18 This study had fewer return visits than typical clinical 
trials do. Without those visits to drive adherence, patients probably do not use the 
medication nearly as well as they do in clinical trials.
 Subgroup analyses on the PASI score were performed based on a more or less 
intensive treatment regimen during the first 4 weeks of treatment. Patients who were 
prescribed the more intensive treatment regimen had higher baseline PASI scores and 
consequently yielded more effect from the two-compound ointment than the less 
intensively treated group (19.7% vs. 0%, respectively, after 24 weeks). Patients with more 
severe disease are likely to yield more effect from any treatment than less affected patients, 
in part because of regression to the mean, or to the greater sensitivity of the PASI in 
patients with more severe disease. 
 We recorded the CDLQI as a patient-reported outcome for quality of life at baseline 
and at 12 weeks follow-up. Despite a limited decrease in PASI score, the CDLQI decreased 
significantly after 12 weeks of treatment. 
 In our study possible treatment-related adverse events were reported in five children 
(7%), of which four had striation of the skin. Striae however, are common in adolescents 
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and occur frequently in association with adolescent growth spurts19 and obesity.20 
Because all of these children grew during the study period and had used other topical 
treatments in the past, it is questionable whether these striations were related to the use 
of calcipotriol/betamethasone dipropionate ointment or not. No serious adverse events 
were reported.  
 The daily clinical practice design of this study resulted in variable time to follow-up 
and consequently interpolated PASI scores. It has to be taken into account that the mean 
PASI score at 48 weeks of treatment was based on only 25 patients. Therefore, this score 
may be less reliable as the remaining population becomes different from the original one. 
This may lead to attrition bias and consequently the remaining results may not be 
generalizable to the original population. Another limitation of real clinical practice analysis 
in general is the absence of a control group or parallel treatment group to compare, and 
the fact that we do not have data on adherence. 
 In conclusion, this study comprised a large, prospective cohort of children with psoriasis 
in daily clinical practice with a long-term follow-up period. Treatment with calcipotriol/
betamethasone dipropionate ointment yielded a mild reduction in PASI score of 17.3% 
with only a few observed side effects and no severe adverse events. Our data indicate that 
this two-compound ointment first improves and then stabilizes mild-to-moderate plaque 
psoriasis during a long-term follow-up period in pediatric psoriasis. 
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Abstract
In 2008, a systematic review revealed that evidence-based data on efficacy and safety of 
treatments in pediatric psoriasis are scarce and with low level of evidence. In recent years, 
publications on this topic have increased exponentially. To present a systematic, 
evidence-based update on the efficacy and safety of systemic treatments in pediatric 
psoriasis and to provide treatment recommendations, an update of the previous review 
was performed. PubMed, EMBASE and the Cochrane Controlled Clinical Trial Register were 
searched between January 2007 and March 2014 for all available literature on efficacy and 
safety of all systemic treatments in pediatric psoriasis. The levels of evidence were 
determined on the Oxford Centre for Evidence-based Medicine Levels of Evidence. The 
newly retrieved evidence was combined with the evidence available in the former review. 
Fifty-two studies were included: 36 from the former review, plus 16 new articles. New 
evidence on induction therapy was mainly available on fumaric acid esters (FAE), which 
are shown to be effective in a subgroup of patients. Long-term (96 weeks) safety and 
efficacy data on etanercept were found. Prospective studies are scarce. Most conclusions 
are formulated on studies with low level of evidence. Of the conventional systemic 
treatments, methotrexate still has the most evidence albeit in a low number of patients 
and with a low level of evidence. FAE seem to be effective in a subgroup of patients, with 
gastrointestinal complaints, flushes and temporary shifts in leukocyte counts and liver 
enzymes being the main side effects. Etanercept has still accumulated most evidence of 
the available systematic treatments, with a large efficacy and reassuring safety profile in a 
96-week follow-up. 
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Introduction
Psoriasis is a chronic inflammatory skin disease that affects 2%-4% of the Caucasian 
population.1,2 In about 30% of these patients, the disease manifests during childhood.3 
Systemic treatments are indicated in children with moderate-to-severe psoriasis. To date, 
evidence on efficacy and safety of systemic treatments in pediatric psoriasis is limited and 
evidence-based guidelines are scarce.4 In 2010, our group published a systematic review 
of all available literature on efficacy and safety of treatments in pediatric psoriasis in the 
period January 1980 till September 2008.4 This review provided evidence-based recom-
mendations in which methotrexate (MTX) was considered the systemic therapy of choice, 
whereas retinoids should be considered in pustular and erythrodermic psoriasis. In 
exceptional cases, cyclosporine could be deliberated and etanercept was thought to be a 
third-line drug.4 
 Nowadays, the interest in pediatric psoriasis is emerging and the number of publications 
on systemic treatments in pediatric psoriasis has increased exponentially.5-14 Therefore, 
the present review aims to present a systematic update on efficacy and safety of all systemic 
treatments in pediatric psoriasis in order to provide evidence-based recommendations 
with grading of evidence for this specific patient-group. 
Methods
The literature on treatments between 1980 and September 2008 has already been 
searched and reviewed in a former publication.4 Therefore, we conducted an extensive 
search on all available literature concerning systemic treatments of pediatric psoriasis, 
published between January 2007 and March 2014, on PubMed, EMBASE and the Cochrane 
Controlled Clinical Trial Register. To avoid an inaccurate lack of evidence, publication date 
was extended to January 2007, to include an overlapping time-frame. The search strategy 
and eligibility criteria were identical to our former study,4 to which we refer for further 
information. In the present study, only systemic therapy was searched for.
 After the initial search was performed, two reviewers (M.v.G and K.M.) independently 
screened titles and abstracts for inclusion and exclusion. Of the 1008 studies found 
between January 2007 and March 2014, in total 47 articles were assessed full-text. Of these 
47 articles, 31 were excluded as they did not fit the inclusion criteria or they were already 
assessed in the previous search.4 Finally, 16 articles were included in the new search. In 
addition, the previously found 36 full-text articles from the period between 1980 and 
September 2008 were assessed again. Thus, in total, 52 articles (16 new articles plus the 36 
articles from the previous review) were included in this review. 
 A pre-designed data extraction form was used by the same two reviewers to 
independently extract and record the data from each full-text article. If no consensus was 
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reached, a third investigator (M.S.) was consulted. Levels of Evidence (LOEs) (Table 1) and 
grading recommendations (A-D) (Table 2) were determined according to the Oxford 
Centre for Evidence-based Medicine Levels of Evidence.15
Table 1  Level of evidence (LOE).
1a Systematic review of RCTs
1b Individual RCT
2a Systematic review of cohort studies
2b Individual cohort study (including low quality RCT)
3a Systematic review of case-control studies
3b Individual case-control study
4 Case series
5 Case reports, expert opinion
Adapted from ‘Oxford Centre for Evidence-based Medicine Levels of Evidence’ version May 2001.15
RCT, Randomized controlled trial.
Table 2  Grades of recommendation.
A Studies with consistent LOE 1a and/or 1b (see Table 1) 
B Studies with consistent LOE 2a, 2b, 3a, or 3b; or extrapolations from studies with LOE 1a or 1b
C Studies with LOE 4 or extrapolations from studies with LOE 2a, 2b, 3a, or 3b.
D Studies with LOE 5 or troublingly inconsistent or inconclusive studies of any level
Adapted from ‘Oxford Centre for Evidence-based Medicine Levels of Evidence’ version May 2001.15
LOE, Level of evidence.
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Results
The details on all 52 included studies are summarized in Table 3. In the section below, a 
short summary of the previous review4 and the new evidence is described. The recom-
mendations are based on all 52 included studies. 
Antibiotics
The previous review included five studies16-20 in which 14 pediatric patients with psoriasis 
were treated with antibiotics. It was concluded that the efficacy of the use of antibiotics in 
pediatric guttate psoriasis remains controversial.4 
 In the present review no new articles were included. 
Conclusion 
Grade C. 
Number of patients treated with antibiotics: 14. 
The efficacy of the use of antibiotics in pediatric guttate psoriasis still remains controversial.4
Retinoids
Previous review described six studies21-26 with a total of 21 children treated with etretinate. 
Etretinate was considered to be an effective treatment for pustular and erythrodermic psoriasis 
but side effects were frequently seen,4 being cheilitis, pruritus and hairloss.21-23,25 The use of 
acitretin had not been sufficiently investigated, therefore no conclusions could be drawn.4 
 In the present review, eight new studies on the use of retinoids were identified.27-34 
Five studies were excluded because of systemic antipsoriatic combination therapy27,30-33 
and one study because of an unclear treatment regimen.34 One case report28 (LOE5) 
described clearance after 6 weeks of treatment with acitretin 1 mg/kg/day in a 6-weeks-old 
girl with generalized pustular psoriasis (GPP); safety data were not reported. The occurrence of 
a pseudotumour cerebri in a 12-year-old boy with GPP using oral acitretin 25-35 mg/day was 
presented in another case report; efficacy data were not included in this review due to 
an unclear outcome measure (LOE5).29 As the two new cases described the use of acitretin 
in GPP, the evidence on the efficacy and safety of retinoids is still mainly shown in pustular 
and erythrodermic pediatric psoriasis.
Conclusion 
Grade C. 
Number of patients treated with retinoids: 24. 
In pustular and erythrodermic pediatric psoriasis, retinoids are an effective treatment with 
frequently reported side effects.4 Most evidence is still available on etretinate. As the use 
of acitretin is only described in three cases, no conclusions could be drawn. 
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Table 3  Summary of included studies.
Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
Antibiotics
Thiamphenicol Juanqin et al.16 4 GPP (2) RCS 2 (2-12 y) 20 mg/kg/d - < 50% Clearance: 100% Gastrointestinal disturbance
Amoxicillin/ 
clavulanic acid
Pacifico et al.17 5 GP (1) CR 1 (7 y) 50 mg/kg/d 20 d Cleared: 100% n.m.
Erythromycin Patrizi et al.18 4 GP (4) CS 4 (5-10 y) 50mg/kg/d 2 wk Psoriasis completely 
resolved: 100% 
n.m.
Rifampin Rosenberg et al.19 4 GP (3); PP (1) RCT 4 (5-10 y) 5 d Excellent response: 25%; 
Good response: 75%
n.m.
Erythromycin or 
penicillin V with 
addition of rifampin
Vincent et al.20 4 GP (3) OL 3 (12-15 y) 14 d No clinical change: 100% n.m.
Retinoids
Acitretin Chao et al.28 5 GPP (1) CR 1 (6 wk) 1 – 0.4 mg/kg/d 34 wk
(6 wk to 
normalize)
Clearance: 100% n.m.
Acitretin Sarkar et al.29 5 GPP (1) CR 1 (12 y) 25-35 mg/d 6 wk Excluded Pseudotumour cerebri
Acitretin Salleras et al.24 5 EP (1) CR 1 (4 y) 0.5 -0.75 mg/kg/d 3 mo Complete remission: 100% No secondary effects
Etretinate Rosinska et al.25 4 EP (5); GPP (5) RCS 10 (3-15 y) 1 – 0.2 mg/kg/d 3 wk -12+ mo EP: 2x complete clearing; 
3x improvement; GPP: 5x 
complete clearing
Pruritus (8); cheilitis (7); skin 
fragility (7); hair loss (2); 
musculoskeletal pain (2). Focal 
osteoporosis of left tibia (1). 
Elevated serum transaminases 
level and positive hepatitis B 
s-antigen, developed 
glomerulonefritis preceded by 
varicella (1)
Etretinate van de Kerkhof26 5 GPP (1) CR 1 (1 y) 10 mg/d 3 mo Complete clearance: 100% No adverse effects related to 
etretinate
Etretinate Pavicic et al.23 4 GPP (5) CS 5 (3- 11 y) 1 mg/kg /d - Complete and 
significant regression of 
erythroderma: 100%
Cheilitis (2); pruritus (1), transient 
diffuse effluvium (1); paronychia 
(1)
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osteoporosis of left tibia (1). 
Elevated serum transaminases 
level and positive hepatitis B 
s-antigen, developed 
glomerulonefritis preceded by 
varicella (1)
Etretinate van de Kerkhof26 5 GPP (1) CR 1 (1 y) 10 mg/d 3 mo Complete clearance: 100% No adverse effects related to 
etretinate
Etretinate Pavicic et al.23 4 GPP (5) CS 5 (3- 11 y) 1 mg/kg /d - Complete and 
significant regression of 
erythroderma: 100%
Cheilitis (2); pruritus (1), transient 
diffuse effluvium (1); paronychia 
(1)
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Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
Retinoids
Etretinate Kim et al.22 4 EP (3) OL 3 (10-12 y) 0.5-0.9 mg/kg/d 4-5 mo Clearance erythema and 
scaling: 100%
Cheilitis (3), skin fragility, hair loss 
and pruritus described in whole 
cohort
Etretinate Van der Rhee  
et al.21
4 PP (2) CS 2 (8 y) 25 mg/d 
(maintenance 12.5 
mg/d)
13-17 mo Excellent: 100% Moderate cheilitis (1)
Cyclosporine
Cyclosporine A Kilic et al.35 4 GPP (3) CS 3 (10 mo – 6 y) 1-2 mg/kg/d 12, 6, 5 mo Almost completely 
disappeared: 33%; 
Completely disappeared 
66%
No side effects
Cyclosporine Alli et al.36 5 GPP (1) CR 1 (9 y) 3 mg/ kg/d 11 mo; 2 wk to 
control
Free of psoriasis: 100% n.m.
Cyclosporine Torchia et al.37 5 Photosensitive 
psoriasis (1)
CR 1 (15 y) 3.5 mg/kg/d 3 wk Lesions healed: 100% n.m.
Cyclosporine Mahe et al.38 4 PPP (1); EP (1); PP 
(1); GPP (1)
CS 4 (2-10 y) 2.5-10 mg/kg/d 3.5-6 mo No response: 100% n.m.
FAE Highest  
daily dose:
FAE Balak et al.44 2b PP (11); PP + GP 
(2); PP + PPP (1)
RCS 14 (8- 17 y) 120-720 mg/d 1-80 mo 
(median 10 
mo)
Complete clearance: 36% 
(5/14); good improvement 
(PASI 82): 7% (1/14); partial 
response: 21% (3/14); 
non-response: (5/14) 36% 
including increase in PASI 
in 2 patients (27% and 
31% increase resp.) 
Abdominal cramps (5); diarrhea 
(4); flushes (2); nausea (1); 
bronchitis (1); fatigue (1); elevated 
liver function- tests (3); mild 
temporary shifts in leukocyte 
counts (3); mild increase in serum 
creatinine level (1); transient mild 
proteinuria (+1) (1) 
FAE Gerdes et al.45 5 PP (1) CR 1 (11 y) 480 mg/d 
(maintenance 
dose120- 240 
mg/d) 
3 y PASI 20.2 → 0.8 
(3 mo)
BSA 20% → 1% 
(3 mo)
Abdominal discomfort and 
flushes; reduction of lymphocytes
FAE Steeman et al.46 5 NS (1) CR  1 (15 y) 480 mg/d; 
maintenance dose 
120-240 mg/d)
20 mo Clearance: 100% Abdominal cramps (1)
FAE Günther et al.43 5 PP (1) CR 1 (14 y) 240mg/d - PASI 19.7 → 1 (16 wk) Reversible lymphopenia
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Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
Retinoids
Etretinate Kim et al.22 4 EP (3) OL 3 (10-12 y) 0.5-0.9 mg/kg/d 4-5 mo Clearance erythema and 
scaling: 100%
Cheilitis (3), skin fragility, hair loss 
and pruritus described in whole 
cohort
Etretinate Van der Rhee  
et al.21
4 PP (2) CS 2 (8 y) 25 mg/d 
(maintenance 12.5 
mg/d)
13-17 mo Excellent: 100% Moderate cheilitis (1)
Cyclosporine
Cyclosporine A Kilic et al.35 4 GPP (3) CS 3 (10 mo – 6 y) 1-2 mg/kg/d 12, 6, 5 mo Almost completely 
disappeared: 33%; 
Completely disappeared 
66%
No side effects
Cyclosporine Alli et al.36 5 GPP (1) CR 1 (9 y) 3 mg/ kg/d 11 mo; 2 wk to 
control
Free of psoriasis: 100% n.m.
Cyclosporine Torchia et al.37 5 Photosensitive 
psoriasis (1)
CR 1 (15 y) 3.5 mg/kg/d 3 wk Lesions healed: 100% n.m.
Cyclosporine Mahe et al.38 4 PPP (1); EP (1); PP 
(1); GPP (1)
CS 4 (2-10 y) 2.5-10 mg/kg/d 3.5-6 mo No response: 100% n.m.
FAE Highest  
daily dose:
FAE Balak et al.44 2b PP (11); PP + GP 
(2); PP + PPP (1)
RCS 14 (8- 17 y) 120-720 mg/d 1-80 mo 
(median 10 
mo)
Complete clearance: 36% 
(5/14); good improvement 
(PASI 82): 7% (1/14); partial 
response: 21% (3/14); 
non-response: (5/14) 36% 
including increase in PASI 
in 2 patients (27% and 
31% increase resp.) 
Abdominal cramps (5); diarrhea 
(4); flushes (2); nausea (1); 
bronchitis (1); fatigue (1); elevated 
liver function- tests (3); mild 
temporary shifts in leukocyte 
counts (3); mild increase in serum 
creatinine level (1); transient mild 
proteinuria (+1) (1) 
FAE Gerdes et al.45 5 PP (1) CR 1 (11 y) 480 mg/d 
(maintenance 
dose120- 240 
mg/d) 
3 y PASI 20.2 → 0.8 
(3 mo)
BSA 20% → 1% 
(3 mo)
Abdominal discomfort and 
flushes; reduction of lymphocytes
FAE Steeman et al.46 5 NS (1) CR  1 (15 y) 480 mg/d; 
maintenance dose 
120-240 mg/d)
20 mo Clearance: 100% Abdominal cramps (1)
FAE Günther et al.43 5 PP (1) CR 1 (14 y) 240mg/d - PASI 19.7 → 1 (16 wk) Reversible lymphopenia
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Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
MTX
MTX Collin et al.47 4 PP (11), 
Suberytrodermic 
(2)
RCS 13 (5-16 y) 0.03-0.41 mg/kg/wk 2-267 wk 
(mean 71 wk)
Good response: 10 (76.9%); 
moderate 
response: 1 (7.7%); poor 
response: 1 (7.7%).
Raised liver enzymes (9), gastro-
intestinal symptoms (6), mouth 
ulcers and easy bruising (1), 
transient nocturnal cough and 
leg pains (1)
MTX Kaur et al.48 4 PPP (1); EP (3); PP 
(17); GPP (3)
RCS 24 (2-14 y) 0.2-0.4 mg/kg/wk 2-16 mo 
(mean 4.97)
PASI 75: 91.7%;  
PASI 50-75: 8.3%
Nausea, vomiting, and loss of 
appetite: 9/24 (37.5%)
MTX Kumar et al.49 4 EP (3); PP (2); GPP 
(2)
RCS 7 (3-16 y) 0.2-0.4 mg/kg/wk 6-10 wk to 
control (mean 
7.9): duration 
31.2-46.4 wk 
(mean 38.8)
>75% Clearance: 100% Nausea and vomiting 3/7 (42.9%). 
MTX Juanqin et al.16 4 GPP (4) RCS 4 (2-12 y) 0.2-0.4 mg/kg/wk - >80% Clearance: 100% n.m.
MTX Kalla and Goyal.50 5 GPP (1) CR 1 (4 y) 0.2 mg/kg/wk ≥10 wk Marked improvement: 
100%
n.m.
MTX Dogra et al.52 5 GPP (1) CR 1 (2 y) 0.4 mg/kg/wk - Clearance of pustules: 
100%
No side effects
MTX Dogra et al.51 5 GPP (1) CR 1 (4 y) 0.3 mg/kg/wk 12 wk Almost complete 
remission: 100%
No side effects
MTX Ivker et al.53 5 GPP (1) CR 1 (3 mo) 0.3 -0.5 mg/kg/
wk im 
4 wk Clearing: 100% n.m.
Biologics
Adalimumab Alvarez et al.82 5 GPP (1) CR 1 (13 y) 40 mg sc week 0, 
1; thereafter every 
2 wk
15 mo BSA >90% (8 wk); 
clearance (16 wk)
n.m. 
Adalimumab Dini et al.83 5 ACH (1) CR 1 (9 y) 80 mg sc week 0; 40 
mg wk 1; thereafter 
40 mg every 2 wk
12 mo PP- PASI 62 → 6 (4 wk); 
Complete resolution of 
clinical aspects (8 wk)
No adverse events
Etanercept Beikert et al.69 4 PP (4)
EP (4)
RCS 8 (7-16 y) 0.8 mg/kg/wk 5-16 mo 
(median  
11 mo)
PASI-75: 75% (12 wk) Injection site reaction n = 2
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Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
MTX
MTX Collin et al.47 4 PP (11), 
Suberytrodermic 
(2)
RCS 13 (5-16 y) 0.03-0.41 mg/kg/wk 2-267 wk 
(mean 71 wk)
Good response: 10 (76.9%); 
moderate 
response: 1 (7.7%); poor 
response: 1 (7.7%).
Raised liver enzymes (9), gastro-
intestinal symptoms (6), mouth 
ulcers and easy bruising (1), 
transient nocturnal cough and 
leg pains (1)
MTX Kaur et al.48 4 PPP (1); EP (3); PP 
(17); GPP (3)
RCS 24 (2-14 y) 0.2-0.4 mg/kg/wk 2-16 mo 
(mean 4.97)
PASI 75: 91.7%;  
PASI 50-75: 8.3%
Nausea, vomiting, and loss of 
appetite: 9/24 (37.5%)
MTX Kumar et al.49 4 EP (3); PP (2); GPP 
(2)
RCS 7 (3-16 y) 0.2-0.4 mg/kg/wk 6-10 wk to 
control (mean 
7.9): duration 
31.2-46.4 wk 
(mean 38.8)
>75% Clearance: 100% Nausea and vomiting 3/7 (42.9%). 
MTX Juanqin et al.16 4 GPP (4) RCS 4 (2-12 y) 0.2-0.4 mg/kg/wk - >80% Clearance: 100% n.m.
MTX Kalla and Goyal.50 5 GPP (1) CR 1 (4 y) 0.2 mg/kg/wk ≥10 wk Marked improvement: 
100%
n.m.
MTX Dogra et al.52 5 GPP (1) CR 1 (2 y) 0.4 mg/kg/wk - Clearance of pustules: 
100%
No side effects
MTX Dogra et al.51 5 GPP (1) CR 1 (4 y) 0.3 mg/kg/wk 12 wk Almost complete 
remission: 100%
No side effects
MTX Ivker et al.53 5 GPP (1) CR 1 (3 mo) 0.3 -0.5 mg/kg/
wk im 
4 wk Clearing: 100% n.m.
Biologics
Adalimumab Alvarez et al.82 5 GPP (1) CR 1 (13 y) 40 mg sc week 0, 
1; thereafter every 
2 wk
15 mo BSA >90% (8 wk); 
clearance (16 wk)
n.m. 
Adalimumab Dini et al.83 5 ACH (1) CR 1 (9 y) 80 mg sc week 0; 40 
mg wk 1; thereafter 
40 mg every 2 wk
12 mo PP- PASI 62 → 6 (4 wk); 
Complete resolution of 
clinical aspects (8 wk)
No adverse events
Etanercept Beikert et al.69 4 PP (4)
EP (4)
RCS 8 (7-16 y) 0.8 mg/kg/wk 5-16 mo 
(median  
11 mo)
PASI-75: 75% (12 wk) Injection site reaction n = 2
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Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
Biologics
Etanercept Fabrizi et al.63 5 EP (1) CR 1 (22 mo) 0.4 mg/kg b.i.w., ≥ 
12 wk once weekly
6 mo At week 12:
PASI 37 → 1.2 
BSA 80% → 7% 
No considerable side effects
Etanercept Farnsworth et al.66 5 PP (1) CR 1 (14 y) 25 mg b.i.w. 8 mo No improvement:100%
 
Without side effects
Etanercept Fotiadou et al.79 5 PP (1) CR 1 (14 y) 0.8 mg/kg/wk 16 wk PASI 18 → 15.8 
(16 wk)
n.m. 
Etanercept Hoang and 
Burruss.62
5 PP (1) CR 1 (14 y) 25 mg b.i.w. 8 mo Clearance of all lesions 
except those plaques on 
elbows and knees: 100%
Localized cutaneous 
Cryptococcus albidus infection 
scalp 
Etanercept Kress et al.67 4 PP (3) CS 3 (9-18 y) 0.4 mg/kg b.i.w. 
(<50 kg) or max  
50 mg/wk
27; 27; 30 mo PGA almost clear: 100% Injection site reaction n = 1 in 
whole cohort
Etanercept Mazzotta et al.73 5 PPP (1) CR 1 (11 y) 0.4 mg/kg b.i.w. 1) 48 wk
2) 288 wk 
1)  PASI 25.8 → 0 (12 wk);  
0 (48 wk)
2)  PASI 21.7 → 1.2 (12 wk); 
0 (48 wk); 0 (288 wk) 
Adverse events have not been 
noticed or reported
Etanercept Paller et al.61 1b PP (211); treated 
(106), placebo 
(105)
RCT 211 (4-17 y) 0.8 mg/kg/wk, max 
50 mg
48 wk; 12 
double 
blinded, 24 
open label 
etanercept, 
12 double 
blinded
Week 12
PASI 90: 27%;
PASI 75: 57%;
PASI 50: 75%; Mean 
improvement in PASI: 68%; 
PGA (almost) clear: 53%
Week 24:
PASI 75: 69%; Mean 
improvement in PASI: 77%; 
PGA (almost) clear: 57%
Week 36:
PASI 75: 68%; Mean 
improvement in PASI: 77%; 
PGA (almost) clear: 53%
Non-infectious AEs: 
287.6 per 100 patient-years
Infections: 229.3 per  
100 patient-years
Total AEs: 554.5 per  
100 patient-years
No SAEs up to wk 12.
Wk 12-36: 
Removal of ovarian cyst (1)
Concurrent infectious 
gastroenteritis and associated 
dehydration (1)
Basilar pneumonia (1)
Siegfried et al.78 PP (138);  
treated (69), 
placebo (69)
138 (4-17 y) 12 wk (after 
12 wk double 
blinded, 24 
open label ETN)
ETN group:
Week 48:
PASI 75: 80%
PGA (almost) clear: 58%
No SAEs, no serious infections
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Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
Biologics
Etanercept Fabrizi et al.63 5 EP (1) CR 1 (22 mo) 0.4 mg/kg b.i.w., ≥ 
12 wk once weekly
6 mo At week 12:
PASI 37 → 1.2 
BSA 80% → 7% 
No considerable side effects
Etanercept Farnsworth et al.66 5 PP (1) CR 1 (14 y) 25 mg b.i.w. 8 mo No improvement:100%
 
Without side effects
Etanercept Fotiadou et al.79 5 PP (1) CR 1 (14 y) 0.8 mg/kg/wk 16 wk PASI 18 → 15.8 
(16 wk)
n.m. 
Etanercept Hoang and 
Burruss.62
5 PP (1) CR 1 (14 y) 25 mg b.i.w. 8 mo Clearance of all lesions 
except those plaques on 
elbows and knees: 100%
Localized cutaneous 
Cryptococcus albidus infection 
scalp 
Etanercept Kress et al.67 4 PP (3) CS 3 (9-18 y) 0.4 mg/kg b.i.w. 
(<50 kg) or max  
50 mg/wk
27; 27; 30 mo PGA almost clear: 100% Injection site reaction n = 1 in 
whole cohort
Etanercept Mazzotta et al.73 5 PPP (1) CR 1 (11 y) 0.4 mg/kg b.i.w. 1) 48 wk
2) 288 wk 
1)  PASI 25.8 → 0 (12 wk);  
0 (48 wk)
2)  PASI 21.7 → 1.2 (12 wk); 
0 (48 wk); 0 (288 wk) 
Adverse events have not been 
noticed or reported
Etanercept Paller et al.61 1b PP (211); treated 
(106), placebo 
(105)
RCT 211 (4-17 y) 0.8 mg/kg/wk, max 
50 mg
48 wk; 12 
double 
blinded, 24 
open label 
etanercept, 
12 double 
blinded
Week 12
PASI 90: 27%;
PASI 75: 57%;
PASI 50: 75%; Mean 
improvement in PASI: 68%; 
PGA (almost) clear: 53%
Week 24:
PASI 75: 69%; Mean 
improvement in PASI: 77%; 
PGA (almost) clear: 57%
Week 36:
PASI 75: 68%; Mean 
improvement in PASI: 77%; 
PGA (almost) clear: 53%
Non-infectious AEs: 
287.6 per 100 patient-years
Infections: 229.3 per  
100 patient-years
Total AEs: 554.5 per  
100 patient-years
No SAEs up to wk 12.
Wk 12-36: 
Removal of ovarian cyst (1)
Concurrent infectious 
gastroenteritis and associated 
dehydration (1)
Basilar pneumonia (1)
Siegfried et al.78 PP (138);  
treated (69), 
placebo (69)
138 (4-17 y) 12 wk (after 
12 wk double 
blinded, 24 
open label ETN)
ETN group:
Week 48:
PASI 75: 80%
PGA (almost) clear: 58%
No SAEs, no serious infections
503687-L-bw-van Geel
64
chapter 2
Table 3  Continued.
Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
Biologics
Paller et al.75 PP (182) 182 (4-17 y) 96 wk (open 
label extension 
after 48 wk 
RCT)
PASI 90: 30%; PASI 75: 
61%; PASI 50: 89%; Mean 
improvement in PASI: 75.4%; 
PGA (almost) clear: 47%
5 SAEs not considered to be related 
to ETN 
80.1% (n= 145) one or more AE.
Etanercept Papoutsaki et al.64 4 PP (2)
PPP (1)
GPP and EP (1)
CS 4 (6-15 y) 0.4 mg/kg b.i.w. 24-86+ wk PASI 25.8 → 0 (GPP and 
EP); PASI 21.2 → 0 (PP); 
PASI 27.4 → 5.9 (PP);  
PASI 9.2 → 2.2 (PPP) 
No adverse events
Etanercept Ruiz et al.77 4 PP (3) RCS 3 (3-12 y) 25 mg/wk 1 y PASI 75: 100% Mild injection site reaction 
Etanercept Sachdev et al.80 5 PP (1) CR 1 (14 y) 50 mg/wk 8 mo Almost cleared: 100% < 12-48 hours headache, fever, 
neutropenia
Etanercept Safa et al.65 5 EP (1) CR 1 (7 y) 0.4 mg/kg, b.i.w. ≥ 6 mo Significant clinical 
improvement: 100%
Treatment was well tolerated 
without any adverse reactions. 
Infliximab Farnsworth et al.66 5 PP (1) CR 1 (14 y) 5 mg/kg ≥ 6 wk Marked clearing of 
psoriasis: 100%
Without complications
Infliximab Menter and 
Cush.88
5 PP and PPP (1) CR 1 (13 y) 3.3 mg/kg ≥ 30 wk Trunk and limb plaques 
cleared, with significant 
improvement of 
palmoplantar disease: 100%
Without side effects
Infliximab Pereira et al. 87 5 GPP (1) CR 1 (3 y) 5 mg/kg 10 mo Completely clear: 100% in 
2 wk, after 13 wk flare, after 
10 mo insufficient effect
No adverse events
Infliximab Weishaupt et al.86 5 GPP (1) CR 1 (16 y) 5 mg/kg 1 
administration
Pustules resolved, 
erythema lightened: 100% 
Neither patient experienced 
adverse drug effects
Ustekinumab Dixit et al.85 5 PP (1) CR 1 (16 y) 90 mg 18 mo PASI 100: 100%  
(PASI 21.2 → 0 at week 8)
No side effects
Ustekinumab Fotiadou et al.79 5 PP (1) CR 1 (14 y) 45 mg 1y PASI 90: 100% at week 16; 
PASI 100 at 1y  
(PASI 15.8 → 0 at 1y)
No adverse events
Colchicine Zachariae et al.97 5 GPP (1) OL 1 (12 y) 0.5 mg b.i.d. - Symptoms disappeared: 
100%
Mild abdominal discomfort (1)  
in whole cohort
Colchicine Wahba and 
Cohen.98
5 GP and PP (1) OL 1 (4 y) 0.25 mg t.i.d. 2 mo Excellent: 100% Mild gastrointestinal symptoms 
in whole cohort
ACH, acrodermatitis continua of hallopeau; AEs, adverse events; b.i.d., two times a day; b.i.w., twice weekly; BSA, 
body surface area; CR, case report; CS, case series; d, days; EP, erythrodermic psoriasis; ETN, etanercept; FAE, 
fumaric acid esters; GP, guttate psoriasis; GPP, pustular psoriasis; im, intramuscular; LOE, level of evidence; mo, 
months; MTX, methotrexate; n.m., not mentioned; NS, not specified; OL, open-label trial; PASI, Psoriasis Area and 
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Treatment Author LOE Diagnosis 
(no. of patients)
Study 
type
No. of patients 
(age) 
Dose regimen Duration of 
treatment
Outcome Safety
Biologics
Paller et al.75 PP (182) 182 (4-17 y) 96 wk (open 
label extension 
after 48 wk 
RCT)
PASI 90: 30%; PASI 75: 
61%; PASI 50: 89%; Mean 
improvement in PASI: 75.4%; 
PGA (almost) clear: 47%
5 SAEs not considered to be related 
to ETN 
80.1% (n= 145) one or more AE.
Etanercept Papoutsaki et al.64 4 PP (2)
PPP (1)
GPP and EP (1)
CS 4 (6-15 y) 0.4 mg/kg b.i.w. 24-86+ wk PASI 25.8 → 0 (GPP and 
EP); PASI 21.2 → 0 (PP); 
PASI 27.4 → 5.9 (PP);  
PASI 9.2 → 2.2 (PPP) 
No adverse events
Etanercept Ruiz et al.77 4 PP (3) RCS 3 (3-12 y) 25 mg/wk 1 y PASI 75: 100% Mild injection site reaction 
Etanercept Sachdev et al.80 5 PP (1) CR 1 (14 y) 50 mg/wk 8 mo Almost cleared: 100% < 12-48 hours headache, fever, 
neutropenia
Etanercept Safa et al.65 5 EP (1) CR 1 (7 y) 0.4 mg/kg, b.i.w. ≥ 6 mo Significant clinical 
improvement: 100%
Treatment was well tolerated 
without any adverse reactions. 
Infliximab Farnsworth et al.66 5 PP (1) CR 1 (14 y) 5 mg/kg ≥ 6 wk Marked clearing of 
psoriasis: 100%
Without complications
Infliximab Menter and 
Cush.88
5 PP and PPP (1) CR 1 (13 y) 3.3 mg/kg ≥ 30 wk Trunk and limb plaques 
cleared, with significant 
improvement of 
palmoplantar disease: 100%
Without side effects
Infliximab Pereira et al. 87 5 GPP (1) CR 1 (3 y) 5 mg/kg 10 mo Completely clear: 100% in 
2 wk, after 13 wk flare, after 
10 mo insufficient effect
No adverse events
Infliximab Weishaupt et al.86 5 GPP (1) CR 1 (16 y) 5 mg/kg 1 
administration
Pustules resolved, 
erythema lightened: 100% 
Neither patient experienced 
adverse drug effects
Ustekinumab Dixit et al.85 5 PP (1) CR 1 (16 y) 90 mg 18 mo PASI 100: 100%  
(PASI 21.2 → 0 at week 8)
No side effects
Ustekinumab Fotiadou et al.79 5 PP (1) CR 1 (14 y) 45 mg 1y PASI 90: 100% at week 16; 
PASI 100 at 1y  
(PASI 15.8 → 0 at 1y)
No adverse events
Colchicine Zachariae et al.97 5 GPP (1) OL 1 (12 y) 0.5 mg b.i.d. - Symptoms disappeared: 
100%
Mild abdominal discomfort (1)  
in whole cohort
Colchicine Wahba and 
Cohen.98
5 GP and PP (1) OL 1 (4 y) 0.25 mg t.i.d. 2 mo Excellent: 100% Mild gastrointestinal symptoms 
in whole cohort
Severity Index; PGA, Physician Global Assessment; PP, plaque psoriasis; PPP, palmoplantar psoriasis; PP-PASI, 
Palmoplantar Pustular Psoriasis Area and Severity Index; RCS, retrospectively reviewed case series; RCT, 
randomized controlled trial; SAEs, serious adverse events; sc, subcutaneous; t.i.d., three times a day; wk, weeks; y, 
years; -, unknown; italicized, same cohort described in the original study from Paller et al., 200861.
503687-L-bw-van Geel
66
chapter 2
Cyclosporine
In former review four studies35-38 were included, based on which cyclosporine treatment 
was considered to be ambiguous. Description of safety profiles was rare.4 In the present 
review four new studies39-42 were found. All were excluded because of the use of systemic 
antipsoriatic combination therapy39 (n = 1), unclear outcome measure (n = 1)40 and a 
combination of these (n = 2).41,42 
Conclusion 
Grade C. 
Number of patients treated with cyclosporine: 9. 
As a new recommendation with respect to the use of cyclosporine in the treatment of 
pediatric psoriasis cannot be made, the described efficacy of cyclosporine treatment still 
remains ambiguous. Safety issues were sparsely described.4
Fumaric acid esters (fumarates)
In the former review, fumaric acid esters (FAE) were not described, as at that time only one 
case report existed.43 Between 2008 and 2014 three new studies44-46 were published. All 
four articles were included: three case reports (LOE5)43,45,46 and one case series (LOE2b).44 
In two case reports, more than 90% improvement in Psoriasis Area and Severity Index 
(PASI) was achieved after 16 weeks43 and 3 months45 respectively. In one patient FAE were 
continued for more than 3 years.45 Another case report described 100% clearance after 3 
months.46 The retrospective case series44 of 14 children denotes complete clearance in 
36% of patients, good improvement (more than 80% in PASI) in 7%, partial response in 
21% and non-response in 36%. FAE were given in a starting dose of dimethylfumarate 30 
mg, with an incremental increase up to a maximum daily dosage of 720 mg based on 
clinical response and tolerability.44 Duration of treatment was up to 80 months (median 10 
months).44
 Abdominal cramps, diarrhea, transient shifts in leukocyte counts, temporary elevated 
liver function tests and flushes were the most frequently reported side effects.43-46 Mild 
increase in the serum creatinine level was reported in one patient44 and transient mild 
proteinuria in another patient.44 
Conclusion 
Grade C. 
Number of patients treated with FAE: 17. 
FAE are effective in a subgroup of patients with the main side effects being gastrointestinal 
complaints, transient shifts in leukocyte counts, transient elevated liver function tests and 
flushes. 
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Methotrexate
Former review included eight studies,16,47-53 based on which MTX was considered to be 
effective in moderate to severe pediatric psoriasis. Mild to severe nausea and vomiting 
were the most frequently reported side effects.4 
 In our search nine31,33,54-60 new publications were found. All studies were excluded; 
because of an unclear treatment regimen (n = 1),54 a combination of an unclear treatment 
regimen and an unclear outcome measure (n = 1),55 no separate data available on pediatric 
psoriasis (n = 1),57 and systemic combination therapy (n = 6).31,33,56,58-60 
Conclusion 
Grade C. 
Number of patients treated with MTX: 52. 
As no new evidence on efficacy and safety of MTX in pediatric psoriasis could be added, 
MTX still seems to be an effective treatment option in moderate to severe pediatric 
psoriasis with a reasonable safety profile. Most evidence is available for plaque-type 
psoriasis.4 
Biologics
Etanercept
Based on the former seven included studies,61-67 etanercept was concluded to be an 
effective treatment in plaque-type psoriasis with infections being the most common 
short-term side effects.4 Fourteen new studies were found.60,68-80 Seven studies were 
exluded,60,68,70-72,74,76 because of an unclear outcome measure and/or systemic 
combination therapy (n = 4),60,68,70,74 subgroup analyses of an original double-blind 
randomized controlled trial (RCT)61 which was already mentioned in our previous review4 
(n = 2),72,76 and only quality of life (QoL) outcomes of the same previously mentioned 
cohort (n = 1).71 
 In the present review, new publications on the cohort described in the 48-week 
phase III double-blind RCT (LOE1b)61 were included, containing long-term data.75,78 
At week 48 and 96 PASI 75 was achieved in 80% and 61% of patients respectively.75,78 
 In a retrospective case series (LOE4) in eight children PASI 75 was achieved in 75% at 
week 12.69 In another case series77 and two case reports,73,80 all patients achieved at least 
75% improvement in PASI. In one 14-year-old boy with plaque-type psoriasis PASI 
decreased from 18 to 15.8 after 16 weeks.79 
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During the open-label part of the above mentioned RCT, four serious adverse events 
(SAEs) occurred in three patients including three infections; all resolved without sequelae.61 
During 96 weeks of follow-up, three patients (1.7%) reported five SAEs: anxiety (n = 1), 
postoperative intestinal obstruction (n = 1), dehydration, abdominal pain, hospital 
admission and subsequently abortion (n = 1).75 None were considered to be related to 
etanercept.75 Opportunistic infections, malignancies or deaths were not reported.75 In 
total 145 patients (80.1%) reported one or more adverse event (AE), mostly infections.75 
 Ten patients (5.5%) reported injection site reactions.75 Mild injection site reactions 
were also reported in two other studies.69,77 In one case report a rapid-onset neutropenia 
was described within 48 h after etanercept injection; subsequent rechallenge after 1 
month was well tolerated without side effects.80 
Conclusion 
Grade A. 
Number of patients treated with etanercept: 236. 
Etanercept is an effective biologic in the treatment of pediatric plaque-type psoriasis. The 
most common reported short-term side effects are infections.4 In a 96-week follow-up 
period, etanercept shows a large efficacy and reassuring safety profile. Long-term safety 
profiles are not available. 
Adalimumab
In 2005, one case report described an adolescent girl with recalcitrant GPP treated with a 
combination of adalimumab, methotrexate and cyclosporine.81 This study was excluded 
because of systemic combination therapy. Current literature search revealed three new 
studies.82-84 One study was excluded because separate data on pediatric psoriasis were 
not available.84 In a 13-year-old girl with GPP, more than 90% improvement in body surface 
area (BSA) was achieved after 8 weeks, with clearance after 16 weeks using adalimumab 
40 mg at week 0, 1 and every 2 weeks thereafter. Safety data were not available (LOE5).82 
In another case report (LOE5) describing a 9-year old girl with acrodermatitis continua of 
hallopeau (ACH), complete resolution of clinical aspects was achieved after 8 weeks with 
adalimumab; adverse events did not occur.83 
Conclusion
Grade D.
Number of patients treated with adalimumab: 2. 
A solid conclusion on efficacy and safety of adalimumab could not be drawn on two 
patients. 
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Ustekinumab
Up to September 2008, evidence on the use of ustekinumab in the treatment of pediatric 
psoriasis was lacking.4 Nowadays, two new case reports (LOE5) were identified.79,85 
Ustekinumab was used in two children with plaque psoriasis in a dosage of 90 mg85 and 
45 mg79, respectively; injections were administered at week 0 and 4 and every 12 weeks 
thereafter. Both patients responded very well with more than 90% improvement in PASI at 
week1679 and 100% improvement at week 8 respectively.85 Adverse events did not occur. 
Conclusion 
Grade D.
Number of patients treated with ustekinumab: 2. 
Due to the low number of patients, a solid conclusion on efficacy and safety of ustekinumab 
could not be drawn. 
Infliximab
The use of infliximab in pediatric psoriasis was already described in four cases in the 
former review (LOE5).66,86-88 Currently, two new studies were identified.27,59 Both were 
excluded because of systemic antipsoriatic combination therapy. 
Conclusion 
Grade D.
Number of patients treated with infliximab: 4. 
As no new evidence could be added to our previous review, a solid conclusion with 
respect to infliximab in the treatment of pediatric psoriasis could not be drawn. 
Other systemic therapies
One new study on the use of dapsone was excluded89 due to an unclear outcome 
measure. In addition, literature search revealed one new study on thalidomide90 but this 
study was excluded due to the combination with ultraviolet B radiation therapy. One case 
report describing an infant with GPP treated with anakinra was excluded as this child had 
an interleukin-36-receptor antagonist deficiency.91 
Discussion
In daily clinical practice, the management of moderate to severe pediatric psoriasis is 
intriguing and challenging.9,10 Several issues will influence the choice of (systemic) 
treatment e.g. age, disease severity, previous treatments, level of disability (the influence 
on QoL), presence of comorbidities, practicality of the regimen, costs, accessibility and 
patient preferences.6,8,9,12 
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Although these aspects will differ for each child and also between countries, the benefits 
and risks of a treatment and especially the long-term health risks of medication or 
inadequate treatment are a general concern for all dermatologists treating children with 
psoriasis.6 It is therefore very important to make the decisions based on the available 
evidence. In this review, the evidence on systemic treatments in pediatric psoriasis is 
updated until March 2014. 
 Based on the present review, we suggest the following adapted treatment algorithm 
(Figure 1) for children who need to be treated with systemic agents. MTX is still considered 
to be the first systemic treatment of choice with most data available on plaque-type 
psoriasis.4 Although the body of evidence of MTX has not increased, and is only retrospec-
Figure 1   Treatment algorithm.
Systemic treatment needed
In pustular or 
erythrodermic psoriasis, 
consider: 
If MTX is ineffective 
or contraindicated, 
consider:
Retinoids
Fumaric acid
Adalimumab, 
Ustekinumab
Methotrexate (MTX)
Etanercept
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tively collected, it is still the most extensive of the conventional systemic treatments and 
is found to be effective. Side effects most frequently reported in the pediatric psoriasis 
literature are nausea, vomiting and transient elevation of liver enzymes.4,47-49 In addition 
to the evidence found in the pediatric psoriasis literature, MTX has been used for a long 
time and has a track record of well-tolerated and effective use in juvenile idiopathic 
arthritis (JIA) literature.92 Based on the evidence presented in this review in combination 
with the long-term safety aspects of MTX in JIA, we recommend this conventional 
systemic treatment as preferred before use of other systemic treatments. 
 The evidence on the efficacy and safety of retinoids is still mainly shown in pustular 
and erythrodermic psoriasis with the majority of data describing etretinate. In those 
subtypes, it is an effective treatment with frequently reported side effects. Up to now, the 
efficacy of cyclosporine treatment in pediatric psoriasis remains ambiguous and a solid 
conclusion could not be drawn.
 In case of plaque-type psoriasis and ineffectiveness or contraindication for MTX, FAE 
could be considered in a subgroup of patients. Based on the limited new evidence 
available on induction therapy, fumarates have shown to be reasonably effective and safe 
in a subgroup of pediatric patients. To date, prospective studies are not available, but are 
currently being performed.13 As up to now, the evidence on FAE is limited, and only retro-
spectively collected, we placed this agent with a dotted line in the treatment algorithm.  
 Etanercept is shown to be effective and has still accumulated most evidence of all 
available systemic treatments, with a large efficacy and reassuring safety profile in a 
96-week follow-up.75 In JIA, 8 years of continuous etanercept seems well tolerated with a 
rate of serious infections at 0.03 per patient-year.93 The promising efficacy of biologics, 
however, needs to be balanced against the relative lack of long-term safety data and high 
costs.8,9 In addition, an increased risk of lymphoma and other malignancies in children 
and adolescents with arthritis, inflammatory bowel disease or sarcoidosis treated with 
tumour necrosis factor-α (TNF-α) blokkers is speculated.6,94 However, it has to be taken 
into account that the majority of patients also used other immunosupressives and the 
contribution of the underlying disease states on the risk of malignancy could not be 
assessed.6,94 To date, the Food and Drug Administration (FDA) concluded that it is unable 
to fully characterize the strength of the association between the use of TNF blockers and 
development of malignancy.6,94 Therefore, we still consider etanercept a third-line drug in 
severe and/or recalcitrant psoriasis when the conventional systemic treatments are 
ineffective, contraindicated or discontinued because of adverse events. In the future, 
when sufficient long-term safety data are collected, etanercept will probably get a more 
prominent position in the treatment algorithm. In the present review, a solid conclusion 
on the use of adalimumab and ustekinumab could not be drawn due to the low number 
of patients. At the moment, there are two ongoing Phase III multicenter RCTs evaluating 
the use of ustekinumab and adalimumab in pediatric psoriasis respectively.95,96 Therefore, 
we placed them with a dotted line in Figure 1.
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 In conclusion, there is still limited evidence on the efficacy and safety of systemic 
treatments in pediatric psoriasis and there is especially a lack of long-term safety data. 
Therefore, there is a compelling need for a prospective, multicenter, international registry 
on systemic treatments in pediatric psoriasis to investigate in a consequent and 
standardized manner the effectiveness and safety of systemic treatments in this vulnerable 
age group.
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Abstract
Background: Evidence on effectiveness and safety of methotrexate (MTX) in pediatric 
psoriasis is scarce. 
Objectives: To study the effectiveness and safety of MTX in pediatric plaque-type 
psoriasis and its influence on quality of life (QoL) in daily clinical practice.
Methods: Subset analysis of prospectively collected data extracted from the Child- 
CAPTURE registry, a single center, longitudinal, long-term, observational daily practice 
cohort of pediatric psoriasis patients. A maximum dose between 0.14 and 0.63 mg/kg 
once weekly was prescribed in 25 children. Primary endpoints were percentages of 
patients with ≥75% improvement in the Psoriasis Area and Severity Index (PASI) at week 
12 and 24.
Results: PASI 75 was achieved in 4.3% and 33.3% of patients at week 12 and 24, whereas 
40% and 28.6% reached PASI 75 at week 36 and 48. Median PASI and body surface area 
decreased from 10.0 (range 3.8-42.4) and 11.0 (range 3.5-72.0) at baseline to 4.3 (range 
0-19.8) and 2.6 (range 0.0-39.6) at week 24, respectively. Physician Global Assessment 
improved significantly from 3.0 to 1.2 at week 24. A significant decrease in Children’s 
Dermatology Life Quality Index from 9.0 to 3.8 at week 24 was found. Most reported 
adverse events were severe nausea (n = 5), infections requiring antibiotics (n = 5) and 
tiredness (n = 4). 
Conclusions: MTX shows a positive effect on PASI scores, improves QoL and has a 
reasonable safety profile. 
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Introduction
In 30% of patients with psoriasis, the onset of disease is before adulthood.1 Pediatric 
psoriasis has a negative impact on the quality of life (QoL), self-esteem and psychosocial 
development.2 Methotrexate (MTX) is a well-known systemic treatment for moderate to 
severe pediatric psoriasis3; however, evidence on its effectiveness and safety is scarce, 
and prospective data are not available. Until now, three retrospective case series on MTX 
in pediatric plaque-type psoriasis were published.4-6 Only one study used the Psoriasis 
Area and Severity Index (PASI) as an objective treatment outcome measure 4 and neither 
study evaluated the influence on the QoL or the drug survival. For a balanced positioning 
of MTX in the systemic treatments of pediatric psoriasis, prospective evidence is of major 
importance. 
 This study aims to evaluate the effectiveness of MTX in the treatment of pediatric 
plaque-type psoriasis by means of data extraction from the existing Child-CAPTURE 
registry (Continuous Assessment of Psoriasis Treatment Use Registry), a prospective, 
long-term, longitudinal, observational daily practice cohort of pediatric patients with 
psoriasis. In addition, safety data, the influence on QoL and the 48-and 96-week drug 
survival of MTX were evaluated. In sub-analysis, we investigated the influence of body 
mass index (BMI) and waist circumference (WC) on the effectiveness of MTX. 
Patients and methods
Study design
This study was a subset analysis of a single-group, prospective, observational, daily clinical 
practice cohort enrolling children with moderate to severe plaque-type psoriasis treated 
with MTX. This study has been carried out in the Netherlands in accordance with the 
applicable rules concerning the review of research ethics committees and informed 
consent.
Study population 
Data were prospectively collected using the Child-CAPTURE, a prospective, longitudinal, 
long-term, observational, daily practice pediatric psoriasis registry. The Child-CAPTURE 
was set up in September 2008 to monitor the effectiveness, safety of treatments and 
QoL in all pediatric psoriasis patients (≤ 18 years old) visiting the outpatient clinic of the 
Department of Dermatology at the Radboud university medical center.7 At baseline, 
patient and treatment characteristics were prospectively collected in the Child-CAPTURE 
using a standard case record form including: age, sex, age of onset, family history of 
psoriasis, presence of psoriatic arthritis, medical history, present and previous antipsoriatic 
treatments and concomitant non-dermatological medication. At each visit, disease 
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severity scores (PASI; Physician Global Assessment, PGA; and body surface area, BSA) were 
recorded for every child. In addition, physical parameters (body height, weight and WC), 
Children’s Dermatology Life Quality Index (CDLQI) and the occurrence of (serious) adverse 
events (AEs) were noted. In this study, a subset analysis was performed on all pediatric 
plaque-type psoriasis patients (age <18 years) treated with MTX for their psoriasis at our 
outpatient clinic between September 2008 and December 2013. 
 Children were treated with MTX if they failed to respond to topical corticosteroids 
and/or dithranol, and/or UVB phototherapy (if adolescent). MTX was prescribed if PASI 
and/or CDLQI were 10 or higher. If any of the following PASI, BSA and CDLQI were ≥ 7 
and < 10, and in addition the areas that were affected were more likely to have functional 
or psychosocial impact, these patients were included. 
 Exclusion criteria were: age ≥ 18 years, the use of MTX at the first visit, pustular, guttate 
or erythrodermic psoriasis, concomittent antipsoriatic treatment other than topical 
treatment and the presence of a contraindication for treatment with MTX.8 
Protocol
Before commencing MTX, screening laboratory tests were conducted including 
hematological analysis, serum chemistry, hepatitis B and C serology and in females of 
childbearing potential, a pregnancy test. The proposed MTX starting dose was an oral 
dose of 0.2-0.4 mg/kg once a week followed by folic acid 5 mg once weekly9, 24 hours 
later. However, the MTX starting dose never exceeded 20 mg/week. The oral tabs were 
taken all at once. Visits were scheduled at week 6 and 12 and every 12 weeks thereafter. 
Routine laboratory tests were conducted at week 1 (before the second intake of MTX), 
week 3, 6, 9 and 12 and every 12 weeks thereafter. Patients and parents were instructed 
to interrupt MTX in case of fever, illness or malaise. Patients were allowed to use topical 
therapies on all areas of the body according to their own discretion. According to the daily 
clinical practice design, no wash-out period was performed. 
Outcome measures
The PASI (score 0-72) and the percentage of affected BSA (score 0-100) were used to 
measure the extent and the severity of psoriasis.10 PASI 50, PASI 75, and PASI 90 were 
calculated. These measures denote improvements in the PASI of 50%, 75% and 90% 
relative to baseline, respectively. The PGA was used to assess the overall severity of 
psoriasis graded from 0 to 5 (0 indicates clear and 5 very severe). 
 A validated Dutch version of the CDLQI was used (10 items; score 0-30) to quantify the 
impact of psoriasis. More impairment in QoL is indicated by higher scores in CDLQI.11,12 
AEs of interest and serious adverse events (SAEs) were recorded. The AEs of special interest 
were: nausea and/or other gastrointestinal complaints, tiredness, laboratory abnormalities 
(all requiring adjustment of treatment regimen), infections requiring medication to resolve, 
bone marrow suppression and malignancies. Multiple occurrence of identical AE in a 
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single subject were counted once. SAE was defined as an event that resulted in death, 
was life threatening, required inpatient or prolonged hospitalization or resulted in persistent 
or significant disability or incapacity. BMI was calculated as weight in kilograms divided 
by height in meters squared.13 An age- and sex-adjusted BMI was assigned14 with cutoffs 
for overweight and obesity. WC was measured midway between the lowest rib and the 
superior border of the iliac crest with an inelastic measuring tape.13,15 An age- and 
sex-adjusted WC was determined based on a cutoff > 1.3 SDS for overweight and > 2.3 
SDS to detect obesity in Dutch children.15 
Endpoints
Primary endpoints included PASI 75 at week 12 and 24. Secondary endpoints included 
PASI 50 and PASI 90 at week 12 and 24, PGA/BSA reduction, improvement in QoL, 
evaluation of the effectiveness at week 36 and 48 as well as safety data. In addition, the 
influences of BMI and WC on the effectiveness of MTX and 48-and 96-week drug survival 
times and reasons for discontinuation were analysed. Drug survival is the amount of time 
a patient remains on a specific treatment.16,17 
Statistical methods
PASI, BSA, PGA and CDLQI were analysed for a 48-week period and were interpolated to 
obtain outcome measures at week four and every four weeks thereafter. Effectiveness 
analysis using PASI and BSA were performed in two ways: (1) according to an as-treated 
principle and (2) intention-to- treat analysis using last observation carried forward (LOCF) 
until 48 weeks in patients who discontinued MTX treatment.18 End of the treatment 
episode was defined as a discontinuation of MTX therapy during 12 weeks or more. 
 A linear mixed model for repeated measurements was used to study the influence of 
age at start of MTX, BMI, WC, age-and sex-adjusted BMI, age-and sex-adjusted WC and 
subcutaneous administration on the effectiveness of MTX, separately. The dependent 
variable was PASI. The independent continuous variables were age at start of MTX (BMI, 
WC, age-and sex-adjusted BMI, age-and sex-adjusted WC and subcutaneous administration, 
respectively), time since start of treatment and the baseline PASI value. Initially, also all 
first-order interaction terms with time were included in the linear part of the model, but 
these terms were removed from the final model because these did significantly improve 
the fit to the data. Furthermore, the intercept of each patient was treated as a random 
variable. This allows different levels for different patients.
 The Wilcoxon signed-rank test was used to test the change since baseline of the 
outcomes at weeks 12, 24, 36, and 48, respectively, for statistical significance. The Kaplan- 
Meier method was used to study the time to MTX discontinuation and the estimate 48- 
and 96- week drug survival of MTX with the 95% confidence interval (CI) are presented. 
 p Values <0.05 (two-sided) were considered statistically significant. The statistical 
analyses were performed using SPSS® version 20.0 for Windows® (SPSS Inc., Chicago, IL), 
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SAS® version 9.2 for Windows® (SAS Institute Inc., Cary, NC) and Microsoft Office Excel 2007 
SP3 MSO (Microsoft Corporation, Redmond, WA). 
Results
Patient characteristics
Twenty-five children (52% male) were included. In total, six patients (24%) used MTX 
subcutaneously. Five patients switched from oral MTX to subcutaneous administration 
because of ineffectiveness of oral MTX tabs (n = 3), nausea (n = 1) and active arthritis (n = 1). 
One patient directly started with subcutaneous administration of MTX because of nausea 
during a previous treatment episode with MTX, which was before foundation of our 
registry. Median time of switching from oral to subcutaneous administration (n = 5) was 
37.1 weeks (range 13.0-88.3).
 Most patients were treated with dithranol any time before commencing MTX, but in 
the three months prior to start of MTX, 14 patients (56%) used systemic therapy and/or 
UVB phototherapy and/or dithranol (Table 1). The median start dose of MTX was 15 mg 
once weekly with a maximum start dose of 20 mg once weekly, based on the weight of 
the patient. In 12 children, initial MTX dosages were increased between week 6.7 and 
week 31.3 (median 14.4) until a maximum dose of 25 mg once weekly. In four of these 12 
patients, dosage was tapered. In addition, in four other children dosage was also tapered.
 The median BMI of the children in our study was 21.2 (range 13.4-35.3). Of the 25 
children, 32% (n = 8) had an age-and sex-adjusted BMI above the normal range (overweight 
32%; obesity 24%). Of the 24 children of which a WC was available, 33.3% had an age-and 
sex-adjusted WC above the normal range (overweight 33.3%; obesity 20.8%). At week 12, 
24, 36 and 48, the number of patients was 23 (92%), 21 (84%), 15 (60%) and 14 (56%), 
respectively, compared with 25 patients (100%) at baseline (Table 2).
Effectiveness
As treated analysis
PASI 75 was reached in 4.3%, 33.3%, 40% and 28.6% of patients after 12, 24, 36 and 48 
weeks. Rates of PASI 50 were 39.1%, 66.7%, 80% and 71.4% at week 12, 24, 36 and 48; PASI 
90 was achieved in 0%, 23.8%, 20% and 14.3%, respectively (Figure 1). Median PASI at 
baseline was 10.0 (range 3.8-42.4) compared with 5.8 (range 2.4-30.0), 4.3 (0-19.8), 3.6 (0-8.4) 
and 3.4 (0-11.8) at weeks 12, 24, 36 and 48, respectively (Table 2). BSA values at weeks 12, 24, 
36, and 48 and percentage of improvement are described in Table 2 and Figure 1. 
LOCF analysis
PASI 75 was reached in 4%, 32%, 40% and 32% of patients after 12, 24, 36 and 48 weeks. 
Rates of PASI 50 were 40%, 64%, 72% and 68% at week 12, 24, 36 and 48; PASI 90 was 
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achieved in 0%, 20%, 24% and 20%, respectively (Figure 1). Median PASI compared with 
baseline was similar to the results of the as treated analysis. Note that in this figure, the 
results following the principles of intention-to treat (LOCF) show much smoother lines 
compared with the as treated analysis. Moreover, these fluctuations are absent with 
respect to the medians in Table 2 for either analysis. Therefore, fluctuations in the as 
treated analysis are strongly related to drop-outs. 
PGA
At week 12, 24, 36 and 48, median PGA was significantly lower compared with baseline 
(Table 2). PGA decreased from 3.0 at baseline to 2.1 and 1.2 at week 12 and 24, respectively. 
Table 1   The characteristics of the children with plaque-type psoriasis (n = 25)  
in this study.
Patient characteristics median (range)/ n (%)
Age (years) at start MTX 15.0 (6-17)
Age (years) onset psoriasis 9.0 (0-16)
Baseline PASI 10.0 (3.8-42.4)
Duration MTX therapy (weeks) 60.4 (12.6-163.4)
Cumulative dose (mg) 793 (165-2725)
BMI (kg/m2)
Age-and sex-adjusted BMI above the normal range
21.2
8
(13.4-35.3)
(32)
Waist circumference (cm)
Age-and sex-adjusted WC above the normal range
71
8
(51-132)
(33.3)
Male gender 13 (52)
Psoriatic arthritis 3 (12)
Subcutaneous use 6 (24)
Previous therapies
Potent topical corticosteroids 25 (100)
Dithranol 19 (76)
Phototherapy 18 (72)
Fumaric acid 3 (12)
Cyclosporine 1 (4)
Retinoidsa 1 (4)
Etanerceptb 1 (4)
MTX, methotrexate; PASI, Psoriasis Area and Severity Index; BMI, body mass index; WC, waist circumference; 
a For five days.
b Single injection.
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The effectiveness of MTX related to age, BMI, WC and subcutaneous 
administration
We found on an average an increase in the PASI of 0.4 (95% CI: -0.3 to 1.1) per increase of 
one year in age at start of MTX, irrespective of the timepoint of measurement. However, 
this did not reach the level of statistical significance. 
 The PASI was not statistically significant increased neither per unit increase in BMI nor 
per increase in WC (0.16, 95% CI: (-0.03 to 0.35) and 0.06, 95% CI: (-0.01 to 0.13), respectively), 
using a linear mixed model with adjustment for baseline PASI value. So, the baseline PASI 
was predictive for the PASI after treatment and neither BMI nor WC was related to an 
additional statistical increase. Similar results were found with respect to both normal 
age-and sex-adjusted versus abnormal increases in WC and BMI, respectively. The mean T
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Figure 1   The percentage of improvement compared with baseline of the Psoriasis Area 
and Severity Index (PASI) and the body surface area (BSA), using the as treated 
analysis and the Last Observation Carried Forward analysis (LOCF), 
respectively.
The lines represent the percentage of patients with 50% improvement (black solid), the percentage with 75% 
improvement (long dashed), the percentage with 90% improvement (short dashed) and the number of patients 
(gray line).
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PASI in the age-and sex-related abnormal WC was 3.7 (95% CI: -0.5 to 7.9) and in the 
age-and sex-related abnormal BMI was 2.9 (95% CI: -1.4 to 7.2) higher compared to normal, 
irrespective of the timepoint of measurement. Again, these differences did not reach the 
level of statistical significance. 
 We found that the difference between subcutaneous and oral administration was 
statistically significant smaller at the later points of measurement (9.0 (95% CI: 4.1-13.8) at 
baseline, 6.0 (95% CI: 1.1-10.8) at 12 weeks, 4.2 (95% CI: -0.6 to 9.6) at 24 weeks and 3.6 
(95% CI: -1.3, to 8.4) at 36 weeks, all in favor of oral administration). This is in line with clinical 
practice that ‘more severe’ patients have higher probability to receive subcutaneous MTX 
somewhere during treatment (in this study at a median time of 37.1 weeks after start MTX). 
The number of AEs (4/6) is not statistically significant different compared to oral MTX 
(11/19) (Fisher-exact, p = 1.00).
CDLQI
At baseline, median CDLQI was 9.0 (range 2-20); median CDLQI at week 12, 24, 36 and 48 
was 4.6 (range 0-15.8), 3.8 (range 0-21), 3.4 (range 0-20.9) and 3.9 (range 0-13.3), respectively 
(Table 2). The median CDLQI score after 12, 24, 36 and 48 weeks was significantly lower 
compared with baseline. 
Safety
AEs of interest were severe nausea (n = 5) and severe tiredness (n = 4). One patient 
experienced both nausea and tiredness. Of the eight patients with nausea and/or 
tiredness, three children (7-9 years old) had a maximum dose above 0.4 mg/kg/week 
(0.44-0.63 mg/kg), whereas the other children with nausea and/ or tiredness had a 
maximum dose between 0.2 and 0.3 mg/kg/week and were all adolescents. Although 
MTX was administrated subcutaneously in two of the eight patients because of nausea, 
this did not resolve the complaints.
 Infections requiring antibiotics or antiviral medication were reported in five patients: 
one patient had a symptomatic urinary tract infection, in two patients multiple respiratory 
tract infections including tonsillitis occurred, one patient had a herpes zoster infection of 
the arm and another patient developed an eye infection (treated with topical antibiotics) 
and a paronychia requiring oral antibiotics. Later, he was hospitalized because of 
pneumonia, the only SAE reported, which resolved without sequelae. One patient 
reported a six-days-lasting rectal bleeding. 
 MTX was interrupted in two patients because of increased liver enzymes and 
increased creatinine, respectively. After MTX cessation, both laboratory abnormalities 
normalized, and MTX was subsequently reintroduced. No deaths, malignancies or bone 
marrow suppression were reported. 
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Drug survival and reasons for discontinuation
Drug survival after 48 and 96 weeks of treatment was 72.0% (95% CI: 50.1-85.5%) and 18.0% 
(95% CI: 4.7-38.3%), respectively (Figure 2). Eight of 25 patients stopped using MTX ≤ 48 
weeks: one patient because of severe nausea at week 12. Five patients discontinued MTX 
between week >12 and ≤24; one of them discontinued MTX after 22 weeks because 
remission was achieved and MTX became redundant. The other reasons of discontinua-
tion were tiredness (n = 1), multiple respiratory tract infections (n = 1), a combination of 
nausea and ineffectiveness (n = 1) and the wish to consume alcoholic drinks (n = 1). After 
28 and 48 weeks, respectively, two patients discontinued MTX because of ineffectiveness. 
At the time of data lock, two patients with a treatment duration of 29 and 30 weeks, 
respectively, were still on MTX therapy. One patient was lost to follow-up after 39 weeks 
of treatment and was treated elsewhere. 
 Fourteen of 25 patients used MTX for more than 48 weeks. Reasons for discontinua-
tion of MTX therapy after more than 48 weeks were as follows: remission (n = 3), tiredness 
(n = 2), tiredness and nausea (n = 1), ineffectiveness (n = 1), combination of nausea and 
ineffectiveness (n = 2), pregnancy wish (n = 1) and patient’s initiative (n = 1). At data lock, 
three of these 14 patients were still on MTX with a treatment duration of 64, 65 and 
163 weeks, respectively. 
Figure 2   Kaplan-Meier estimate of the time to discontinuation of MTX.
The vertical bars indicate censored data, and the broke lines indicate the 95% confidence interval.   
MTX, methotrexate.
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Discussion
In this single center, daily clinical practice study, 25 children with psoriasis were treated 
with MTX of which the majority continued for more than 48 weeks. At week 24, 33.3% of 
patients achieved PASI 75, and the median CDLQI significantly decreased from 9.0 at 
baseline to 3.8. Until now, MTX treatment in pediatric plaque-type psoriasis was described 
in three retrospective case series with a total of 32 children.4-6 Neither study evaluated the 
PGA and BSA, and only one study, including 17 patients with plaque-type psoriasis, used 
PASI as an objective treatment outcome measure. In this particular study, patients were 
treated with a once weekly oral dose of 0.2-0.4 mg/kg MTX, and an improvement in PASI 
of >75% was found in all but two patients. These data, however, were based on all 24 
included patients, of which six patients had generalized pustular or erythrodermic 
psoriasis.4 In addition, their baseline PASI was 18.4 (range 8.6-31.2), possibly at least partial 
because of the inclusion of children with erythrodermic and generalized pustular psoriasis. 
It is therefore not possible to directly compare the outcomes of this study with our results. 
In two randomized controlled trials (RCTs) in adults with plaque-type psoriasis, the efficacy 
of biologics was compared with MTX.19,20 In the first study, 35.5% of the patients treated 
with MTX reached PASI 75 after 16 weeks.19 In the other study, a PASI 75 was reached in 
39.9% of patients after 24 weeks of treatment with MTX.20 Although the results of the 
present study (33.3% PASI 75 after 24 weeks) are in the same range, they are somewhat 
disappointing. An explanation could be the low baseline PASI (median 10, and lower limit 
3.8), which biases toward difficulty in achieving PASI 75. According to our daily clinical 
practice design, a wash-out period was not performed. Our study describes a selection of 
children who did not respond sufficiently to treatment with potent topical corticosteroids. 
Most of them (92%) did not respond to intensive day care treatment with dithranol21 and/
or phototherapy, or had a flare of their psoriasis shortly after cessation of these therapies. 
Within three months before starting MTX, 14 patients (56%) were treated with either 
systemic therapy, dithranol and/or phototherapy, which most likely explains our relatively 
low baseline score. Another explanation could be the daily clinical practice setting itself, 
of which in general is known that mostly lower response rates are found than in RCTs.22-24
 A clinically meaningful reduction in PASI was achieved between 12 and 24 weeks of 
treatment (Figure 1). Several explanations are plausible for the better effectiveness of MTX 
at week 24: prolonged onset of clinical response, dose adjustment during follow-up or 
change in route of administration during follow-up. Nevertheless, we recommend 
continuing MTX therapy, if possible, for at least 24 weeks, before deciding that it is 
ineffective. This is in line with the guidelines of MTX treatment in adults.25,26
 The median CDLQI significantly decreased from 9.0 at baseline to 3.8 at week 24. Most 
improvement in CDLQI occurred in the first 12 weeks of treatment, which is consistent 
with MTX data in adults.27 Until now, two studies described the influence of systemic 
treatments on the QoL in pediatric psoriasis.7,28 The improvement in QoL in the present 
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study seems to be comparable or higher than found in the other two studies,7,28 describing 
an improvement in mean CDLQI with 52.3%28 and a mean ∆CDLQI of -3.6 (95% CI: -6.4 to 
-0.9; p = 0.0147), respectively.
 The most frequent reported AEs in our study were nausea, tiredness and respiratory 
tract infections. Nausea was already reported in the available literature on MTX in pediatric 
psoriasis4-6, and also in other indications in children nausea is a well-known side effect.29,30 
Possibly, different treatment schedules in folic acid administration can influence the 
presence of nausea and other AEs; the effect of different treatment schedules of folic acid 
administration on the effectiveness and side effects in MTX therapy is still subject of 
debate8,31 and the use and dose regimen of folic acid administration is highly variable.32 
In the pediatric psoriasis literature, tiredness was not reported until now, whereas in this 
study, it was reported as reason for discontinuation. Possibly, this is due to the fact that 
former studies4-6 included younger patients, whereas in our study, many adolescents 
participated in whom tiredness was reported frequently.33 The respiratory tract infections 
found in our study are difficult to interpret, as the frequency of infections in a control 
group of children with psoriasis is not known. 
 The upper limit of normal BMI varies greatly depending on the age and the sex of the 
child. In our study, 32% of the children had an age-and sex-adjusted BMI above the normal 
range. So far, it is not known whether the response to MTX in pediatric psoriasis is 
influenced by excess (central) adiposity or WC. We did not find a significant (additional) 
effect of age, (age- and sex- adjusted) BMI or WC on the effectiveness of MTX. It needs to 
be noted that the dosage of MTX in our study was based on the weight of the child and 
therefore to some extent also on BMI and WC. 
 In contrast, we found that subcutaneous administration of MTX has a significant 
higher effectiveness compared with oral MTX administration. It needs to be stressed that 
according to our protocol, patients were intended to be treated with MTX in a dose of 
0.2-0.4 mg/kg, with a maximum starting dose of 20 mg/week. However, due to the daily 
clinical practice design of this study, this dose regimen was not always strictly followed 
due to for example overweight, AEs and patient preferences. 
 This study is the first to present drug survival times of MTX in the treatment of 
pediatric psoriasis. Our data illustrate that the majority of patients continued MTX therapy 
for more than 48 weeks. After 48 weeks, adherence decreased and more patients 
discontinued MTX therapy. This was partially due to clearance, but also because of nausea, 
tiredness or ineffectiveness. It would be interesting to investigate the patient characteris-
tics of the children with long-term drug survival on MTX. For the clinician, an advise which 
patients should be treated with MTX would be very helpful. Based on this study, however, 
it is difficult to define characteristics of good responders. As we describe only a small 
heterogeneous cohort of pediatric patients with psoriasis, clinical interpretation is difficult, 
so further studies are needed in larger cohorts. 
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 The strengths of this study are the long-term acquisition of data from a prospective 
daily clinical practice patient registry and the use of objective psoriasis severity and QoL 
scores. A limitation is the small number of patients. 
Conclusion
In this small subset analysis from a longitudinal daily clinical practice cohort of pediatric 
plaque-type psoriasis patients, treatment with MTX shows a positive effect on PASI scores, 
improves QoL and has a reasonable safety profile. If possible, we recommend a treatment 
duration of at least 24 weeks before deciding to discontinue MTX because of ineffectiveness. 
A prospective, multicenter, international registry on MTX and other systemic treatments in 
pediatric psoriasis is highly recommended to investigate the effectiveness, QoL and safety 
of these treatments in this specific patient group in a consequent and standardized 
manner. 
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Abstract
Background: Evidence on fumaric acid esters (FAE) in the treatment of pediatric psoriasis 
is scarce. 
Objective: Describe the effectiveness, influence on the quality of life (QoL) and safety of 
FAE in children with recalcitrant psoriasis in daily clinical practice. 
Methods: A prospective case series. 
Results: Fourteen patients with recalcitrant plaque-type psoriasis were described (mean 
age 13.7, range 8-17 years). Mean treatment duration was 48.6 weeks (range 12-124). 
Maximum daily dose varied between 180 and 1200 mg with a mean of 564 mg per day. 
Mean Psoriasis Area and Severity Index (PASI) (± SEM) at baseline was 10.5 (1.0) compared 
to 8.6 (1.1), 6.2 (1.6) and 4.9 (1.5) at week 12, 24 and 36, respectively. An improvement in PASI 
was observed in nine patients (64.3%). Mean CDLQI (± SEM) at week 0, 12, 24 and 36 was 
8.9 (1.4), 6.8 (1.2), 3.7 (1.4) and 3.1 (2.0), respectively. Most common adverse events (AEs) were 
gastrointestinal complaints (n = 13, 92.9%) and flushes (n = 10, 71.4%). Lymphocytopenia 
(n = 5, 45.5%) and eosinophilia (n = 4, 36.4%) were frequently observed laboratory 
abnormalities. AEs were usually mild and transient. One serious adverse event, unrelated 
to FAE, was reported. 
Conclusions: FAE showed improvement of disease severity and QoL in the majority of 
children. Side effects occurred frequently, but were usually mild and transient. FAE may be 
an alternative systemic treatment option for pediatric psoriasis, provided that also the 
long-term safety data are closely monitored, in particular lymphocytopenia. 
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Introduction
Fumaric acid esters (FAE) are used in various countries and are also described in the 
European guideline for the treatment of psoriasis.1 They are mostly used off label, however, 
in Germany a defined mix of FAE (Fumaderm®) has been licensed for moderate to severe 
plaque-type psoriasis in adult patients. Their mechanism of action is based on a broad 
range of immunomodulatory effects, in particular on the interaction of dimethylfumarate 
(DMF) with intra-and extracellular gluthatione.1,2 Because of their favorable long-term 
safety profile, FAE are suggested to be particularly suitable for long-term treatment in 
adult patients with psoriasis.3,4 
 In about one-third of the patients with psoriasis, disease onset is during childhood.5 
Systemic treatments are indicated in children with moderate-to-severe psoriasis, recalcitrant 
to (intensive) topical treatment and/or ultraviolet B (UVB) phototherapy.6 The management 
of these children can be challenging, as most systemic treatments are not approved to 
use in children and evidence on the efficacy and safety of systemic treatments is still 
sparse.7 In this vulnerable patient group, especially long-term safety data are important. 
More evidence on systemic treatments is therefore highly needed, to inform physicians 
about the different treatment options in pediatric psoriasis.
 Up to now, data on the pediatric use of FAE to treat psoriasis are scarce. The available 
evidence to date consists of three case reports8-10 and two retrospective case series11,12 
with a total of 22 children. To our knowledge, prospective data are lacking. In this 
prospective case series, we aimed to evaluate the effectiveness, influence on the quality 
of life (QoL) and safety of FAE treatment in children with recalcitrant psoriasis in daily 
clinical practice. 
Patients and methods
Data collection and study population
Data were extracted from a prospective, observational, longitudinal, long-term, daily 
clinical practice psoriasis registry, the Child-CAPTURE registry (Continuous Assessment of 
Psoriasis Treatment Use Registry).13 The institutional review board considered this study in 
accordance with the applicable rules concerning the review of research ethics committee 
and informed consent. All children with psoriasis (age <18 years) which were treated with 
FAE at our outpatient clinic between September 2008 and January 2015 were analysed. 
Five of these patients were partially described in another publication.11
Treatment regimen
If possible, patients were treated according to a standardized progressive dose regimen 
applied in adult patients, starting with 30 mg of DMF, gradual increasing to a maximum 
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daily dose of 720 mg per day, based on clinical response and tolerability.1,11 However, 
because this study describes a daily clinical practice, the treatment regimen could be 
adjusted according to the physician’s opinion. Before the start of FAE, screening laboratory 
tests (hematological analysis, ALAT, creatinine, bilirubin) and urine analysis were performed. 
During the treatment, laboratory tests were conducted in accordance with the Dutch 
guideline for the use of FAE in adult patients.14 Patients used additional topical treatments 
according to their own discretion. A wash-out period was not performed. 
Outcome measures
At every visit, the Psoriasis Area and Severity Index (PASI) (score 0-72)15 and the percentage 
of affected body surface area (BSA) were calculated to measure the extent and severity of 
psoriasis. Also, the Physician Global Assessment (PGA) was used, graded from 0-5 (0, clear; 
5, very severe) to assess the overall disease severity. To quantify the impact of psoriasis on 
the QoL, a validated Dutch version of the Children’s Dermatology Life Quality Index 
(CDLQI) was used.16
 To grade adverse events (AEs) and laboratory abnormalities, the National Cancer 
Institute Common Toxicity Criteria (version 2.0) were used.17 If these criteria were not 
applicable, AEs were judged as mild when they resolved spontaneously. AEs were defined 
as moderate, when there was a need for initiation of an active treatment to resolve the AE, 
or (temporarily) discontinuation of FAE therapy, or reduction of dosage either by the 
patient themselves or by the treating physician. In addition, serious adverse events (SAEs) 
were recorded and defined as an event that resulted in death, was life threatening, 
required inpatient of prolonged hospitalization, or resulted in persistent or significant 
disability or incapacity18 (Table 3). 
Analyses
PASI, BSA, PGA and CDLQI were interpolated to obtain outcome measures at week 12, 24 
and 36. Two methods of analysis were performed: 1) as-treated analysis and 2) intention- 
to- treat analysis using last observation carried forward (LOCF) until 36 weeks in patients 
who discontinued FAE treatment. Wilcoxon signed-rank test was used to test the change 
since baseline of the outcomes at week 24. The statistical analyses were performed using 
SPSS® version 20.0 for Windows® (SPSS Inc., Chicago, IL) and Microsoft Office Excel 2007 SP3 
MSO (Microsoft Corporation, Redmond, WA).
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Results
Patient characteristics
The studied population consisted of 14 children (n = 8, 57.1% male) with recalcitrant 
plaque-type psoriasis treated with FAE (Table 1). The prospective data of five of these 
children were partially described in a primarily retrospective publication by Balak et al. for 
effectiveness and safety11, but not for patient-reported outcomes. In the present study, 
extended data on effectiveness and safety of these patients are presented in addition to 
the presentation of QoL outcomes.
  Mean age at the commencement of FAE therapy was 13.7 years, ranging from 8 to 17 
years. All patients were previously treated with potent topical corticosteroids and most 
with dithranol (n = 12, 85.7%). In addition, 11 (78.6%) patients were (elsewhere) treated with 
phototherapy and/or systemic therapy at some point previous. In the 3 months prior to 
start of FAE, 10 of 14 patients (71.4%) were treated with systemic therapy and/or dithranol 
and/or phototherapy (Table 1). Two of these patients were still on dithranol treatment at 
the time of start FAE (6 weeks and 1 year, respectively). Concomitant topical treatments 
were prescribed in all patients, but one patient refused using it. Another patient started 
with dithranol therapy 7 weeks after the initiation of FAE because of insufficient clinical 
response. 
FAE formulation and dosage regimen
In all patients, DMF was prescribed by the physician. According to the Dutch regulations, 
the original manufacturer is up to the pharmacist.  Due to this system, 8 of 14 patients 
(57.1%) were treated with a Dutch FAE formulation with slow-release tablets of DMF. 
Another Dutch formulation of non-slow-release tablets of DMF was given to six patients 
(Table 1). 
 The maximum daily dose varied between 180 and 1200 mg with a mean of 564 mg 
per day. Most patients (n = 8; 57.1%) were treated according to a standardized progressive 
dose regimen applied in adult patients with a maximum daily dose of 720 mg per day, 
based on clinical response and tolerability.1,11 In four patients, a more gradual increase in 
dosages was applied, resulting in lower maximum dosages (180, 270, 240 and 360 mg, 
respectively). Two patients exceeded the maximum daily dose of 720 mg per day. In one 
patient, the maximum daily dose was increased up to 960 mg because of insufficient 
response at 720 mg. The other patient was treated elsewhere because of the distance, up 
to a maximum dose of 1200 mg daily. 
Treatment duration and reasons for discontinuation
The mean treatment duration was 48.6 weeks with a range of 12-124 weeks (Table 1). 
At the time of data lock, five patients were still on FAE treatment. As two patients were 
referred to another hospital, it is unknown whether these patients are still on treatment. 
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The other seven patients discontinued FAE therapy: two patients because of ineffectiveness, 
two because of AEs and two patients because of a combination of ineffectiveness and 
AEs. One patient had to stop FAE because of psoriatic arthritis that needed methotrexate 
treatment. The AEs resulting in discontinuation of FAE were persistent  lymphocytopenia 
(about 1 year) and a persistent cough.  A combination of ineffectiveness and AEs (flushes 
Table 1  Patient characteristics.
ID Sex Type of 
psoriasis
Age at 
onset (y)
Previous therapy Therapy 
<3 mo before 
FAE
Age at start of 
FAE (y)
FAE 
formulation
Maximum 
daily dose 
(mg)
Maintenance 
daily dose 
(mg)
Treatment 
duration 
(weeks)
Reasons for 
discontinuation
Concomitant 
therapy
BMI
(kg/m2)
Waist  
circumference
(cm)
Family 
history 
psoriasis
1 M Plaque 2 Potent cs,  dithranol 3x, 
UVB, MTX, Etanercept
UVB,  
topical
12 DMF sr 960 960 47 NA Topical 20.2 72 No
2 F Plaque 12 Potent cs, dithranol, UVB, 
MTX
Topical 17 DMF sr 720 720 110 NA Topical 25.8 89 No
3 M Plaque 9 Potent cs, dithranol, UVB Topical 14 DMF 720 720 49 NA Topical 20.1 73 Yes
4 M Plaque 7 Potent cs, dithranol 2x, UVB Dithranol, 
topical
10 DMF sr 180 - 21 Arthritis Dithranola, 
topical
17.4 67 Yes
5 F Plaque 6 Potent cs, UVB 3x, MTX, 
cyclosporine
MTX,  
topical
17 DMF sr 270 - 48 Unknown Topical 25.5 93 Yes
6 M Plaque 2 Potent cs, dithranol, UVB 2x Dithranol, 
topical
8 DMF 240 - 35 Ineffectiveness Dithranolb, 
topical
14.8 56 Yes
7 M Plaque 14 Potent cs, dithranol, MTX MTX 16 DMF 720 - 12 Ineffectiveness None 36.8 132 Yes
8 F Plaque 7 Potent cs, dithranol 4x, 
UVB 3x
Topical 17 DMF 360 - 15 Ineffectiveness + 
adverse events
Topical 23.3 65 Yes
9 F Plaque 12 Potent cs, UVB UVB 13 DMF sr 1200 - 124 Unknown Topical 15.9 62 No
10 M Plaque 9 Potent cs, dithranol 3x Dithranol, 
topical
14 DMF 480 - 16 Ineffectiveness + 
adverse events
Dithranolc, 
topical
18.2 70 No
11 M Plaque 8 Potent cs, dithranol 2x Dithranol, 
topical
11 DMF sr 480 360-480 51 NA Topical 16.4 57 No
12 F Plaque 13 Potent cs, dithranol, UVB Dithranol, 
topical
17 DMF sr 600 - 68 Adverse events Topical 24.0 86 Yes
13 F Plaque 6 Potent cs, dithranol, PUVA Topical 17 DMF 480 - 32 Adverse events Topical 18.5 70 Yes
14 M Plaque 8 Potent cs, dithranol Dithranol, 
topical
9 DMF sr 480 240-480 52 NA Topical 15.8 62 No
M, male; F, female; cs, corticosteroids; UVB, ultraviolet B phototherapy; MTX, methotrexate; PUVA, Psoralen plus 
ultraviolet A phototherapy; NA, not applicable; FAE, fumaric acid esters; DMF, dimethylfumarate; sr; slow-release; 
mo, months; y, years; wk, weeks; mg, milligram; kg/m2, kilogram per square meter; cm, centimeter. 
a Already treated with dithranol for 6 weeks.
b Already treated with dithranol for almost 1 year. 
c Started additional dithranol treatment after 7 weeks of FAE therapy because of insufficient clinical response.
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and tiredness versus transient lymphocytopenia) were the other reasons. Patient 12 
discontinued FAE treatment after 5 weeks because of a severe episode of flushes after 
the first intake of a tablet of 120 mg FAE, which resolved with oral prednisone and oral 
histamine antagonists. After more than 4 months, FAE was reintroduced and continued 
for 63 weeks. 
Table 1  Patient characteristics.
ID Sex Type of 
psoriasis
Age at 
onset (y)
Previous therapy Therapy 
<3 mo before 
FAE
Age at start of 
FAE (y)
FAE 
formulation
Maximum 
daily dose 
(mg)
Maintenance 
daily dose 
(mg)
Treatment 
duration 
(weeks)
Reasons for 
discontinuation
Concomitant 
therapy
BMI
(kg/m2)
Waist  
circumference
(cm)
Family 
history 
psoriasis
1 M Plaque 2 Potent cs,  dithranol 3x, 
UVB, MTX, Etanercept
UVB,  
topical
12 DMF sr 960 960 47 NA Topical 20.2 72 No
2 F Plaque 12 Potent cs, dithranol, UVB, 
MTX
Topical 17 DMF sr 720 720 110 NA Topical 25.8 89 No
3 M Plaque 9 Potent cs, dithranol, UVB Topical 14 DMF 720 720 49 NA Topical 20.1 73 Yes
4 M Plaque 7 Potent cs, dithranol 2x, UVB Dithranol, 
topical
10 DMF sr 180 - 21 Arthritis Dithranola, 
topical
17.4 67 Yes
5 F Plaque 6 Potent cs, UVB 3x, MTX, 
cyclosporine
MTX,  
topical
17 DMF sr 270 - 48 Unknown Topical 25.5 93 Yes
6 M Plaque 2 Potent cs, dithranol, UVB 2x Dithranol, 
topical
8 DMF 240 - 35 Ineffectiveness Dithranolb, 
topical
14.8 56 Yes
7 M Plaque 14 Potent cs, dithranol, MTX MTX 16 DMF 720 - 12 Ineffectiveness None 36.8 132 Yes
8 F Plaque 7 Potent cs, dithranol 4x, 
UVB 3x
Topical 17 DMF 360 - 15 Ineffectiveness + 
adverse events
Topical 23.3 65 Yes
9 F Plaque 12 Potent cs, UVB UVB 13 DMF sr 1200 - 124 Unknown Topical 15.9 62 No
10 M Plaque 9 Potent cs, dithranol 3x Dithranol, 
topical
14 DMF 480 - 16 Ineffectiveness + 
adverse events
Dithranolc, 
topical
18.2 70 No
11 M Plaque 8 Potent cs, dithranol 2x Dithranol, 
topical
11 DMF sr 480 360-480 51 NA Topical 16.4 57 No
12 F Plaque 13 Potent cs, dithranol, UVB Dithranol, 
topical
17 DMF sr 600 - 68 Adverse events Topical 24.0 86 Yes
13 F Plaque 6 Potent cs, dithranol, PUVA Topical 17 DMF 480 - 32 Adverse events Topical 18.5 70 Yes
14 M Plaque 8 Potent cs, dithranol Dithranol, 
topical
9 DMF sr 480 240-480 52 NA Topical 15.8 62 No
M, male; F, female; cs, corticosteroids; UVB, ultraviolet B phototherapy; MTX, methotrexate; PUVA, Psoralen plus 
ultraviolet A phototherapy; NA, not applicable; FAE, fumaric acid esters; DMF, dimethylfumarate; sr; slow-release; 
mo, months; y, years; wk, weeks; mg, milligram; kg/m2, kilogram per square meter; cm, centimeter. 
a Already treated with dithranol for 6 weeks.
b Already treated with dithranol for almost 1 year. 
c Started additional dithranol treatment after 7 weeks of FAE therapy because of insufficient clinical response.
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Effectiveness
Disease severity: as treated analysis
At baseline and at week 12, 24 and 36 PASI, BSA and PGA were available in 14, 14, 8 and 7 
patients, respectively (Table 2a). Mean PASI ± SEM at baseline was 10.5 (1.0) compared with 
8.6 (1.1), 6.2 (1.6) and 4.9 (1.5) at week 12, 24 and 36, respectively. At week 24, mean PASI had 
statistically significantly improved compared to baseline (p = 0.025). Mean BSA and PGA ± 
SEM at baseline and at week 12, 24 and 36 and the percentage of improvement are 
described in Table 2(a). An overall reduction in PASI was observed in 9 of 14 patients 
(64.3%), while in one patient the psoriasis severity hardly changed. PASI worsened in the 
other four patients. It is remarkable that all patients which were treated with the slow- 
release tablets of DMF (n = 8) showed an improvement in PASI score.
Table 2   PASI, BSA, PGA and total CDLQI of the children with plaque-type psoriasis 
treated with FAE at several time points.
Outcome Weeks  
since baseline
No. of  
patients
Observed Change since 
baseline
mean (SEM) mean (95% CI)
(a)  As treated analysis
PASI 0 14 10.5 (1.0) 0.0 (reference)
12 14 8.6 (1.1) 1.9 (-0.3 to 4.2)
24 8 6.2 (1.6) 5.5 (1.7 to 9.2)
36 7 4.9 (1.5) 7.0 (3.4 to 10.5)
BSA 0 14 13.8 (2.3) 0.0 (reference)
12 14 12.6 (2.3) 1.2 (-3.7 to 6.1)
24 8 8.1 (2.9) 9.0 (0.7 to 17.3)
36 7 5.5 (2.9) 12.1 (2.9 to 21.3)
PGA 0 14 3.4 (0.2) 0.0 (reference)
12 14 3.0 (0.2) 0.4 (-0.1 to 0.8)
24 8 2.2 (0.4) 1.3 (0.3 to 2.3)
36 7 2.0 (0.5) 1.6 (0.6 to 2.6)
CDLQI 0 11 8.9 (1.4) 0.0 (reference)
12 11 6.8 (1.2) 2.1 (-0.2 to 4.3)
24 6 3.7 (1.4) 3.0 (-0.1 to 6.1)
36 5 3.1 (2.0) 4.1 (0.5 to 7.7)
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Disease severity: LOCF analysis
Mean PASI ± SEM at baseline was 10.5 (1.0) compared with 8.6 (1.1), 7.5 (1.4) and 7.3 (1.4) 
at week 12, 24 and 36, respectively. At week 24, PASI improved compared to baseline 
(p =0.056). Mean BSA and PGA ± SEM at baseline and at week 12, 24 and 36 and the 
percentage of improvement are described in Table 2(b).
Quality of life
At baseline, CDLQI was available in 11 patients, with a mean ± SEM of 8.9 (± 1.4). At week 
12, 24 and 36 CDLQI were available in 11, 6 and 5 patients, respectively. Mean CDLQI ± SEM 
Table 2   Continued.
Outcome Weeks  
since baseline
No. of  
patients
Observed Change  
since baseline
mean (SEM) mean (95% CI)
(b)  Last Observation Carried Forward analysis
PASI 0 14 10.5 (1.0) 0.0 (reference)
12 14 8.6 (1.1) 1.9 (-0.3 to 4.2)
24 14 7.5 (1.4) 3.0 (0.1 to 6.0)
36 14 7.3 (1.4) 3.2 (0.1 to 6.4)
BSA 0 14 13.8 (2.3) 0.0 (reference)
12 14 12.6 (2.3) 1.2 (-3.7 to 6.1)
24 14 10.2 (2.5) 3.7 (-2.9 to 10.2)
36 14 9.5 (2.5) 4.3 (-2.7 to 11.3)
PGA 0 14 3.4 (0.2) 0.0 (reference)
12 14 3.0 (0.2) 0.4 (-0.1 to 0.8)
24 14 2.6 (0.3) 0.8 (0.1 to 1.5)
36 14 2.5 (0.4) 0.9 (0.1 to 1.6)
CDLQI 0 11 8.9 (1.4) 0.0 (reference)
12 11 6.8 (1.2) 2.1 (-0.2 to 4.3)
24 11 5.2 (1.2) 3.7 (1.1 to 6.4)
36 11 5.1 (1.3) 3.9 (1.1 to 6.6)
PASI, Psoriasis Area and Severity Index; BSA, Body Surface Area; PGA, Physician Global Assessment; CDLQI, 
Children’s Dermatology Life Quality Index; CI, confidence interval; FAE, fumaric acid esters; LOCF, Last Observation 
Carried Forward.
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at week 12, 24 and 36 was 6.8 (1.2), 3.7 (1.4) and 3.1 (2.0), respectively. Using LOCF, mean 
CDLQI ± SEM at week 12, 24 and 36 was 6.8 (1.2), 5.2 (1.2) and 5.1 (1.3), respectively (Table 2). 
At week 24, CDLQI significantly improved compared to baseline in both the as treated 
analysis (p =0.046) and LOCF analysis (p =0.016). 
Safety
AEs were reported by all patients (Table 3). The most common AEs were gastrointestinal 
complaints (n = 13, 92.9%) and flushes (n = 10, 71.4%). Most frequently reported gastroin-
testinal complaints were diarrhea (n = 10, 71.4%) and abdominal pain (n = 8, 57.1%) which 
were usually mild and transient. In four patients, the gastrointestinal complaints were 
judged as moderate, because either a brief additional treatment was given for their 
diarrhea (antidiarrheal), or FAE was temporary decreased. In all four patients, the complaints 
did not result in a discontinuation of FAE. In six patients (42.9%), a total of nine infections 
were reported including four respiratory tract infections, three skin infections and two 
gastrointestinal tract infections. All these infections were mild or moderate and were 
self-limiting or treated with oral and/or topical therapy. One patient developed a fracture 
of the left clavicle after trauma which was unrelated to the studied medication and was 
the only SAE in this cohort. 
 Routine laboratory tests were available in 11 patients. In three patients laboratory 
tests were performed elsewhere in other hospitals. Abnormal laboratory tests were observed 
in 9 of 11 patients (81.8%). Most common laboratory abnormalities were lymphocytopenia 
(n = 5, 45.5%) and eosinophilia (n = 4, 36.4%). Lymphocytopenia was observed in five 
patients. In three of these patients, the lymphocytopenia was mild and transient. Another 
patient treated with 480 mg DMF per day developed once a severe lympocytopenia (0.45 x 
109 l-1; reference 1.5-3.5 x 109 l-1). This lymphocytopenia was transient and fully reversible 
after temporarily reducing the dose by 50%. In another patient, a long-lasting moderate 
lymphocytopenia (minimum value 0.65 x 109 l-1) was the reason to discontinue the FAE 
treatment. This is the only patient with lymphocytopenia who developed an infection 
(pityriasis versicolor).
 Eosinophilia was observed in four patients. Two patients had a mild eosinophilia 
(0.5-1.0 x 109 l-1), and two a severe eosinophilia (≥1.5 x 109 l-1), with a maximum level of 3.82 
x 109 l-1 in one patient. The mild eosinophilia was already present before start of FAE 
therapy in one patient. In all patients, the eosinophilia was transient and fully reversible. 
A mild monocytosis was found in one patient which completely resolved. While a slight 
decrease in creatinine was found in two patients, an increase in creatinine was not 
observed. Finally, a slight increase in ALAT was observed in three patients; this increase 
was less than twice the upper limit of normal in all patients. 
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Discussion
In this prospective, daily clinical practice case series, 14 children with recalcitrant 
plaque-type psoriasis were treated with FAE. In the majority of these children, FAE 
treatment showed an improvement in PASI and QoL. Although AEs occurred frequently, 
they were usually mild and transient.  
 This case series is unique as it describes the efficacy and safety of FAE in pediatric 
psoriasis patients with a high historical severity, as most were treated with intensive topical 
treatment, dithranol19, phototherapy and/or systemics. In addition, the influence of FAE 
therapy on the QoL was reported, which was never investigated before.
 In our study, mean PASI significantly improved from 10.5 at baseline to 6.2 at week 24. 
This response seemed to be lower than found in previous case series in which the efficacy 
of FAE in pediatric psoriasis was described. Until now, in addition to three case reports8-10, 
there are two retrospective case series11,12, in which a total of 22 children were described. 
In the largest of these case series, complete clearance was found in 36% of patients, good 
improvement in 7%, partial response in 21% and non-response in 36%.11 However, PASI 
was only available in six patients.11 Another case series described six children treated with 
Fumaderm®. All patients (three of which had guttata psoriasis) achieved an improvement 
in PASI of at least 75% or more. However, in four of these patients, an additional 
tonsillectomy was performed.12 In the three pediatric case reports, FAE treatment resulted 
in impressive decreases of PASI scores.8-10 
 An explanation for the lower response rates found in our study could be the selection 
of plaque-type psoriasis patients with a high historical severity recalcitrant to topical 
therapy (n = 14), dithranol (n = 12), phototherapy and/or systemics (n = 11). In addition, a 
washout period before commencement of FAE was not performed, resulting in a relatively 
low baseline PASI (10.5).  
 Another explanation for the differences in response rates might be the use of 
dissimilar FAE formulations or release forms in several studies. Whereas Fumaderm® (a 
commercial mixture of DMF and three salts of ethyl hydrogen fumarate)1 was used in all 
German cases8,9,12, all patients in our study were treated with monotherapy DMF. Eight 
patients were treated with the slow-release form, whereas six patients were treated with 
the non-slow-release form. Remarkably, of the nine patients with an improvement in PASI, 
eight were treated with the slow-release form.  In such small patient populations, it remains 
an open question whether formulation and release forms influence the effectiveness and 
side effects of FAE. Therefore,  prospective comparative studies are needed to investigate 
this issue.   
 As psoriasis can have a negative impact on the QoL in children, that can be improved 
by treatment20,21, it is important to assess patient-reported outcomes. In our patients the 
CDLQI improved from 8.9 at baseline to 3.7 at week 24 (58.4%). To our knowledge, data on 
the influence of FAE treatment on the QoL in pediatric psoriasis are lacking. However, 
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methotrexate treatment in pediatric psoriasis resulted in an improvement in CDLQI from 
9.0 at baseline to 3.8 at week 24 (57.8%)13, whereas etanercept treatment resulted in 52.3% 
improvement in CDLQI from baseline to week 12.22 Therefore, the influence of FAE on the 
QoL of children with psoriasis seems to be in accordance with the available literature on 
other systemic treatments. 
 Although AEs occurred frequently  in our 14 patients, they were usually mild and 
transient (Table 3). The most common AEs were gastrointestinal complaints (n = 13, 92.9%) 
and flushes (n = 10, 71.4%). Lymphocytopenia (n = 5, 45.5%) and eosinophilia (n = 4, 36.4%) 
were frequently observed laboratory abnormalities. The frequency and type of the AEs 
found in our study are in accordance with those found in both children11,12 and adults.1,3,23-26 
In the adult literature, two long-term safety considerations were found that need special 
attention in children. First, several case reports of acute renal failure or Fanconi syndrome 
were described.27-32 In our study, a slight decrease in creatinine was found in two patients, 
whereas an increase in creatinine was not observed. The other safety consideration 
regards long-term lymphocytopenia. In 2003 long-term safety data up to 14 years on FAE 
therapy in adult psoriasis patients were reported.3 Although the development of malignancies 
or an increased risk of infections was not observed1,3, a relative lymphocytopenia of <20% 
occurred frequently in 76% of the patients.3 Lymphocytopenia is a well-known side effect 
of FAE1 and it is hypothesized that long-term immunodeficiency may be related to the 
development of progressive multifocal leukoencephalopathy (PML).33,34 Recently, some 
cases of PML after treatment with FAE were described in adult psoriasis patients.33,35-39 
Because of the described association in the literature between long-term lymphocytopenia 
and PML, it is of utmost importance to avoid long-term lymphocytopenia in children 
treated with FAE. Therefore, we decided to discontinue FAE treatment in the one patient 
who had a long-lasting moderate lymphocytopenia (minimum value 0.65 x 109 l-1). 
 The strengths of the present study are the extraction of data from a prospective, daily 
clinical practice registry and the use of objective outcome measures to assess disease 
severity and the impact on QoL. Although this study is limited by the small number of 
patients, it represents the largest prospective series of children with recalcitrant psoriasis 
treated with DMF so far. 
Conclusion
In this prospective daily clinical practice cases series of 14 children with plaque-type 
psoriasis, FAE lead to improvement of disease severity and QoL in the majority of patients. 
Although AEs occurred frequently, mostly gastrointestinal complaints and flushes, they 
were usually mild and transient. As there is still limited evidence on the efficacy and safety 
of FAE treatment in pediatric psoriasis, and in particular a lack on long-term safety, the 
position of FAE in the systemic treatment of pediatric psoriasis is not clear. Nevertheless, 
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FAE may be an alternative systemic treatment option to manage pediatric psoriasis, 
provided that also the long-term safety data are closely monitored, in particular lympho-
cytopenia. 
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Pediatric psoriasis can have a profound impact on the lives of patients.1 For adult psoriasis 
patients, multidisciplinary training programmes, as an adjunct to standard dermatological 
treatment, can improve physical and psychosocial wellbeing.2,3 However, studies on 
training programmes for pediatric psoriasis are scarce.4 
 This pilot study aimed to assess patient and parent satisfaction with a previously 
described outpatient multidisciplinary training programme for children and adolescents 
with psoriasis and their parents.5 In addition, patients’ and parents’ perceived improvement 
in coping, their complaints, as well as their evaluation on the importance of specific 
training modules, were studied. Finally, the influence of this programme on quality of life 
(QoL), itch and scratch responses, illness cognitions, and impact on family life were 
assessed. 
 The training comprised four sessions of 2.5 hours over a 10-week period. The 
programme was designed for two age-related groups (6-12 and 12-18 years) and included 
several modules: (1) medical information and daily skin care; (2) itch and scratch problems, 
and coping with the pain; (3) coping, self-esteem, sleep hygiene and relaxation exercises; 
and (4) preventing relapse.5,6 
 At the end of the training, an evaluation questionnaire was completed by patients 
and parents to assess satisfaction (scale: 1-10), overall usefulness (scale: 1-10), usefulness of 
specific aspects of the programme (scale: 0-6), improvement in coping and complaints 
(4-point Likert scale; 1=no improvement; 2=little improvement; 3=much improvement; 
4=very much improvement), and importance of the training modules (4-point Likert 
scale; 1=not important; 2=little important; 3=fairly important; 4=very important). 
Additionally, before and after the training and after three months of follow-up, the 
Children’s Dermatology Life Quality Index (CDLQI)7, Impact of Chronic Skin Disease on 
Daily Life (ISDL)8, Stein Impact on Family Scale (SIFS)9, and Dermatitis Family Impact (DFI)10 
were completed by patients and/or parents. These self-reported questionnaires were also 
completed at corresponding measurement points (zero, three and six months) by an age 
and gender-matched control group of pediatric psoriasis patients. 
 Twenty-three of 25 participants (65% female) completed the programme. Median 
age was 11.0 years (range: 6-17). Sixty-five per cent of the patients participated in the 
younger group (6-12 years). The sex and median age of the control group (n = 23) were 
identical. Psoriasis Area and Severity Index (PASI) was slightly higher in the control group 
compared to participants (4.5 versus 3.3), but this was not statistically significant 
(Mann-Whitney test; p = 0.20). In both groups, the majority was treated with topicals. 
Descriptive analysis of the data indicated that patients and parents were highly satisfied 
with the programme (median; patients: 8.0; parents: 9.0). Parents rated the overall 
usefulness high (8.0). In addition, the group format (6.0) and multidisciplinary character 
(5.5) were indicated as very useful. All parents would recommend the programme to 
others. 
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 Between 48% and 100% of patients and parents reported subjective improvement in 
coping, in particular with regard to daily skin care, itching and scratching, and social 
encounters. Indeed, >90% of patients had less complaints about itching and scratching 
and a better mood. Most patients and parents considered all modules to be important. 
Regarding age group differences, younger children were more satisfied (10.0) than 
adolescents (7.5). Also, the parents of children were more satisfied (10.0) than the parents 
of adolescents (8.0). 
 The self-reported questionnaires (CDLQI, ISDL, SIFS and DFI) showed positive changes 
in outcomes for participants, including improvements in QoL, itching, scratching, 
helplessness, acceptance, and impact on family life (Table 1). However, these improvements 
were also found in the control group. The severity of psoriasis (measured by the PASI) 
hardly changed for participants and controls. An explanation for these results could be the 
selection of patients. This training might be more relevant to patients who are at risk of 
psychological adjustment problems. Furthermore, most questionnaires were not validated 
for use in children, and self-assessment questionnaires may have been affected by several 
biases, e.g. social desirability or response bias. In addition, the control group consisted of 
children who refused participation in the programme which could have biased the 
outcomes. 
 In conclusion, this pilot study indicated that an outpatient multidisciplinary training 
programme for children and adolescents with psoriasis and their parents was well-accepted 
and positively evaluated. The majority of patients reported subjective improvements in 
coping and physical and psychosocial wellbeing. 
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Table 1   The outcomes on the self-reported questionnaires and disease severity.
Baseline End of  
programme
Three-month  
follow-up
Median (range) No Median (range) No Median (range) No
Questionnaires
Quality of life
CDLQI1 P 5.0 (0.0-14.0) 23 4.0 (0.0-18.0) 23 3.0 (0.0-14.0) 21
C 2.0 (0.0-10.0) 21 2.0 (0.0-7.0) 21 1.0 (0.0-5.0) 19
Itch and scratching
ISDL-itch total1 P 5.9 (3.0-12.4) 23 5.6 (3.0-10.6) 23 4.4 (3.0-12.8) 21
C 4.2 (3.0-9.5) 21 4.6 (3.0-11.6) 21 3.1 (3.0-10.3) 19
ISDL-scratch 
total1
P 11.0 (7.0-20.0) 23 12.0 (7.0-16.0) 23 9.0 (7.0-20.0) 21
C 10.0 (7.0-20.0) 21 10.0 (7.0-20.0) 21 9.0 (7.0-17.0) 19
Illness cognitions
 Helplessness 
(ISDL)1
P 7.0 (6.0-12.0) 23 6.0 (6.0-16.0) 23 6.0 (6.0-12.0) 21
C 7.0 (6.0-11.0) 21 6.0 (6.0-11.0) 21 6.0 (6.0-11.0) 19
 Acceptance 
(ISDL)1
P 18.0 (8.0-24.0) 23 17.0 (10.0-24.0) 23 21.0 (11.0-24.0) 21
C 21.0 (11.0-24.0) 21 20.0 (17.0-24.0) 21 20.0 (13.0-24.0) 19
Family impact
DFI2 P 3.0 (0.0-19.0) 23 3.0 (0.0-15.0) 21 1.5 (0.0-12.0) 20
C 2.0 (0.0-17.0) 21 1.0 (0.0-9.0) 21 0.0 (0.0-7.0) 18
SIFS2 P 58.0 (41.0-60.0) 22 58.0 (47.0-60.0) 18 59.5 (51.0-60.0) 20
C 60.0 (39.0-60.0) 21 60.0 (50.0-60.0) 21 60.0 (50.0-60.0) 17
Disease severity
PASI P 3.3 (0.0-11.5) 23 4.1 (0.6-8.4) 22 3.7 (0.0-9.9) 18
C 4.5 (0.6-12.0) 11 4.8 (0.4-18.8) 10 4.0 (0.0-16.8) 9
1 Patient-reported; 2 Parent-reported; CDLQI: Children’s Dermatology Life Quality Index; ISDL: Impact of Chronic 
Skin Disease on Daily Life; SIFS: Stein Impact on Family Scale; DFI: Dermatitis Family Impact; PASI: Psoriasis Area 
and Severity Index; P: Participants; C: Controls.
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Abstract 
Background: The Psoriasis Area and Severity Index (PASI) is not able to measure small 
affected areas in a body region which is important for assessing the performance of 
high-effective treatment.
Objective: To present the Low PASI score, show the difference between the classic PASI 
and the Low PASI, evaluate the interobserver agreement of both scores, and compare the 
two scores within investigators.
Methods: Cross-sectional study. Two investigators independently assessed the classic 
PASI and the Low PASI in 10 patients with mild-to-moderate plaque psoriasis. Differences 
in outcome between the two scores were calculated. Intraclass correlation coefficients 
(ICC) were used to determine the interobserver agreement and to compare measurements 
of the two scores within both investigators. Prediction limits of 95% for the errors in 
measurements were provided. 
Results: In both investigators, Low PASI was mean 1.71 and 1.76, whereas the classic PASI 
was mean 4.14 and 4.33. The interobserver agreement (ICC) was excellent for both 
investigators in both scores (ICC classic PASI = 0.95 and Low PASI = 0.87). 
Conclusion: The Low PASI score allows more possible scores at lower levels of psoriasis 
extent (affected areas lower than 10% in a body region) compared to the classic PASI. This 
new score may lead to a more precise analysis of treatment responses and may have 
important clinical implications.
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Introduction
In patients with psoriasis, it is important to measure the severity of the disease in order to 
monitor changes induced by treatment in both clinical trials as well as in daily clinical 
practice.
 The most widely used tool to assess disease severity and extent is the Psoriasis Area 
and Severity Index (PASI).1-3 The PASI score is usually calculated before, during and after 
treatment, and allows us to determine how well patients with psoriasis respond to that 
treatment. Nowadays, for clinical decision making, both the change in absolute PASI is 
used, as well as the percentage of PASI improvement such as PASI 50. PASI 50 denotes a 
reduction of 50% of the PASI score of a single patient, compared to the PASI score at the 
start of the intervention. Since the introduction of very effective treatments such as the 
biologics, many patients reach PASI 75 or PASI 90 after treatment. At this point, the most 
important and widely criticized limitation of the classic PASI score arises, namely that this 
PASI score is insufficient to measure and discriminate involved areas lower than 10% of a 
body region. A minimal involvement (lower than 10% of the body area involved) will 
always lead, according to the classic PASI six-point area scale classification, to an area of 
1.1,4-8 Consequently, reduction of areas of minimal involvement will not lead to changes in 
the outcome of the classic PASI score. However, a change in the severity scores (erythema, 
induration and desquamation) of the lesions might change the outcome of the classic 
PASI score. This means that the classic PASI score in the smallest involved areas does not 
give an accurate representation of the involvement of the affected skin and of the real 
clinical improvement.8 For this purpose, a PASI for small affected areas is needed. Therefore, 
we developed the Low PASI score, a refined PASI score for psoriasis patients with small 
involved areas.
 For example, a patient with one psoriasis plaque of 8 cm (lower than 10% of the body 
area involved) on each body region, with minimal erythema, induration and desquamation, 
will have a classic PASI score of 3. If the plaque improves 4 cm (in each body region), 
without any change on erythema, induration and desquamation, the absolute score will 
remain 3. Although, there is a clinically perceptible improvement, this will not be reflected 
in the classic PASI score. This implies that the reduction of the PASI score could easier be 
reached in a larger percentage of patients than the present classic PASI score indicates. 
 In order to assess the effectiveness of treatments more accurately, it is important to 
enable a good assessment of the small involved areas (affected areas lower than 10% of 
each body region). 
 The aim of this study is to present the Low PASI score (a PASI score refined for patients 
with small involved areas) and to show the difference between the absolute PASI scores 
achieved with the classic PASI and the Low PASI. In addition, to evaluate the interobserver 
agreement of the classic PASI and the Low PASI and to compare the measurements of the 
two scores within both investigators.
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Methods
Participants
In the period between 1st October 2013 and 6th March 2014, 10 psoriasis patients visiting 
the outpatient clinic of the department of Dermatology at the Radboud University Medical 
Center were enrolled. Inclusion criteria were: age of at least 18 years, mild-to-moderate 
plaque psoriasis, and involvement of at least one body area involvement lower than 10%.
Study design
In this cross-sectional study, two investigators (experienced PASI assessors), independently 
assessed the classic PASI score and the Low PASI score of the included patients at the same 
day. This study did not required approval from an institutional review board according 
to ethics guidelines in the Netherlands.
Psoriasis Area and Severity Index (PASI)
The classic Psoriasis Area and Severity Index (PASI) score assesses the extent and severity of 
psoriasis. The extent of psoriasis is measured by the body area involved and the severity 
by erythema (E), induration (I) and desquamation (D) of the plaques.
 The body area involved is the percentage of area involved in a particular body region. 
For calculating classic PASI, the body is divided into four body regions: head (H), upper 
extremities (U), trunk (T), and lower extremities (L). These four body regions correspond to 
approximately 10, 20, 30, and 40% of the total body surface area (BSA), respectively.  One 
per cent of the BSA is for the purpose of clinical estimation equivalent approximately to 
the total palmar surface (palm plus five digits) or a ‘handprint’ of the patient.9 Converting 
a handprint (1% BSA) to the extent of each body region (H = 10%, U = 20%, T = 30% and L 
= 40%) results in approximately: 1/10 = 10% of the head, 1/20 = 5% of the upper extremities, 
1/30 = 3.3% of the trunk, and  1/40 = 2.5% of the lower extremities. 
 The body area involved in a body region  is classified into a six-point scale called area 
(A): 1, < 10% involvement; 2, 10 - 29%; 3, 30 - 49%; 4,  50 - 69%; 5, 70 - 89%; 6, 90 - 100%. 
 The severity of psoriasis in a body region is the sum of the scores for erythema, 
induration and desquamation in that body region, and each is assessed according to a 
four-point scale: 0, no symptoms; 1, slight symptoms; 2, moderate symptoms; 3, marked 
symptoms; 4, very marked symptoms. 
 Calculating classic PASI, the classified body area involved (A), and the severity 
parameters are assessed for each of the four body regions (H, U, T and L), separately. 
Subsequently, A and the disease severity [erythema (E), induration (I) and desquamation (D)] 
are multiplied, and the result of this is multiplied by the BSA that corresponds to the 
assessed body region; 0.1 (H); 0.2 (U); 0.3 (T) or 0.4 (L). The sum of the PASI scores for all four 
body regions is the total classic PASI score.
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 The total classic PASI score is calculated using the following formula:
PASI = 0.1 x (EH+ IH+ DH)AH+ 0.2 x (EU+ IU+ DU)AU + 0.3 x (ET+ IT+ DT)AT+ 0.4 x (EL+ IL+ DL)AL1
The total classic PASI score ranges from 0 to 72.1
Low Psoriasis Area and Severity Index (Low PASI)
Low PASI comprises the same components as the classic PASI. To refine the body areas 
involved lower than 10%, we divided the area score of the classic PASI into four fractional 
components that are reflected in a four- point scale also called area (A): 0.25, 0.1 - 2.5% 
involvement; 0.50, 2.6 -  5%; 0.75,  5.1 - 7.5%; 1, 7.6 -  9.9%. 
 This means that an involved area of a half ‘handprint’ (0.5% of the BSA) on the head 
(10%), converted to that body area, as we earlier explained, will result in 0.5/0.1= 5% of 
the head involved, this is equivalent of a classified body area involved of A equal to 0.5. 
In the classical PASI, this would be an A equal to 1 (Table 1).
Statistical methods
Linear mixed models were used to study the interobserver agreement of the PASI and the 
Low PASI, separately. Note that a linear mixed model is an extension of a linear regression 
model. The dependent variable was the PASI score (Low PASI, respectively). The independent 
class variable was investigator (two levels), and the intercept of each patient was treated 
as a random variable. The intraclass correlation coefficient (ICC) of agreement with the 
95% confidence interval (CI) and the mean difference between the investigators with 
95% CI are presented.
 Similar linear mixed models were used to study differences between the two 
methods of each investigator, separately. At this point, the independent class variable was 
method (two levels: PASI, Low PASI). Again, the ICC (95% CI) and the mean difference (95% 
CI) are presented. The ICC assesses the consistency, or conformity, of measurements made 
by the two investigators (the two methods, respectively) measuring the same event 
simultaneously and independently.10  Values of the ICC range from 0 to 1, with a higher 
value indicating better reliability. ICC less than 0.40 is considered as poor; 0.40 to 0.59 as 
fair; 0.60 to 0.74 as good, and 0.75 to 1.00 as excellent. The statistical significance level was 
set at 0.05. Statistical analysis was performed using SAS® version 9.2 for Windows® (SAS 
Institute Inc., Cary, NC).
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Results
Ten patients (five men and five women) participated in this study. The mean age was 
41.4 years. The youngest patient was 18 years old and the oldest 65 years old. Table 2 
shows the classic PASI scores and the Low PASI scores for the two investigators. The mean 
classic PASI score for investigator 1 was 4.33 (SD 2.06) and for the second investigator 4.14 
(SD 2.37). The mean of the Low PASI scores for investigator 1 was 1.76 (SD 1.14) en for the 
second investigator 1.71 (SD 1.15). 
 The classic PASI scores of the two investigators ranged from 0.8 to 8.5, whereas the 
Low PASI scores ranged from 0.3 to 3.9. As can be seen in Table 2, one patient would have 
had a PASI of 8.5 using the classic PASI score, whereas this would be 3.9 using the Low PASI. 
Consequently, in this particular patient a difference of 4.6 in the score of the extent and 
severity of the disease was achieved by assessing the Low PASI.
Table 1   Upper boundaries conversion table from handprints to classified body area 
involvement scale in PASI and Low PASI scores in small involved areas.
PASI Low PASI
HEAD
Body area involveda (%) 0.1 –  0.9 0 - 0.25 0.26 - 0.5 0.6 - 0.75 0.76 - 0.9
Handprints < 1 ≤ 1/4 > 1/4 ≤ 1/2 > 1/2 ≤ 3/4    > 3/4 < 1
Area 1 0.25 0.5 0.75 1
UPPER EXTREMITIES
Body area involveda (%) 0.1 –  1.9 0.1 - 0.5 0.6 - 0.75    0.76 - 1.5 1.6 - 1.9
Handprints < 2 ≤ 1/2 > 1/2 ≤ 3/4 > 3/4 ≤ 1 ½      > 1 ½  < 2
Area 0.1 –  0.9 0.25 0.5 0.75 1
TRUNK
Body area involveda (%) 0.1 –  2.9 0.1 - 0.75 0.76 - 1.5     1.6 -  2.25 2.26 - 2.9
Handprints < 3 ≤ 3/4 > 3/4 ≤ 1 ½ > 1 ½ ≤ 2 ¼ > 2 ¼  < 3
Area 1 0.25 0.5 0.75 1
LOWER EXTREMITIES
Body area involveda (%) 0.1 –  3.9 0.1 - 1 1.1 - 2     2.1 - 3 3.1 - 3.9
Handprints < 4 ≤ 1 > 1 ≤ 2 > 2 ≤ 3 > 3 < 4
Area 1 0.25 0.5 0.75 1
Area score of the classic PASI is classified into a four-point scale. Bold values represent used score system.
503687-L-bw-van Geel
131
3
assessment measures on disease severity and psychosocial impact
Table 2   The observed PASI and Low PASI scores of each patient by investigator.
PASI Low PASI
Patient Inva 1 Inva 2 Inva 1 Inva 2
1 0.8 1.0 0.6 0.8
2 7.3 8.5 3.6 3.9
3 2.8 2.2 1.0 0.8
4 4.5 5.2 1.5 2.5
5 6.7 6.6 3.9 2.9
6 3.7 3.0 1.3 0.9
7 1.9 1.2 0.7 0.3
8 4.8 4.2 1.9 1.7
9 5.6 5.0 1.7 2.4
10 5.2 4.5 1.4 1.1
Mean 4.33 4.14 1.76 1.71
SD 2.06 2.37 1.14 1.15
Min 0.80 1.00 0.60 0.30
Max 7.30 8.50 3.93 3.93
SD: standard deviation.
a Inv: Investigator.
Table 3   The ICC and the mean differences between investigators of the PASI and  
the Low PASI, and between the methods of each investigator using a linear 
mixed model.
Methods ICCa (95% CIb) 
n = 10
Differences (95% CIb)
PASI inv1 – inv2c 0.95 (0.82; 0.99) 0.19 (-0.30; 0.68)
Low PASI inv1 – inv2c 0.87 (0.56; 0.97) 0.05 (-0.37; 0.46)
PASI inv1 - Low PASI inv1c 0.74 (0.25; 0.93) -2.57 (-3.44; -1.71)
PASI inv2 - Low PASI inv2c 0.75 (0.27; 0.93) -2.43 (-3.37; -1.49)
Note that the Low PASI in these patients is by definition lower than the classic PASI.
a ICC: intraclass correlation coefficient; b CI: confidential interval; c Inv: investigator.
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 The ICC of interobserver agreement was excellent for both the classic PASI (ICC: 0.95 
[95% confidence interval (CI): 0.82; 0.99)] and for the Low PASI [ICC: 0.87 (95% CI: 0.56; 0.97)]. 
However, the agreement between the methods is less [investigator 1: ICC: 0.74 (95% CI: 
0.25; 0.93); investigator 2: ICC: 0.75 (95% CI: 0.27; 0.93)]. In addition, on average the classic 
PASI scores were statistically significantly higher than Low PASI scores (investigator 1: 
mean difference, -2.57 (95% CI: -3.44; -1.71); investigator 2: mean difference: -2.43 (-3.37; -1.49) 
(Table 3)).
Discussion
The Low PASI score showed a strong interobserver agreement for the measurement of 
affected body areas lower than 10%. Furthermore, it allows more possible scores at lower 
levels of psoriasis extent (affected areas lower than 10% in a body region) than the classic 
PASI. Although, this is a pilot study, these findings may have important implications for 
earlier achievement of treatment goals (achievement of PASI 75 / 90).11 
 In our study, the Low PASI scores were on average 2.5 lower compared to the classic 
PASI scores, especially for classic PASI scores higher than 4.2. As was mentioned earlier, 
several studies have emphasized the limitation of the PASI score in small areas; the score 
in the small areas might only change if the severity scores (erythema, induration and 
desquamation) change.4-8 This limitation of the classic PASI score is the strength of the 
Low PASI score. The Low PASI score is able to measure and discriminate involved areas 
lower than 10% of a body region regardless changes in the severity scores. 
 Due to the lack of accuracy of the classic PASI score in the small areas, many authors 
attempted to modify or invent alternatives to replace the PASI score. These scores, 
however, were always based on new measurements (e.g. the PEASI and the PLASI) or the 
addition of extra measurements, such as quality of life assessments.7,9,12,13 These changes 
imply that professionals have to alter their daily practice, and eventually it can lead to 
avoidance and problems with its implementation. On the contrary, the Low PASI does not 
pretend to substitute the classic PASI score, but to refine it in the small areas. Besides, we 
attempted to preserve all principles of the classic PASI. Therefore, our score is easy to learn 
and to use in daily practice. 
 As mentioned before, the patient that scored in the classic PASI 8.5 will get a score of 
3.9 using the four-point scale for body areas involved lower than 10% of the Low PASI. This 
means a difference of 54.1% compared to the classic PASI. In daily practice, this difference 
may have consequences for treatment decisions.
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Conclusion
The Low PASI score allows more possible scores at lower levels of psoriasis extent (affected 
areas lower than 10% in a body region) compared to the classic PASI. Especially, it could 
be a useful score for assessing the effectiveness of treatments. The PASI assessment in 
the lowest ranges becomes more and more important to represent differences between 
the treatments. In the present analysis, our sample size of 10 participants was sufficient 
to show differences between the absolute scores of the classic PASI and Low PASI in 
the lowest ranges. Therefore, the Low PASI adds important and relevant information to 
the classic PASI which could  contribute to a better analysis of response to treatments. 
 To confirm the value of Low PASI in daily practice and in clinical studies, further 
studies should be focused on the validation of the Low PASI with a larger number of 
patients with mild-to-moderate psoriasis, the responsiveness to treatment and its stability 
over time.
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Abstract
Background: Dermatology Life Quality Index (DLQI) and Children’s Dermatology Life 
Quality Index (CDLQI) are widely used to assess quality of life (QoL) in adults (≥16 years) 
and children (4-16 years) with psoriasis. In the age group 16-17 years, it is not known 
whether DLQI and CDLQI reflect QoL impairment in the same way.
Objectives: To compare DLQI and CDLQI scores in patients with psoriasis aged 16-17 
years.
Methods: Patients with psoriasis aged 16-17 years were asked to complete both the DLQI 
and CDLQI. 
Results: Fifty-six patients were included. There was a high correlation between DLQI and 
CDLQI scores (r = 0.90, P  < 0.001). The mean DLQI score (5.41 ± 5.20) was lower than the 
mean CDLQI (6.61 ± 5.74) (P < 0.001). The major part of this difference (∆ 0.61) was caused 
by the low score regarding sexual difficulties in the DLQI  (0.11 ± 0.49) and the high score 
concerning sleep in the CDLQI (0.71 ± 0.93). In addition, the question related to sports 
scored 0.34 in the DLQI, but 0.86 in the CDLQI (∆0.52). The question related to work/study 
in the DLQI scored lower than the question on school/holiday in the CDLQI (∆0.41). 
Conclusions: In patients with psoriasis aged 16-17 years, DLQI and CDLQI scores closely 
correlate, but the mean DLQI score was lower than the mean CDLQI score. This was caused 
primarily by differences in the answers to questions regarding sexual difficulties and sleep. 
As the QoL impacts experienced by people aged 16-17 may differ from those experienced 
by children or adults, QoL measures designed for use in this age range may have 
advantages over both child- and adult-specific measures.
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Introduction
Psoriasis can have a negative impact on quality of life (QoL).1-8 The Dermatology Life 
Quality Index (DLQI)9,10 and the Children’s Dermatology Life Quality Index (CDLQI)11 are 
commonly used dermatology-specific QoL questionnaires in adults (≥16 years) and 
children (4-16 years) with psoriasis. As the lives and concerns of people with psoriasis aged 
> 16 years but < 18 years may differ from those of children or adults, it is not clear how best 
to measure their QoL.
 Both the DLQI and the CDLQI are simple, self-administered questionnaires with the 
same total score range (0-30), consisting of 10 questions reflecting the impact of skin 
diseases on the patients’ QoL over the last week.10,12 Table 1 gives the individual questions. 
Six questions in both questionnaires are substantially the same, differing only slightly.9,11 
These questions concern itch, embarrassment, clothing, social or leisure activities, sports 
and problems caused by treatment [questions (Q) 1, 2, 4, 5, 6 and 10]. Four questions differ 
widely between the DLQI and CDLQI. In the DLQI these questions concern shopping or 
looking after the home or garden (Q3), work or study (Q7), problems with partners, close 
friends or relatives (Q8) and sexual difficulties (Q9). In the CDLQI the questions concern 
friendships (Q3), school and holiday (Q7), adverse comments (Q8) and sleep (Q9).
 It is not known whether the DLQI and the CDLQI reflect QoL in the same way when 
used by people with psoriasis aged 16-17 years. Although the CDLQI is not validated for 
patients aged 17-18 years, the use of this questionnaire might provide additional 
information. The aim of this descriptive study was to examine and compare the way in 
which adolescents aged 16-17 years with psoriasis completed the DLQI and the CDLQI. 
This is important because the life issues that matter most to people of this age may not 
be fully captured by adult or children measures.13
Patients and methods
Study population and data collection
Data were extracted from the Child-CAPTURE (Continuous Assessment of Psoriasis 
Treatment Use Registry), a prospective, observational, longitudinal, daily clinical-practice 
pediatric psoriasis registry.5 Since August 2011, patients aged 16 and 17 years were asked 
to complete both the DLQI and the CDLQI at the same visit. As part of the routine data 
collection for the clinical-practice pediatric psoriasis registry, all patients were given the 
same series of questionnaires in which the CDLQI was presented first. In the present study, 
all patients aged 16-17 years who completed both the DLQI and the CDLQI from September 
2011 to October 2014 were included. 
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Outcome measures
Validated Dutch translations of the DLQI and the CDLQI (each with 10 questions; score 
range 0-30) were used.14 Each question was scored on a four-point Likert scale from 0 to 
3: 0, not at all/not relevant; 1, (only) a little; 2, (quite) a lot; 3, very much.9-12 Higher scores 
indicate more impact on QoL.9-12
Analyses 
The outcomes of all included patients were evaluated and described. SPSS version 20.0 for 
Windows (IBM, Armonk, NY, U.S.A) was used to calculate the characteristics of the patients. 
The Wilcoxon signed-rank test was used to compare the DLQI and CDLQI scores. The 
correlation coefficient between the DLQI and the CDLQI was calculated with the Pearson 
correlation test. P-values < 0.05 (two sided) were considered statistically significant. 
 As data were extracted from the Child-CAPTURE registry, the institutional review board 
considered this study in accordance with the applicable rules concerning the review of 
research ethics committees and informed consent. 
Results 
All patients agreed to participate. In total 56 patients (43% male) were included (Table 2). 
The mean age was 16.6 years. Patients attending the clinics were using topical therapy 
only (68% of all patients), systemic therapy (20%) or no therapy (13%). 
Most and least affected topics in the questionnaires
The mean DLQI score (5.41 ± 5.20) was 1.20 points lower than the mean CDLQI (6.61 ± 5.74) 
(P < 0.001) (Table 1). The major part of this difference (∆0.61) was caused by the low score 
regarding sexual difficulties in the DLQI (0.11 ± 0.49) and the high score concerning sleep 
in the CDLQI (0.71 ± 0.93). In addition, the question related to sports (present in both 
questionnaires) scored 0.34 in the DLQI but 0.86 in the CDLQI (∆0.52). The question related 
to work/study in the DLQI scored lower than the question on school/holiday in the CDLQI 
(∆0.41). 
 In the DLQI, the question topics with the highest mean scores were itch (1.18 ± 0.92), 
embarrassment (0.88 ± 0.92), clothing (0.71 ± 0.97) and problems with treatment (0.71 
± 0.95). In the CDLQI the question topics with highest mean scores were itch (1.18 ± 0.92), 
embarrassment (0.86 ± 1.0), sports (0.86 ± 1.09), school/ holiday (0.86 ± 0.88) and problems 
with treatment (0.84 ± 0.85). In contrast, the DLQI questions related to sexual difficulties 
(0.11 ± 0.49) and to shopping or looking after the home or garden (0.27 ± 0.62) scored 
lowest. The lowest-scoring questions in the CDLQI concerned friendships (0.07 ± 0.26) and 
adverse comments (0.30 ± 0.60).
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Correlation between Dermatology Life Quality Index and Children’s 
Dermatology Life Quality Index scores
Figure 1 shows the relationship between the individual DLQI and CDLQI scores (correlation 
= 0.90, P < 0.001).
Score descriptor banding of the Dermatology Life Quality Index and 
Children’s Dermatology Life Quality Index
The mean scores for the DLQI (5.41) and the CDLQI (6.61) were both at the borderline 
between the relevant score band descriptors of ‘small effect on QoL’ and ‘moderate effect 
on QoL’ (Table 3). In 15 of the 56 patients (27%) the DLQI was interpreted as there being 
Table 1   Individual question scores for the Dermatology Life Quality Index (DLQI) and 
Children’s Dermatology Life Quality Index (CDLQI).
Question DLQI CDLQI DLQI score CDLQI score
n = 56 n = 56
Total 5.41 ± 5.20 6.61 ± 5.74
1 Itch/pain Itch/pain 1.18 ± 0.92 1.18 ± 0.92
2 Embarrassment Embarrassment 0.88 ± 0.92 0.86 ± 1.0
3 Shopping/
looking after home or 
garden
Friendships 0.27 ± 0.62 0.07 ± 0.26
4 Clothing Clothing 0.71 ± 0.97 0.59 ± 0.89
5 Social or leisure 
activities
Going out/playing/doing 
hobbies
0.46 ± 0.66 0.34 ± 0.64
6 Sports Swimming/sports 0.34 ± 0.61 0.86 ± 1.09
7 Work/study School/holiday 0.45 ± 0.87 0.86 ± 0.88
8 Problems with 
partners/close friends/
relatives
Teasing/bullying/ asking 
questions/ avoiding
0.30 ± 0.60 0.30 ± 0.60
9 Sexual difficulties Sleep 0.11 ± 0.49 0.71 ± 0.93
10 Treatment Treatment 0.71 ± 0.95 0.84 ± 0.85
Values are the mean ± SD. The possible score range for each individual question of the DLQI and CDLQI is 0-3.
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no effect on the patient’s life (band 0, score 0-1), whereas the impact was observed as 
small (band 1, score 2-5), moderate (band 2, score 6-10), very large (band 3, score 11-20) and 
extremely large (band 4, score 21-30) in 32%, 20%, 20% and 2%, respectively. 
Table 2   Patient characteristics (n = 56).
Patient characteristic Value
Age (years), mean (range) 16.6 (16-17)
Sex male, n (%) 24 (43)
Prescribed treatment, n (%)
Topical 38 (68)
Systemic
With additional topical therapy
11
7
(20)
(13)
No additional topical therapy 4 (7)
None 7 (13)
Figure 1   Correlation between Dermatology Life Quality Index (DLQI) and Children’s 
Dermatology Life Quality Index (CDLQI) scores.
Correlation = 0.90, P < 0.001. 
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 However, for the CDLQI the impact was interpreted as none (band 0, score 0-1), small 
(band 1, score 2-6), moderate (band 2, score 7-12), very large (band 3, score 13-18) and 
extremely large (band 4, score 19-30) in 18%, 43%, 21%, 14% and 4% of the patients, 
respectively (Figure 2). 
 With both the DLQI and the CDLQI, approximately 60% of patients were in band 0 or 1. 
However, in band 0 the percentage (27%) of DLQI subjects was higher than the percentage 
of CDLQI subjects, and in band 1, the percentage (43%) of CDLQI subjects was higher 
than the percentage of DLQI subjects.
Table 3   Headings and banding descriptors for the Dermatology Life Quality Index 
(DLQI) and the Children’s Dermatology Life Quality Index (CDLQI).
DLQI   CDLQI
Headings
Symptoms and feelings (Q1-2) Symptoms and feelings (Q1-2)
Daily activities (Q3-4) Leisure (Q4-6)
Leisure (Q5-6) School or holidays (Q7)
Work and school (Q7) Personal relationships (Q3,8)
Personal relationships (Q8-9) Sleep (Q9)
Treatment (Q10) Treatment (Q10)
Bandings
0 0-1 No effect 0-1
1 2-5 Small effect 2-6
2 6-10 Moderate effect 7-12
3 11-20 Very large effect 13-18
4 21-30 Extremely large effect 19-30
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Discussion
In our study, in which only patients aged 16-17 years with psoriasis were included, the 
mean total DLQI score was 1.2 points lower than the mean total CDLQI score. The major 
part of this difference was due to Q9, which is related to sexual difficulties in the DLQI. 
In the CDLQI this question concerns sleep (∆0.61). In the DLQI the mean score of the sexual 
difficulties question was the lowest for all questions (0.11), whereas the sleep question in 
the CDLQI scored highly (0.71). Sexual issues could be important to some people with 
psoriasis aged 16-17 years; however, it is unknown whether the low mean score implied 
that the subjects experienced few sexual difficulties, whether this item was not relevant 
for them, or whether embarrassment and/or the presence of a parent during questionnaire 
completion influenced their answers. 
 The high-scoring CDLQI question regarding sleep is clearly relevant for this age 
group. Sleep impairment has been reported in a cohort of 125 children with psoriasis, of 
which a subgroup was aged 16-17 years old.5 Sleep impairment has also been described 
in adults with psoriasis.15-17 Sleep problems because of psoriasis are more likely to persist 
over a lifetime in patients with earlier age of disease onset.18  Some QoL instruments 
incorporate a question related to sleep,15,17 although not the DLQI. If patients aged 16 
years and above complete only the DLQI9, the impact of their psoriasis on their sleep is not 
highlighted, even though it is possible that some aspects of the results of sleeping poorly, 
such as the impact on work or study, may be reflected in the answers to other questions. 
Figure 2   Score descriptor banding of the Dermatology Life Quality Index (DLQI) and 
Children’s Dermatology Life Quality Index (CDLQI).
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When choosing which questionnaire to use to measure QoL in this age group, 
consideration should be given to whether or not the instrument incorporates a question 
concerning sleep.
  The question concerning work/study in the DLQI scored remarkably lower (∆0.41) 
than the question relating to school/holiday in the CDLQI. It seems that the concepts of 
school and holiday are more appropriate than work and study for this age group. In the 
Netherlands, most people start their higher education ‘study’ after the age of 18 years, and 
only a minority of 16-17 year olds have paid employment. 
 Although a similar question (Q6) concerning sports occurs in both the DLQI and the 
CDLQI, there was a considerable difference in the way this question was scored, with the 
CDLQI question scoring much higher (∆0.52). This might be caused by the additional word 
‘swimming’ in the CDLQI question. Swimming may be an important activity at this age, or 
the word swimming may give rise to other associations. 
 It is remarkable that low scores were recorded for effects on friendships. This may 
reflect that the question relates more to established friendships than meeting new 
people, which is likely to be much more of an issue in this age group.
 In a recent study in which the DLQI was completed by 192 patients aged 16-91 years 
with 20 different skin conditions, the most affected topics were the items 1, 2 and 4 
regarding physical symptoms, embarrassment and impact on clothes, whereas the least 
affected topic was Q9 on sexual difficulties.19 These findings are in accordance with our 
results. 
 As the QoL impacts experienced by subjects aged 16-17 years may differ from those 
experienced by children or adults,13 QoL measures designed for use in this age range may 
have advantages over both child- and adult-specific measures. Some specific instruments 
to assess QoL in adolescents with skin diseases have already been developed (e.g. the 
Skindex-Teen20 and T-QoL).21 Indeed, the Skindex-Teen20 incorporates more items in the 
psychosocial functioning domain, and T-QoL21 includes eight questions on self-image 
and six questions on psychological impact. These measures may therefore be more 
sensitive for this specific age group than either the DLQI or CDLQI. Also, acne-specific 
measures (e.g. the Cardiff Acne Disability Index, CADI),14 were designed for use in this age 
group. To our knowledge, psoriasis-specific QoL instruments designed for use in patients 
16-17 years are lacking. 
 In our study the mean total DLQI was 1.20 points lower than the mean total CDLQI. 
This difference was minor compared with the minimal clinically important difference 
(MCID) (score change = 4.0) for the DLQI.19 Therefore, although this study has focused on 
differences in the scoring between the DLQI and CDLQI, it is reassuring that there is such 
a close correlation between the overall scores, with the difference between the means 
being well below the MCID for the DLQI.  So far, data on the MCID for the CDLQI are not 
available. In 2005, a score descriptor banding system was established to improve the 
clinical interpretation of the DLQI (Table 3).10,22 Comparable score descriptor bands were 
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suggested for the CDLQI, but these data have been published only as an abstract; the 
detail of their validation is therefore not known.12,23 
 In this study, the percentage of patients in band 1 was highest in both the DLQI and 
the CDLQI, corresponding to a small effect on a patient’s life. Whereas for the DLQI the 
percentage of patients was higher in band 0, for the CDLQI this percentage was higher in 
band 1 (Figure 2). This suggests that when patients with psoriasis experience lower levels 
of QoL impact, this is detected more successfully by the CDLQI. However, in band 3, 
corresponding to a very large effect on a patient’s life, the percentage of patients was 
higher for the DLQI than for the CDLQI. It would be interesting to understand from the 
patients’ perspective whether in their view the DLQI or CDLQI scores best reflect their 
experience. However, as this study reports data collected routinely in the clinic for a daily 
clinical-practice pediatric psoriasis registry it was not possible to address this.
 The close correlation between the two measures does give some reassurance in the 
context of those studies that have used the CDLQI in subjects aged 17-18 years. Although 
the CDLQI was not originally designed for or validated in this age range, the scores and 
associated score meaning bands recorded in this study are appropriate in the context of 
the parallel DLQI scores, and may even be more sensitive in detecting low levels of impact.
 The data reported are based on questionnaires that had been collected routinely for 
the clinical-practice pediatric psoriasis registry. As this was not a prospective study there 
was not the opportunity to present the CDLQI and DLQI in random order. It is possible 
that routinely presenting the CDLQI for completion before the DLQI may have biased the 
DLQI completion.
 In conclusion, in patients with psoriasis aged 16-17 years, the DLQI overall scored 
lower than the CDLQI. This was caused primarily by differences in the answers given to the 
questions regarding sexual difficulties (low score in the DLQI) and sleep (high score in 
the CDLQI). In addition, the question related to sports (present in both questionnaires) 
revealed a remarkable difference, with lower scores in the DLQI. The question related to 
work/study in the DLQI scored lower than the question on school/holiday in the CDLQI. 
Neither the DLQI nor the CDLQI are specifically designed for people aged 16-17 years, 
but up to now it has not been clear how these questionnaires perform comparatively in 
this age group. In studies designed to assess QoL in this specific age group, consideration 
should be given to using measures validated specifically for patients of these ages. 
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Abstract
Background: The Simplified Psoriasis Index (SPI) is a three-domain assessment measure 
for psoriasis, including separate indicators of current severity (SPI-s), psychosocial impact 
(SPI-p), and past history and interventions (SPI-i). There are two complementary versions 
available designed for completion by a health professional (proSPI) or by patient self- 
assessment (saSPI). The validity and reliability of proSPI versus saSPI have already been 
demonstrated in adults. To date, validated severity measures for pediatric psoriasis do not 
exist. 
Objective: To validate the current severity (SPI-s) and psychosocial impact (SPI-p) domains 
of proSPI and saSPI in children and adolescents with psoriasis. 
Methods: All patients <18 years with psoriasis visiting the dermatology outpatient 
department of the Radboud university medical center in the Netherlands between 
September 2013 and April 2014 were asked to complete Dutch versions of saSPI and the 
Children’s Dermatology Life Quality Index (CDLQI). The original English versions of proSPI 
and PASI (Psoriasis Area and Severity Index) were completed by the physician at the same 
visit. 
 Results: 113 patients (median age 12.0, range 4-17 years) were included. There was a close 
correlation between proSPI-s and PASI (r = 0.87), which was higher than that between 
saSPI-s and PASI (r = 0.69). The correlation between SPI-p and CDLQI was 0.78. The full 
range of scores was utilized in both proSPI-s and SPI-p, although the highest saSPI-s score 
was 30 (maximum 50). 
Conclusions: In pediatric psoriasis, proSPI and saSPI are shown to be valid and usable. 
SPI-s and SPI-p can be readily introduced into routine clinical practice. 
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Introduction
Psoriasis is a common chronic inflammatory skin disorder which can have a major negative 
impact on quality of life (QoL).1,2 For optimal therapeutic decision-making, it is essential to 
have valid and reliable clinical measures to assess psoriasis severity and its impact on 
patients’ lives as precisely as possible. In about one third of patients, psoriasis starts before 
adulthood.3 In pediatric psoriasis, the most widely used measures for assessing disease 
severity and QoL are the Psoriasis Area and Severity Index (PASI)4 and the Children’s 
Dermatology Life Quality Index (CDLQI)5 respectively. The CDLQI has been validated in 
children aged between 4 and 16 years5, whereas validation of PASI in children and 
adolescents has never been performed. 
 The Simplified Psoriasis Index (SPI) is a three-domain assessment measure for psoriasis, 
including separate indicators of current severity (SPI-s), psychosocial impact (SPI-p), and 
past history and interventions (SPI-i).6,7 The first domain, SPI-s (range 0-50), is calculated by 
multiplying a composite psoriasis extent score (range 0-10) by an overall average severity 
score (range 0-5).6 The former is derived using a three-point scale (0, absent or minimal; 
0.5, noticeable; 1, extensive) to allocate a psoriasis extent score to each of ten body areas, 
with extra weight given to the scalp, face, hands, feet and anogenital skin in order to 
reflect their greater functional and psychosocial impact.6 The second domain, SPI-p, 
records the psychosocial impact of psoriasis as a Likert scale (0-10) derived from the 
patient’s (or parent’s) marking of a 10-cm visual analogue score line.6 The third domain, 
SPI-i, comprises four questions about disease course and six about previous interventions 
received.6 Detailed information is described by Chularojanamontri et al.6 The original SPI 
proformas are freely available for download.6
 SPI is available in two complementary versions, enabling it to be completed either by 
health professionals (proSPI) or by patients using a simplified self-assessment proforma 
(saSPI).6,7 The validity and reliability of proSPI and saSPI have been demonstrated in adults.6 
To date, validated severity measures for pediatric psoriasis do not exist. This study was 
designed to investigate the criterion validity, construct validity and response distribution6 
of SPI-s and SPI-p in both the professional and the self-assessment versions of SPI in a 
Dutch population of children and adolescents (<18 years of age) with psoriasis. 
Methods
Criterion validity, construct validity and response distribution
We used the same methodology for defining and assessing validity as were used in the 
original publication by Chularojanamontri et al.6 
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Criterion validity compares the extent to which a measure relates to a gold standard.6,8 
We used PASI and CDLQI as the standards against which to measure SPI-s and SPI-p respectively 
by investigating the correlations between: 
a) proSPI-s and PASI
b) saSPI-s and PASI
c) SPI-p and CDLQI
Construct validity measures the extent to which an instrument relates to other measures.6,8 
The relationships between the three psoriasis severity scores and the two psychosocial 
impact scores were investigated as follows: 
a) proSPI-s, saSPI-s, and PASI versus CDLQI
b) proSPI-s, saSPI-s, and PASI versus SPI-p
Response distribution measures whether the entire range of a scale is used.6,8 We examined 
the response distributions of proSPI-s, saSPI-s and SPI-p. 
Study population and data collection6
From September 2013 to April 2014 all children and adolescents <18 years with psoriasis 
attending the dermatology outpatient department at the Radboud university medical 
center in the Netherlands were asked to complete saSPI and CDLQI. The order in which 
patients filled out the questionnaires was random. A photographic image key with several 
examples of psoriasis severity6 was attached to the saSPI. At the same visit, proSPI and PASI 
were completed by author MJvG who was familiar with PASI-scoring but not with SPI. 
The proSPI and saSPI scores were collected as part of the routine data collection for a daily 
clinical practice pediatric psoriasis registry, the Child-CAPTURE (Continuous Assessment of 
Psoriasis Treatment Use Registry).2 The present study was considered by the institutional 
review board in accordance with the applicable rules concerning the review of research 
ethics committees and informed consent. 
Assessment tools
Simplified Psoriasis index
Detailed description on the original development and contents of the validated SPI in 
adults is described by Chularojanamontri et al.6 The proSPI-s and proSPI-p proforma used 
in this study was identical to the one described in adults.6 The saSPI-s and saSPI-p, were 
however, slightly modified with the agreement of the original authors to make the 
proforma more easily understood by children (and/or their parents). The modified saSPI 
proforma was then translated into Dutch. Children were allowed to get help in completing 
saSPI from their parent and/or guardian. 
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CDLQI
To quantify the psychosocial impact of psoriasis a validated Dutch translation of the CDLQI 
was used as the reference standard.5,9 The CDLQI is a commonly used dermatology- 
specific QoL self-administered questionnaire in children including ten questions (score 
range 0-30).5 Higher scores indicate more impact on QoL.5 
PASI
PASI was used to assess the extent and severity of psoriasis (score range 0-72).4 
Analyses
All proSPI and saSPI proformas with one or more missing values were excluded. SPSS® 
version 22.0 for Windows® (SPSS Inc., Chicago, IL, U.S.A) was used to perform the statistical 
analyses. Correlation coefficients were calculated using two-tailed Spearman’s correlation 
coefficients with values of >0.8, 0.5-0.8, and <0.5 indicating a good, average and poor 
correlation respectively.6,10 
Results 
Patient characteristics
In total 113 patients with psoriasis (54.9% female) were included, whereas 10 patients 
were excluded because of one or more missing values. Median age was 12.0 years with a 
range between 4 and 17 years. In most of the patients (72.6%) disease onset was before 
age 10. Median PASI was 4.0 (range 0-19.9), while median CDLQI was also 4.0 (range 0-23). 
 Criterion validity (Table 1): proSPI-s was closely correlated with PASI (r = 0.87). 
Correlation between saSPI-s and PASI was lower (r = 0.69). The correlation between SPI-p 
and CDLQI (r = 0.78) indicated that SPI-p was a valid summary measure of QoL impairment 
in children and adolescents. 
 Construct validity (Table 1): saSPI-s was moderately correlated with SPI-p (r = 0.68) and 
CDLQI (r = 0.64). This correlation was higher than the correlations between the two 
psychosocial impact measures and either PASI (PASI vs. SPI-p: r = 0.40; PASI vs. CDLQI: 
r = 0.39) or proSPI-s (proSPI-s vs. SPI-p: r = 0.43; proSPI-s vs. CDLQI: r = 0.44). 
 Response distribution: A wide range of scores was obtained for all measures, although 
saSPI-s scores >30 were not utilized: the median proSPI-s and saSPI-s scores were 3.0 
(range 0-50) and 3.5 (range 0-30) respectively (Figure 1). Median SPI-p was 3.0 (range 0-10). 
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Table 1   The correlation between proSPI-s, saSPI-s, PASI, SPI-p and CDLQI in  
113 children and adolescents aged <18 years with psoriasis.
Spearman rank  
correlation coefficients
proSPI-s saSPI-s PASI SPI-p CDLQI
proSPI-s - 0.67 0.87 0.43 0.44
saSPI-s 0.67 - 0.69 0.68 0.64
PASI 0.87 0.69 - 0.40 0.39
SPI-p 0.43 0.68 0.40 - 0.78
CDLQI 0.44 0.64 0.39 0.78 -
proSPI-s, severity component of the professional Simplified Psoriasis Index; saSPI-s, severity component of the 
self-assessment Simplified Psoriasis Index; SPI-p, psychosocial impact component of the Simplified Psoriasis 
Index; PASI, Psoriasis Area and Severity Index; CDLQI, Children’s Dermatology Life Quality Index.
Figure 1   The response distributions of proSPI-s and saSPI-s in 113 patients.
SPI, Simplified Psoriasis Index; proSPI-s, severity component of the professional Simplified Psoriasis Index; 
saSPI-s, severity component of the self-assessment Simplified Psoriasis Index.
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Discussion
This study has shown that both the professional and self-assessment versions of SPI are 
valid assessment tools and suitable for routine clinical use in documenting psoriasis 
severity and psychosocial impact in children and adolescents. Our findings are similar to 
those reported in adults,6 with a close correlation between proSPI-s and PASI (r = 0.87) and 
a rather lower correlation between saSPI-s and PASI (r = 0.69). The correlation between 
SPI-p and CDLQI (r = 0.78) was satisfactory, although somewhat lower than that reported 
between SPI-p and Dermatology Life Quality Index (DLQI) in adults (r = 0.89).6
 Valid and reliable severity measures are essential in order to plan and monitor psoriasis 
therapy optimally. Although there are many psoriasis severity measures available for use in 
adults, none was found to be adequately validated and no best instrument was identified 
in a systematic review published in 2010.7,8 The authors of the review did, however, 
suggest that, as PASI was the most commonly reported measure in research publications, 
it permitted some comparison of results from clinical trials.8 Neither PASI nor any other 
psoriasis measure has ever been validated in children. 
 It is important to note the differences between PASI and SPI-s. The latter dispenses 
with the need to estimate body surface area involvement and replaces it with a three 
option choice for each of its ten body areas.6 Furthermore, the added weight given to 
functionally or psychosocially important body sites such as the face, scalp and hands 
enables SPI-s to capture areas of involvement which cannot be adequately represented by 
PASI.6 Complete agreement between PASI and SPI-s is not to be expected. We chose PASI, 
however, as the best available reference standard for psoriasis severity against which to 
validate SPI-s. 6-8,11 To our knowledge, SPI-s is now the first validated severity measure for 
pediatric psoriasis. 
 An advantage of SPI over other psoriasis assessment measures is that the SPI includes 
a self-assessment version (saSPI), which can provide valuable insight into patients’ 
perceptions of their disease, whether they be adults or children, particularly where saSPI 
and proSPI scores diverge.6 The correlation between saSPI-s and PASI in our pediatric 
population (r = 0.69) was essentially the same as that observed in an adult population (r = 
0.70) with a closer correlation between severity and psychosocial impact (SPI-p and 
CDLQI) when scored by patients using saSPI-s rather than by health professionals using 
proSPI-s or PASI in both studies.6 
 Apart from saSPI, there are few patient-administered psoriasis severity measures for 
adults:8,11,12 they include the Self-Administered PASI (SAPASI)13,14, the Patient Report of 
Extent of Psoriasis Involvement (PREPI)15 and the Patient’s Global Assessment (PaGA).8 Of 
these, to the best of our knowledge, only SAPASI has been compared with PASI. The 
correlation between PASI and SAPASI has been described as moderate to good in adults, 
with correlation rates similar to those between PASI and saSPI-s in our study of children 
and adolescents.8,11-14,16-22 It is, however, complex to use, requiring a professional to 
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estimate body surface area involvement from the patient’s sketches.23 We have been able 
to show that saSPI-s is a valuable quantitative patient self-assessment measure of disease 
severity for children and adolescents with psoriasis. 
 It has to be noted that the photographic image key illustrating grades of psoriasis 
severity as a guide to scoring saSPI-s for adults6 was not developed for use in children. We 
observed that children found these images disturbing; however, a visual guide to 
distinguish the different severity grades might be of added benefit, especially for children, 
perhaps utilizing a computer-generated 3d graphic doll mannequin. 
 In addition to the clinical severity measures discussed above, SPI includes a 
psychosocial impact component (SPI-p).6 In our pediatric population SPI-p was closely 
correlated with CDLQI (r = 0.78), which is in line with the correlation between SPI-p and 
DLQI in adults (r = 0.89).6 SPI-p could be simply and rapidly obtained in children and 
adolescents, though, in contrast to CDLQI5, it gives the professional no specific information 
on which aspects of QoL are impaired. 
 As noted above, it is noteworthy that both psychosocial impact measures (SPI-p 
and CDLQI) were more closely correlated with saSPI-s than with the other two severity 
parameters (proSPI-s and PASI), as was observed in adults by Chularojanamontri et al. 
This suggests that both adults and children are influenced by the psychosocial impact of 
their disease when scoring their disease severity.6 
 The original SPI as described by Chularojanamontri et al.6 includes a third domain 
(SPI-i) intended to capture summary information about past history and interventions 
received. Initially, a slightly modified version of SPI-i was incorporated into the proforma 
given to patients and parents. We found, however, that this was difficult and time- 
consuming for them to complete and added little information which we did not already 
know. We therefore decided to remove this domain from our pediatric version of SPI.  
 In conclusion, it is reassuring that there is such concordance between our pediatric 
psoriasis data and the validated data described in adults.6 Although we feel that our 
modified children’s SPI can be readily introduced into clinical practice and provides a 
simple and valuable way of assessing and monitoring psoriasis in children and adolescents, 
further studies are needed to determine the suitability of the pediatric version of SPI for 
use in clinical trials as well as in routine clinical practice. 
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summary, discussion and main conclusions
In the summary and discussion below, all aims of the thesis will be separately summarized, 
addressed and discussed. In addition, main conclusions of this thesis will be formulated. 
Treatments
Aim 1: To investigate prospectively the effectiveness, safety and influence on quality of life of 
calcipotriol/ betamethasone dipropionate ointment in pediatric psoriasis in daily clinical practice.
In Chapter 2.1 we provided a prospective, daily clinical practice study on the effectiveness, 
safety and influence on quality of life (QoL) of calcipotriol/betamethasone dipropionate 
ointment in 73 children and adolescents with psoriasis. Median treatment duration was 35 
weeks (range 1-176). At week 12, mean Psoriasis Area and Severity Index (PASI) was slightly 
improved from 5.2 to 4.4 (15.4%), whereas at week 24 its effect was maintained (PASI 4.3, 
17.3% improvement). Patients who were assigned to the more intensive treatment regimen 
(prescription of the ointment for once-daily use for four weeks, thereafter once daily four 
times per week) started with higher baseline PASI scores and revealed more improvement 
in PASI than patients who were prescribed the less intensive treatment regimen (starting 
directly with once-daily application four times per week). At week 12, median Children’s 
Dermatology Life Quality Index (CDLQI) significantly improved from 5.5 at baseline to 4.0 
and visual analogue scale (VAS) scores for pain and itch declined. In five patients (7%) 
possible treatment-related adverse events (AEs) were described of which four patients 
had striae. Related serious adverse events (SAEs) did not occur. 
 To the best of our knowledge, studies on the use of this two-compound ointment in 
pediatric psoriasis are lacking. However, three recent studies were published on the use of 
calcipotriol/ betamethasone dipropionate gel to treat pediatric scalp psoriasis.1-3 One of 
these studies described a prospective, daily clinical practice cohort of pediatric psoriasis 
patients aged 4-17 years (84 treatment episodes) and demonstrated significant 
improvements in Psoriasis Scalp Severity Index from 18.7 ± 11.8 to 12.7 ± 9.4 in the first 
12 weeks. Its effect was maintained through 48-weeks follow-up. Striation of the skin was 
reported in three patients (4.1%).1 The other two studies were both phase II, prospective, 
open-label, multicenter, single-arm, eight-week studies in respectively 782 and 313 
adolescents with scalp psoriasis (aged 12-17 years) with safety as the primary endpoint. 
AEs, which were mostly mild, were reported in 35%2 and 52%3 of the patients respectively.2-4 
Neither clinically relevant changes in parameters of calcium metabolism nor SAEs were 
observed.2-4 Direct comparison, however, between our data on the two-compound 
ointment and these studies on the formulation in gel vehicle to treat scalp psoriasis, is not 
possible due to differences in assessment measures, treatment regimens, and the used 
vehicle. 
 The adherence to treatment in the two multicenter, eight-week trials on the use of 
the two-compound gel was reasonably high.2-4 Due to the daily clinical practice design of 
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our study, we did not measure treatment adherence. Adherence to topical treatments in 
psoriasis and other skin diseases is known to be poor5-9, especially in adolescents.2,3,5,10,11 
One of many strategies to improve treatment adherence is the scheduling of early and 
more frequent follow-up visits5-7,12-14, which might induce better treatment outcomes.7,15 
As the return visits in our daily clinical practice study were variable and not scheduled to 
drive adherence, treatment adherence was probably lower than reported in the 
eight-week trials. In addition, the follow-up time was much longer in our study, which is 
not driving adherence too. It is also known that treatment adherence can be influenced 
by the kind of vehicle used3,5,7,16,17 and that adult psoriasis patients preferred the 
two-compound gel to the ointment in real life clinical practice, as it was more convenient, 
easier to use, and faster to apply.15 However, whether pediatric patients prefer the gel to 
the ointment has not been investigated yet. The fact that we used an ointment in our 
study might have negatively influenced adherence. At the moment, an international, 
multicenter, prospective, open-label, non-controlled, single-group, four-week trial on the 
safety and efficacy of once-daily topical treatment with the two-compound formulation 
in aerosol foam in adolescents (aged 12 < 17 years) with plaque psoriasis is in the 
developmental pipeline.18 Theoretically, it may well be that in adolescents with body and 
scalp plaque psoriasis this aerosol foam will be preferred due to its less greasy and messy 
vehicle.4,19,20 Hopefully, this new vehicle will improve adherence and therefore, indirectly, 
improve clinical outcomes.
 In our study AEs were addressed by the patient and/or parent or noticed by the 
physician. As striae distensae are commonly observed in adolescents, particularly with 
rapid growth spurts21,22 and obesity,22,23 and a control group was lacking, a conclusion on 
the (relative small) number of striae in our study was not possible. Due to its daily clinical 
practice design, routine laboratory tests and urine analyses to detect systemic absorption 
were not performed. Ideally, it would be interesting to investigate the effects on the hypo-
thalamic-pituitary-adrenal (HPA) axis and calcium metabolism. Fortunately, at the moment, 
there are two upcoming trials investigating the safety and effects of the two-compound 
product in gel and aerosol foam vehicle respectively on HPA axis and calcium metabolism 
in adolescents (aged 12 < 17 years) with psoriasis.18,24 
 In conclusion, it is very important to obtain data from a daily clinical practice setting 
in addition to the information provided by randomized controlled trials (RCTs). Although 
RCTs will include scheduled follow-up visits to drive adherence and will assess the effects 
on HPA axis and calcium metabolism, advantages of daily clinical practice data include the 
possibility to provide long-term data and to reveal information on patients not strictly 
fitting the inclusion criteria of RCTs.25 Therefore, daily clinical practice data will probably 
reflect real-life treatment practice more precisely. 
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Aim 2: To present a systematic overview on the efficacy and safety of systemic treatments in 
pediatric psoriasis.
 
and
Aim 3 and 4: To investigate prospectively the effectiveness, safety and the influence on quality of 
life of methotrexate (aim 3) and fumaric acid esters (aim 4) in pediatric psoriasis in daily clinical 
practice. 
In Chapter 2.2 we presented a systematic evidence-based update of the literature on efficacy 
and safety of all systemic treatments in pediatric psoriasis until March 2014. Regarding 
the conventional systemic treatments, most data were available on methotrexate (MTX), 
although the evidence was retrospectively collected and of low level. New was the 
evidence on fumaric acid esters (FAE), albeit retrospectively collected in a low number 
of patients. Of all systemic treatments, etanercept has accumulated most evidence, 
demonstrating maintained efficacy and reassuring safety through 96 weeks.26 Overall, 
the available evidence on efficacy and safety of systemic treatments in pediatric psoriasis 
was concluded to be limited as prospective studies were scarce and most studies had low 
level of evidence. In addition, apart from 96-weeks safety and efficacy data on etanercept, 
long-term safety data were lacking. 
Because the evidence on the conventional systemic treatments was still sparse, we 
decided to analyse daily clinical practice data from our prospective Child-CAPTURE registry 
on the use of MTX (Chapter 2.3) and FAE (Chapter 2.4) in children and adolescents 
with psoriasis. 
 In Chapter 2.3 we investigated prospectively the effectiveness, safety and the 
influence on QoL of MTX in 25 pediatric psoriasis patients in daily clinical practice. 
Treatment duration ranged from 12.6 to 163.4 weeks, with a median of 60.4 weeks. Rates 
of PASI 75 were achieved in 4.3%, 33.3%, 40% and 28.6% of patients at week 12, 24, 36 and 
48, respectively. Median PASI improved from 10.0 (range 3.8-42.4) at baseline to 4.3 (range 
0-19.8) at week 24, whereas median CDLQI decreased from 9 (range 2-20) to 3.8 (range 
0-21). MTX seemed to have a reasonable safety profile with severe nausea (n = 5), infections 
requiring antibiotics or antiviral medication (n = 5) and severe tiredness (n = 4) as most 
frequently reported AEs of interest. The only reported SAE was hospitalization because of 
pneumonia which resolved without sequelae. 
 This study was the first to present prospective data in the literature on the 
effectiveness, safety and influence on QoL of MTX in children and adolescents with 
psoriasis. Based on our clinical impression of the effectiveness of MTX before analysing 
our Child-CAPTURE data, we were somewhat disappointed by the results of our own 
study. Very recently however, more or less similar effectiveness data were found in a 
prospective, multicenter, randomized, double-blind trial which investigated the safety 
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and efficacy of two doses of adalimumab (0.4 mg/kg up to 20 mg and 0.8 mg/kg up to 
40 mg) versus MTX in 114 pediatric patients with severe chronic plaque-type psoriasis.27-29 
Thirty-seven patients (mean age 13.4 years) were treated with MTX (0.1-0.4 mg/kg weekly 
up to 25 mg/week) for 16 weeks.28 PASI 75 was achieved in 32.4% of patients at week 16. 
AEs occurred in 75.7% of patients of which 54.1% infections, whereas deaths, serious 
infections, malignancies or SAEs did not occur.27,28 Direct comparison, however, is difficult 
as effectiveness data were presented at different time points (week 16 in the RCT28 and 
week 12 and 24 in our study). Despite the higher baseline PASI in the RCT (mean 19.2, SD 
10.0)28 compared to our study (median 10.0, range 3.8-42.4) effectiveness results were, 
however, in the same range. 
The other conventional systemic treatment we decided to gather more evidence on was 
FAE. In Chapter 2.4 we described a prospective daily clinical practice case series on 14 
children and adolescents with recalcitrant plaque-type psoriasis treated with FAE. FAE 
(mean treatment duration 48.6 weeks, range 12-124) resulted in an improvement of 
psoriasis severity and QoL in the majority of children. Mean PASI (±SEM) improved from 
10.5 (1.0) at baseline to 8.6 (1.1), 6.2 (1.6) and 4.9 (1.5) at week 12, 24 and 36, whereas mean 
CDLQI (±SEM) improved from 8.9 (1.4) at baseline to 6.8 (1.2), 3.7 (1.4) and 3.1 (2.0), 
respectively. Although side effects occurred frequently, they were usually mild and 
transient. Most frequently reported side effects were gastrointestinal complaints (n = 13, 
92.9%) and flushing (n = 10, 71.4%), whereas lymphocytopenia (n = 5, 45.5%) and 
eosinophilia (n = 4, 36.4%) were most commonly observed laboratory abnormalities. One 
SAE, unrelated to FAE, was reported. 
 Last month, a retrospective, non-interventional, multicenter study in Germany (KIDS 
FUTURE study) on the efficacy and safety of FAE treatment in 127 children and adolescents 
(aged 6-17 years) with psoriasis reported that long-term FAE therapy seemed to be 
effective and safe in daily practice.30 In this particular study, PASI was available in 59 
patients at baseline and improved from 17.3 (mean) at baseline to 9.0 (n = 54) at 3 months 
and further improved to 4.8 (n = 22) at 36 months. At least one FAE-related AE was reported 
in 28.4% of patients (n = 36), mostly gastrointestinal complaints and flushing. SAEs did not 
occur.30 
 Gradually, more evidence on the efficacy and safety of FAE in pediatric psoriasis 
becomes available. Currently, a prospective, placebo-controlled study on the efficacy and 
safety of FAE in children (aged 10 to 17 years) is ongoing in Germany.30,31 Apart from the 
reassuring data that have become available in the recent literature, there is an increased 
concern about the possibility of FAE-induced lymphocytopenia and the described 
manifestation of progressive multifocal leukoencephalopathy (PML) in adults.32-41 
Therefore, it is extremely important to obtain prospective, long-term safety data in this 
vulnerable age group, and to abide by the recommendations from the updated European 
S3-guideline on FAE-induced leukocytopenia and/or lymphocytopenia.42 
503687-L-bw-van Geel
165
4
summary, discussion and main conclusions
Apart from the evidence we have added to the literature in the past few years, other 
publications on conventional systemic and biologic treatments in pediatric psoriasis have 
appeared, of which most important evidence will be discussed below. The evidence on 
cyclosporine has augmented since publication of our systematic review (Chapter 2.2). 
The majority of new evidence comes from three recently published retrospective studies 
with a total of 85 children.43-45 In these studies, treatment duration varied between 1-24 
months and cyclosporine seemed to show acceptable efficacy and safety data.43-45 Only 
one study used PASI as a severity measure and reported achievement of PASI 75 in 39.5% 
of patients at week 16, whereas another 39.5% were non-responders.43 Long-term safety 
data were not available.
In addition to the conventional systemic treatments, the evidence on biologicals in 
pediatric psoriasis has also largely increased. To date, etanercept, adalimumab and 
ustekinumab are licensed for use in pediatric psoriasis43, while at the start of this thesis, 
etanercept was the only approved biological. Etanercept is licensed to treat chronic severe 
plaque-type psoriasis in children and adolescents aged six years and older in case of an 
inadequate response to, or intolerance to, other systemic therapies or phototherapy.43,46,47 
Its evidence was primarily based on a double-blind, multicenter, phase III RCT in 211 
children and adolescents (aged 4-17 years) with plaque-type psoriasis.48 One hundred and 
six children were treated with once-weekly subcutaneous injections of etanercept 0.8 
mg/kg (maximum 50 mg).48 At week 12, PASI 75 was achieved in 57% of patients. During 
the open-label part of the study, four SAEs (of which three infections) occurred in three 
patients which all resolved without sequelae.48 Long-term safety and efficacy data with a 
follow-up period of 264 weeks have been described in the literature just now.49 The 
number of patients remaining on the study at week 264, however, was small.49 Through 
week 264, AEs occurred in 89.0% of patients, mostly infections, whereas malignancies or 
opportunistic infections did not occur. Efficacy at week 264 was maintained.49 At the 
moment, a post-authorization safety study on the long-term safety and efficacy of 
etanercept in pediatric psoriasis patients (PURPOSE) in several centers in Europe is still 
ongoing.47,50
 In 2015, adalimumab and ustekinumab, have been approved in Europe for use in the 
pediatric psoriasis population. Adalimumab has been registered by the European 
Medicines Agency (EMA) for the treatment of severe chronic plaque-type pediatric 
psoriasis patients (age ≥4 years) who have had an inadequate response to, or are 
inappropriate candidates for topical therapy and phototherapy.43,51 A recent multicenter, 
randomized, double-blind study evaluated two doses of adalimumab (0.8 mg/kg up to 40 
mg and 0.4 mg/kg up to 20 mg, at week 0 and then every other week from week 1) versus 
MTX in 114 pediatric patients with severe chronic plaque-psoriasis.27-29,52 In the 38 patients 
treated with adalimumab 0.8 mg/kg, PASI 75 at week 16 was achieved in 57.9% of patients. 
AEs occurred in 68.4% of the patients through 16 weeks, mostly infections (47.4%). There 
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were no deaths, malignancies or SAEs.28 However, long-term safety data in pediatric 
psoriasis patients are lacking. 
 Ustekinumab is the other biological which has been approved since June 2015 for the 
treatment of moderate-to-severe plaque-type psoriasis in adolescents aged 12 years and 
older who are inadequately controlled by, or are intolerant to phototherapy or other 
systemic therapies.43,53 In a recent phase III, multicenter, double-blind RCT on 110 patients 
(aged 12-17 years), 36 patients were treated with standard dosage ustekinumab (0.75 mg/
kg [≤60 kg], 45 mg [>60-≤100 kg], and 90 mg [>100 kg]) at weeks 0 and 4 and every 12 
weeks through week 40. At week 12, PASI 75 was achieved in 80.6% of patients, whereas 
AEs were reported in 44.4% of patients, mostly infections.54 
 To date, the literature about these three biologicals accounts for the largest body of 
evidence on systemic treatments in pediatric psoriasis.26,28,48,49,52,54-58 Although these 
biologicals in general showed large efficacy and a reasonably safety profile, caution 
should be taken to the relative lack of long-term safety data in children and adolescents 
with psoriasis. In patients with juvenile idiopathic arthritis (JIA), however, biological 
treatment has been used for about 15 years25 and long-term safety data on etanercept up 
to 14 years are available.25,59,60 Major areas of concern with respect to treatment with 
biologics include the risk on infusion and injection reactions, development and 
aggravation of infections and limited antibody production in case of vaccinations, 
occurrence of a second autoimmune disease, cytopenias and the development of 
malignancies, particularly lymphoma.25 Although some cases of lymphomas and other 
malignancies have been described in pediatric patients with arthritis, inflammatory bowel 
diseases or sarcoidosis treated with tumour necrosis factor-α (TNF-α) blockers,25,47,61,62 to 
date the assessment of causality is not clear. Confounding factors include the unknown 
potential risk on malignancy of the underlying diseases and the use of other immuno-
suppressive medication.47,61-63 The association between the use of TNF-α blockers and 
the risk on lymphoma and other malignancies or the development of a second auto- 
immune disease in pediatric psoriasis patients is still unknown. Therefore, more long-term 
safety data are indispensable and the benefits and risks of a biologic treatment in pediatric 
psoriasis should be weighted carefully, and discussed with the children and their 
caregivers.64 
In conclusion, given the newly retrieved evidence on both conventional systemic 
treatments and biologicals, the proposed treatment algorithm stated in Chapter 2.2 
needs more consideration. In this respect, long-term safety data are pivotal. Given the fact 
that long-term safety data in this vulnerable group are very important and in JIA a track 
record of long-term use on MTX is available60,65-72, we consider MTX as the preferential 
conventional systemic treatment in pediatric psoriasis. Although gradually more evidence 
has appeared on FAE in pediatric psoriasis, suggesting it to be an effective treatment 
option, there is increased concern about the potential of FAE-induced lymphocytopenia 
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and its possible manifestation of PML in adults. Furthermore, evidence on its long-term 
safety and efficacy in children and adolescents is still limited. Therefore, the position of 
FAE in the systemic treatment of pediatric psoriasis should still be after treatment with 
MTX. In pustular or erytrodermic psoriasis, retinoids could be considered. The available 
evidence on cyclosporine is still limited and only retrospectively collected. Therefore, and 
because of the nephrotoxic potential of cyclosporine73 and the relative lack on long-term 
safety data, prospective studies are warranted in order to define more clearly the position 
of cyclosporine in the treatment of pediatric psoriasis. Biologicals are effective in pediatric 
plaque-type psoriasis28,48,54, but long-term safety data are limited, although the safety 
data of five-year etanercept in pediatric psoriasis and 14-year etanercept in JIA are reassuring. 
Caution should be taken to the unclear association between TNF-α blockers and the 
development of malignancies (particularly lymphoma) and other autoimmune diseases. 
Therefore (and also because of the high costs), we suggest biologicals to be a third-line 
drug and recommend a balanced discussion of risks and benefits in patients and parents. 
Aim 5: To explore the efficacy of an outpatient multidisciplinary training programme for children 
and adolescents with psoriasis and their parents. 
In Chapter 2.5 we described a pilot study on the effects of an outpatient multidisciplinary 
training programme for children and adolescents with psoriasis and their parents. 
Satisfaction with the programme was found to be high and was observed to be higher in 
younger children and their parents compared to adolescents and their parents. In both 
participants and age- and sex-matched controls, the outcomes on the self-reported 
questionnaires (CDLQI74, ISDL75, SIFS76 and DFI77) showed positive changes after training 
and at three-month follow-up, whereas psoriasis severity (PASI) hardly changed. 
 Although the training programme generally was well-accepted and positively 
evaluated by patients and parents, results on the self-reported questionnaires seemed to 
be somewhat disappointing. An explanation could be the selection of patients. Patients 
who are at risk for psychological adjustment problems might obtain more benefit from 
psychological support. Second, apart from the CDLQI, the self-reported questionnaires 
used in this pilot study were not validated for use in children with psoriasis. Possibly, these 
questionnaires were not sensitive enough to detect changes in children. 
 QoL in children and adolescents with psoriasis can be detrimental affected,78-83 and 
early-onset psoriasis is reported to be associated with depression84,85 and anxiety.85 In 
addition, also in the caregivers of children with psoriasis anxiety and depression are 
frequently observed.86 Therefore, psychosocial support for patients and parents is 
essential. To our knowledge, one study described the efficacy of an educational 
programme in 34 pediatric psoriasis patients, which was performed in an inpatient 
setting.87 Direct comparison with our study is, however, not possible due to differences in 
programme design and assessment measures. 
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 In particular the contact with peers in group format was assessed as being very useful 
by both the patients and their parents in our study. This suggests the preference for 
psychological support in a group format. However, the question arises whether other 
forms of psychological support might be more optimal in children and adolescents with 
psoriasis and their parents. Satisfaction with our programme was lower in adolescents. In 
addition, adolescents were less willing to participate in the programme. Especially in 
adolescents, telepsoriasis services e.g. internet-based interventions88,89 including online 
support communities90, might be valuable. Internet-based interventions might be more 
convenient and flexible due to its potential of reducing waiting lists and traveling time. In 
addition, it could be an option for patients who did not want to participate in face-to-face 
groups because of feelings of shame or stigmatization of needing psychological support. 
Consequently, a larger number of patients could be reached.88,89 Furthermore, mobile-
phone-based interventions could be useful to improve adherence.5,91 Apart from 
face-to-face training groups delivered by trained dermatologists and/or psychologists, 
other potential forms of psychological support might include interventions by specialized 
dermatology nurses92-94 (eventually in day-care setting), or camps.95
Assessment measures on disease severity and psychosocial impact
For optimal therapeutic decision-making clinicians should take both the assessment of 
disease severity as well as the impact of psoriasis on the patients‘ lives into account. To 
quantify psoriasis severity and the impact on physical, psychological and social functioning 
of those affected as precisely as possible, reliable and valid assessment measures are 
needed. Nowadays, the PASI96 is the most commonly used psoriasis severity measure73,97-
99, whereas the CDLQI74 and the Dermatology Life Quality Index (DLQI)100 are widely used 
dermatology-specific questionnaires to assess the impact of skin diseases on QoL in 
children (4-16 years) and adults (≥ 16 years) respectively. 
 In scientific literature, there is some debate on the correct use of the term ‘outcome 
measures’, which intrinsically should be able to detect changes as a result of treatment 
(e.g. PASI 75), whereas ‘severity measures’ focus on the assessment of disease severity (e.g. 
PASI).98,101 In this respect, it might be more appropriate to use the term ‘assessment 
measures’ or ‘assessment tools’ instead of ‘outcome measures’.101 Consequently, this might 
also apply for the term ‘patient-reported assessment measures’ or ‘patient-reported 
assessments’ instead of the commonly used term ‘patient-reported outcome (PRO) 
measures´ . A PRO is defined by the Food and Drug administration (FDA) as ‘any report of 
the status of a patient’s health condition that comes directly from the patient, without 
interpretation of the patient’s response by a clinician or anyone else’.101,102 In addition, 
there are also questionnaires available which assess the impact on the lives of partners, 
parents or other family members and are therefore not strictly ‘patient-reported’103, like 
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the SIFS76 or DFI77 which both are used in Chapter 2.5 of this thesis to assess the impact 
on family life.
 Nevertheless, in scientific literature the term ‘outcome measures’ is often used inter-
changeably for both the detection of changes as a result of treatment and for the 
assessment of the severity itself.101 For the assessment of severity itself however, 
‘assessment measure’ would be more appropriate.101 In the introduction and discussion of 
this thesis, the term ‘assessment measures’ will be used to describe assessment of disease 
severity and/or psychosocial impact. It has to be noted that in some articles included in 
this thesis, the term ‘outcome measures’ has been used, although the term ‘assessment 
measures’ would probably be more appropriate. 
Aim 6: To develop a refined PASI score for patients with small affected areas (Low PASI). 
As a response on the frequently described criticism that PASI is not able to assess small 
involved areas,98,104-107 we developed a refined PASI score for psoriasis patients with small 
affected areas in a body region (<10% of a body region), called the Low PASI score. In 
Chapter 3.1 the Low PASI score is presented and the scores obtained with the Low PASI 
(measured by two independent investigators) are compared to the classic PASI scores. In 
both investigators, the Low PASI was significantly lower (1.71 and 1.76) than the classic PASI 
(4.14 and 4.33 respectively). Furthermore, in both scores the interobserver agreement was 
excellent for both investigators (ICC classic PASI = 0.95 and Low PASI = 0.87).
 PASI however, has been most extensively studied and is most widely used in a 
research setting as was concluded in two systematic reviews from 2010.97,98 In addition, it 
is often used as a standard reference to validate new severity measures.97-99 It has to be 
noted that in the Low PASI score, all principles of the classic PASI are preserved except for 
the area score <10% which is dived into four fractional components. Therefore, the Low 
PASI aimed to refine the classic PASI score in small involved areas by allowing more 
possible scores at lower levels of psoriasis extent, and it does not pretend to replace the 
classic PASI. Furthermore, from our experience, Low PASI is a quick tool which will be easy 
to learn for experienced PASI-assessors. 
 Based on this pilot study, we feel that the Low PASI could be a valuable instrument in 
the assessment of psoriasis severity in small involved areas. As nowadays the therapeutic 
arsenal has expended and highly effective psoriasis treatments have become available, 
there is an increasing need for measures to assess severity of psoriasis as precisely as 
possible when only a small body area of the patient is affected. However, as this was only 
a pilot study with a sample size of 10 participants with psoriasis, further research in much 
larger psoriasis populations is needed before implementation can take place.
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Aim 7: To compare DLQI and CDLQI scores in psoriasis patients aged 16-17 years. 
In Chapter 3.2 DLQI and CDLQI scores in 56 patients with psoriasis aged 16-17 years were 
compared. Although DLQI and CDLQI scores closely correlated (r = 0.90, p < 0.001), the 
mean DLQI score (5.41 ± 5.20) was lower than the mean CDLQI score (6.61 ± 5.74) (p < 
0.001). This difference was mainly caused by the low score related to sexual difficulties in 
the DLQI (0.11 ± 0.49) and the high score regarding sleep in the CDLQI (0.71 ± 0.93). 
Furthermore, the questions in the DLQI regarding sports and work/study scored lower 
than the questions on sports and school/holiday in the CDLQI respectively. 
 The DLQI100 and the CDLQI74 are widely used dermatology-specific questionnaires to 
assess QoL and are validated in adults (patients aged ≥ 16 years) and children (4-16 years) 
with a variety of skin diseases respectively. As adolescents are a unique group who have 
to deal with specific QoL concerns, the nature and extent of the impact of skin diseases on 
their QoL may be different compared to children or adults.108 From our study, in which 
only patients aged 16-17 years with psoriasis were included, both the DLQI and CDLQI 
probably did not to capture all QoL issues which might be important in this specific age 
range. For example, both sexuality108,109 (low score in the DLQI) and sleep108 (high score in 
the CDLQI) may be important QoL issues for adolescents, although the importance of 
sexual difficulties could not be confirmed in our study.
 Psoriasis-specific QoL measures specifically designed for use in adolescents in this age 
range are not available, and the only validated psoriasis-specific QoL measure for children 
is the Scalpdex, which has been validated in Dutch pediatric patients (aged 6-18 years) 
with scalp psoriasis.110 In adolescents however, there are some dermatology-specific 
instruments to assess the QoL impact of skin diseases, like the Skindex-Teen111 and 
Teenagers’ Quality of Life (T-QoL©) Index.112 As both the Skindex-Teen111 and the T-QoL112 
have been designed and validated specifically for adolescents and include more items on 
psychosocial functioning111 and self-image and psychological impact112 respectively, 
these instruments might be more sensitive for patients aged 16-17 years than either the 
DLQI or CDLQI. Theoretically, when assessing QoL, it would be most appropriate to use 
validated QoL measures specified to several age ranges. It is however, questionable 
whether such approach would be realistic and applicable in a daily clinical practice 
setting. An advantage of the DLQI and CDLQI is that both are easy to use with an average 
completion time of two minutes.113,114 From a practical point of view therefore, the use of 
these relatively quick and well-known dermatology-specific questionnaires is more feasible, 
taking into account its limitations when given to adolescents. The DLQI and CDLQI could 
be used as a first screening instrument to point out the presence of QoL issues. Additionally, 
for adolescents whose QoL seemed to be impaired, further in-depth investigation could 
take place with specific age suitable measures. 
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Aim 8: To investigate the criterion validity, construct validity, and response distribution of the 
severity (SPI-s) and psychosocial impact (SPI-p) domains of the professional (proSPI) and self- 
assessment (saSPI) versions of SPI in children and adolescents with psoriasis. 
This aim has been described in Chapter 3.3 in 113 children and adolescents with psoriasis 
with a median age of 12.0 years (range 4-17 years). ProSPI-s was closely correlated with PASI 
(r = 0.87), whereas the correlation between saSPI-s and PASI was lower (r = 0.69). The 
correlation between the two psychosocial impact measures (SPI-p and CDLQI) was 0.78. 
Furthermore, the correlation between these two psychosocial impact measures (SPI-p 
and CDLQI) and saSPI-s was higher than the correlations of these two impact measures 
with either PASI or proSPI-s. In both proSPI-s and SPI-p the full range of scores was 
obtained, whereas the highest saSPI-s score was 30 (maximum 50). 
 At the moment, it is too early to recommend whether PASI, CDLQI and/or SPI should 
be the assessment measures of preference in clinical trials and/or routine clinical practice 
in pediatric psoriasis. It has to be noted that the SPI-p encompasses only a visual analogue 
scale line giving the professional an overall assessment of psychosocial impairment. This 
is in contrast to the CDLQI74, which gives additional information on which aspects of QoL 
are impaired. Consequently, we feel that SPI-p cannot replace the CDLQI. In routine clinical 
practice, however, SPI-p can be readily introduced as a very quick instrument to assess 
the psychosocial impact of psoriasis in children and adolescents. Furthermore, in clinical 
studies, the saSPI proforma could give the health professional valuable additional information 
on patients’ and/or parents’ perception of their disease. 
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Main conclusions 
Treatments (Chapter 2)
• Treatment of mild-to-moderate pediatric psoriasis with calcipotriol/betamethasone 
dipropionate ointment in daily clinical practice yielded a mild improvement in psoriasis 
severity. Its effect maintained during 24 weeks of follow-up. (Chapter 2.1)
• Evidence on the efficacy and safety of systemic treatments in pediatric psoriasis was 
limited and mostly of low level. Of the conventional systemic treatments, most data 
were available on methotrexate, while etanercept had the largest body of evidence on 
biologic treatment in pediatric psoriasis. Apart from 96-weeks safety and efficacy data 
on etanercept, long-term safety data were not available. (Chapter 2.2) 
• Treatment with methotrexate in 25 children and adolescents with plaque-type psoriasis 
demonstrated a positive effect on psoriasis severity, improved quality of life and showed 
a reasonable safety profile in daily clinical practice. (Chapter 2.3)
• Treatment of 14 pediatric psoriasis patients with fumaric acid esters in daily clinical 
practice resulted in an improvement of disease severity and quality of life in the majority 
of patients. Side effects occurred frequently, but were usually mild and transient. 
(Chapter 2.4)
• An outpatient multidisciplinary training programme for children and adolescents with 
psoriasis and their parents was well-accepted and positively evaluated. (Chapter 2.5)
Assessment measures (Chapter 3)
• A refined PASI score for small involved areas (Low PASI) was developed. It allowed more 
possible scores at lower levels of psoriasis extent compared to the classic PASI. (Chapter 3.1)
• In psoriasis patients aged 16-17 years, DLQI and CDLQI scores closely correlated. The 
mean DLQI score was lower than the mean CDLQI score. (Chapter 3.2)
• In pediatric psoriasis, the modified children’s proSPI and saSPI were shown to be valid 
and usable. (Chapter 3.3) 
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Dit proefschrift over kinderen en adolescenten met psoriasis bestaat uit twee delen: 
behandelingen bij kinderen en adolescenten met psoriasis en uitkomstmaten. Het 
overkoepelende doel van het eerste deel was het verwerven van meer inzicht in de 
veiligheid en effectiviteit van een aantal behandelingen bij kinderen en adolescenten met 
psoriasis, te weten calcipotriol/ betamethasondipropionaat zalf, methotrexaat, fumaraten 
en een multidisciplinair trainingsprogramma. In het tweede deel van dit proefschrift staan 
uitkomstmaten ter beoordeling van de ernst van psoriasis en/of psychosociale impact 
centraal. Uiteindelijk heeft dit geleid tot acht publicaties die hieronder kort worden 
samengevat en waarvan de belangrijkste conclusies worden besproken.
De meeste data die gebruikt zijn in dit proefschrift zijn afkomstig van de gegevens die 
verzameld zijn in de Child-CAPTURE. In deze prospectieve database worden sinds 2008 
gegevens verzameld uit de dagelijkse praktijk over de effectiviteit, veiligheid en invloed 
op kwaliteit van leven (KvL) van alle kinderen en adolescenten met psoriasis die op onze 
polikliniek worden gezien op twee kinderpsoriasis spreekuren. Op dit moment zijn 340 
kinderen geïncludeerd en de inclusie van patiënten duurt nog steeds voort.
Het eerste deel van dit proefschrift (hoofdstuk 2) bestaat uit vijf studies over 
therapeutische interventies bij kinderen en adolescenten met psoriasis. In hoofdstuk 2.1 
onderzochten wij prospectief de effectiviteit, veiligheid en invloed op KvL van calcipotriol/ 
betamethasondipropionaat zalf in 73 kinderen en adolescenten met psoriasis in de 
dagelijkse praktijk. De mediane behandelingsduur was 35 weken (variërend van 1-176 
weken). Op week 12 was de gemiddelde Psoriasis Area and Severity Index (PASI) verbeterd 
van 5.2 naar 4.4 (15.4%). Dit effect bleef behouden na 24 weken behandeling (PASI 4.3, 
17.3% verbetering). De mediane Children’s Dermatology Life Quality Index (CDLQI) 
verbeterde significant van 5.5 naar 4.0 na 12 weken behandeling en de visual analogue 
scale (VAS) scores voor pijn en jeuk waren gedaald. Er werden bij vijf patiënten (7%) 
bijwerkingen beschreven, die mogelijk aan de behandeling gerelateerd waren. Vier van 
deze vijf patiënten hadden striae. Er werden geen ernstige bijwerkingen gevonden. 
 In hoofdstuk 2.2 wordt een systematisch review over de effectiviteit en veiligheid 
van systemische behandelingen bij kinderen met psoriasis gepresenteerd. In dit review 
werd gekeken naar de beschikbare evidence in de literatuur tot maart 2014. Van de 
conventionele systemische behandelingen waren de meeste gegevens beschikbaar over 
methotrexaat. Deze studies waren echter retrospectief en hadden een lage bewijskracht. 
Er werden vooral enkele nieuwe publicaties over fumaraten gevonden. Maar ook deze 
studies waren retrospectief en beschreven een klein aantal patiënten. Van alle systemische 
behandelingen had etanercept de meeste evidence. Op basis van dit review concludeerden 
wij dat de beschikbare evidence over de effectiviteit en veiligheid van systemische 
behandelingen bij kinderen met psoriasis beperkt was. Er waren nauwelijks prospectieve 
studies en de meeste publicaties hadden een lage bewijskracht. Bovendien waren er 
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geen gegevens beschikbaar over de lange termijn veiligheid, met uitzondering van een 
publicatie over de veiligheid en effectiviteit van etanercept na 96 weken behandeling.1 
 Aangezien de beschikbare evidence over de conventionele systemische behandelingen 
beperkt was en retrospectief verzameld, besloten wij het gebruik van methotrexaat 
(hoofdstuk 2.3) en fumaraten (hoofdstuk 2.4) bij kinderen en adolescenten met 
psoriasis te analyseren door gebruik te maken van onze prospectieve database. In 
hoofdstuk 2.3 onderzochten wij de effectiviteit, veiligheid en de invloed op KvL van 
methotrexaat bij 25 kinderen met psoriasis in de dagelijkse praktijk. De behandelingsduur 
varieerde van 12.6 tot 163.4 weken (mediaan 60.4 weken). Een verbetering in PASI van 75% 
of meer (PASI 75 ) werd bereikt in 4.3%, 33.3%, 40% en 28.6% van de patiënten op week 12, 
24, 36 en 48, respectievelijk. De mediane PASI verbeterde van 10.0 (range 3.8-42.4) bij 
start naar 4.3 (range 0-19.8) op week 24, terwijl de mediane CDLQI score daalde van 
9 (range 2-20) naar 3.8 (range 0-21). MTX leek een redelijk veiligheidsprofiel te hebben. 
De meest frequent gerapporteerde bijwerkingen waren ernstige misselijkheid (n = 5), 
infecties met noodzaak voor antibiotica of antivirale medicatie (n = 5) en ernstige 
vermoeidheid (n = 4). De enige ernstige bijwerking was een longontsteking waarvoor 
ziekenhuisopname. Deze verbeterde zonder consequenties. 
 In hoofdstuk 2.4 wordt een prospectieve studie beschreven waarin 14 kinderen en 
adolescenten met recalcitrante plaque psoriasis werden behandeld met fumaraten in de 
dagelijkse praktijk. De behandelingsduur varieerde van 12 tot 124 weken, met een 
mediaan van 48.6 weken. Behandeling met fumaraten resulteerde in een verbetering in 
de ernst van de psoriasis en KvL in de meerderheid van de patiënten. De gemiddelde PASI 
(±SEM) verbeterde van 10.5 (1.0) bij start naar 8.6 (1.1), 6.2 (1.6) en 4.9 (1.5) op week 12, 24 en 
36, terwijl de gemiddelde CDLQI (±SEM) verbeterde van 8.9 (1.4) bij start naar 6.8 (1.2), 3.7 
(1.4) en 3.1 (2.0), respectievelijk. Hoewel bijwerkingen frequent voorkwamen, waren zij 
meestal mild en tijdelijk van aard. De meest frequent gerapporteerde bijwerkingen waren 
maag-darmklachten (n = 13, 92.9%) en opvliegers (n = 10, 71.4%), terwijl lymfocytopenie 
(n = 5, 45.5%) en eosinofilie (n = 4, 36.4%) de meest voorkomende lab afwijkingen waren. 
Er werd één ernstige bijwerking gerapporteerd; deze was niet gerelateerd aan de 
behandeling met fumaraten. 
 Voor de discussie van dit proefschrift werd de literatuur over systemische behandelingen 
bij kinderen met psoriasis bestudeerd die tussen maart 2014 en januari 2016 was verschenen, 
zodat het bestaande review geüpdate werd. Aan de hand van het systematische review 
beschreven in hoofdstuk 2.2 en de nieuw gevonden literatuur werd het volgende 
 behandelingsalgoritme voorgesteld. De lange termijn veiligheid was bij het bepalen van 
het algoritme zeer belangrijk. Van de conventionele systemische middelen zijn de meeste 
prospectieve gegevens beschikbaar over methotrexaat.2,3 Bovendien wordt methotrexaat 
bij kinderen met juveniele idiopathische artritis (JIA) al sinds decennia gebruikt, met een 
acceptabel veiligheidprofiel.4-10 Derhalve beschouwen wij methotrexaat als de eerste 
keus conventionele systemische behandeling bij kinderen met psoriasis. Geleidelijk is er 
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meer evidence beschikbaar gekomen over fumaraten als effectieve behandeloptie voor 
kinderen met psoriasis.11-13 Er bestaat echter toegenomen bezorgdheid over de mogelijkheid 
van een door fumaraten geïnduceerde lymfocytopenia en een mogelijke manifestatie 
van progressieve multifocale leukoencephalopathie (PML) bij volwassenen.14-23 Bovendien 
zijn er slechts beperkte gegevens beschikbaar over de lange termijn veiligheid en 
effectiviteit van fumaraten bij kinderen en adolescenten. Derhalve achten wij de positie 
van fumaraten in het behandelalgoritme van systemische behandelingen bij kinderen 
met psoriasis na die van methotrexaat. Bij pustuleuze of erytrodermatische psoriasis kan 
behandeling met retinoiden worden overwogen. De meeste evidence over ciclosporine 
als behandeloptie bij kinderen met psoriasis bestaat uit een beperkt aantal recent 
gepubliceerde retrospectieve studies.24-26 Bovendien kan ciclosporine een nefrotoxisch 
effect hebben27 en zijn gegevens over de lange termijn veiligheid beperkt. Derhalve zijn 
prospectieve studies noodzakelijk om meer inzicht te krijgen in de positie van ciclosporine 
in de systemische behandeling van kinderen met psoriasis. Biologicals zijn effectief bij 
kinderen met plaque psoriasis.2,28,29 Gegevens over de lange termijn veiligheid zijn echter 
beperkt; hoewel de data van vijf-jaar behandeling met etanercept bij kinderen met 
psoriasis30 en 14-jaar behandeling met etanercept bij kinderen met JIA31-33 een geruststellend 
veiligheidsprofiel laten zien. Voorzichtigheid is geboden gezien de onduidelijke associatie 
tussen TNF-α blockers en de ontwikkeling van maligniteiten (in het bijzonder lymfoom), 
die beschreven worden bij kinderen met artritis, inflammatoire darmziekten of sarcoidosis, 
en de ontwikkeling van andere auto-immuunziekten.31,34-37 Derhalve (en ook vanwege 
de hoge kosten) beschouwen wij biologicals als een derdelijns behandeling en adviseren 
wij een gebalanceerde afweging van de voor- en nadelen in overleg met kinderen en 
adolescenten en ouders.38 
 Naast medicamenteuze behandeling zijn educatie en psychosociale steun een 
belangrijke additionele behandelingsinterventie.39-41 In hoofdstuk 2.5 exploreerden wij 
in een pilotstudy de effecten van een poliklinisch multidisciplinair trainingsprogramma 
voor kinderen en adolescenten met psoriasis en hun ouders op de tevredenheid van 
patiënten en ouders, KvL, jeuk en krabben, ziektecognities en invloed op het gezin. De 
tevredenheid met het programma was hoog bij zowel patiënten als ouders. Jongere 
kinderen en hun ouders waren meer tevreden dan adolescenten en hun ouders. De 
uitkomsten van de zelfgerapporteerde vragenlijsten [CDLQI42, Impact of Chronic Skin 
Disease on Daily Life (ISDL)43, Stein Impact on Family Scale (SIFS)44 en Dermatitis Family 
Impact Questionnaire (DFI)45] vertoonden positieve veranderingen na de training en bij 
drie-maanden follow-up bij zowel de deelnemers als bij op leeftijd- en geslacht gematchde 
controles. De ernst van de psoriasis (PASI) veranderde nauwelijks. 
Het tweede deel van dit proefschrift (hoofdstuk 3) bestaat uit drie studies over 
uitkomstmaten ter beoordeling van de ernst van de psoriasis en/of psychosociale impact. 
Wij ontwikkelden een verfijnde PASI score voor patiënten met psoriasis bij wie een klein 
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deel van het lichaamsoppervlak (<10% van een lichaamsregio) is aangedaan, de Low PASI. 
In hoofdstuk 3.1 presenteerden wij de Low PASI score en vergeleken wij de scores 
verkregen met de Low PASI (gemeten door twee onafhankelijke onderzoekers) met de 
scores van de klassieke PASI. In beide onderzoekers was de Low PASI significant lager (1.71 
en 1.76) dan de klassieke PASI (4.14 en 4.33, respectievelijk). Bovendien was de interobserver 
agreement in beide scores uitstekend voor beide onderzoekers (ICC klassieke PASI = 0.95 
en Low PASI = 0.87). 
 In hoofdstuk 3.2 vergeleken wij twee dermatologiespecifieke vragenlijsten om de 
KvL te meten in 56 patiënten met psoriasis in de leeftijd van 16-17 jaar: de Dermatology 
Life Quality Index (DLQI)46 en de CDLQI.42 De CDLQI is gevalideerd voor kinderen met 
huidaandoeningen in de leeftijd van 4-16 jaar42, terwijl de DLQI is gevalideerd voor 
patiënten van 16 jaar en ouder.46 Hoewel de DLQI en CDLQI scores nauw correleerden 
(r = 0.90, P <0.001), was de gemiddelde DLQI score (5.41 ± 5.20) lager dan de gemiddelde 
CDLQI score (6.61 ± 5.74) (P < 0.001). Dit verschil werd voornamelijk veroorzaakt door de 
lage score op de vraag naar seksuele problemen in the DLQI (0.11 ± 0.49) en de hoge score 
op de vraag naar slaap in de CDLQI (0.71 ± 0.93). Tevens scoorden de vragen in de DLQI 
over sport en respectievelijk werk/studie lager dan de vragen over sport en school/
vakantie in de CDLQI. 
 De Simplified Psoriasis Index (SPI) is een nieuwe uitkomstmaat die zowel de ernst van 
de psoriasis als de psychosociale impact beoordeeld.47 De SPI kan worden ingevuld door 
de zorgprofessional (proSPI) of door de patiënt zelf (saSPI). De SPI is gevalideerd bij 
volwassenen met psoriasis.47 Hoofdstuk 3.3 beschrijft de validatie van de ziekte-ernst 
(SPI-s) en psychosociale impact (SPI-p) domeinen van de proSPI en de saSPI in 113 kinderen 
en adolescenten met psoriasis. De proSPI-s correleerde nauw met de PASI (r = 0.87), terwijl 
de correlatie tussen de saSPI-s en de PASI lager was (r = 0.69). De correlatie tussen de twee 
psychosociale impact maten (SPI-p en CDLQI) was 0.78. In zowel de proSPI-s als SPI-p 
kwam het volledige bereik van de scores voor, terwijl de hoogste saSPI-s score 30 was 
(maximum 50). Een voordeel van de SPI boven andere uitkomstmaten is het feit dat hierin 
een ernstmaat en een psychosociale maat worden gecombineerd, terwijl de uitkomsten 
wel apart te interpreteren zijn.47 
503687-L-bw-van Geel
185
5
nederlandse samenvatting
Belangrijkste conclusies
Behandelingen (hoofdstuk 2)
• Behandeling van mild tot matig ernstige psoriasis bij kinderen en adolescenten met 
calcipotriol/ betamethasondipropionaat zalf in de dagelijkse praktijk resulteerde in een 
milde verbetering in de ernst van psoriasis. Dit effect bleef gehandhaafd na 24 weken. 
(Hoofdstuk 2.1)
• De evidence over de effectiviteit en veiligheid van systemische behandelingen bij 
kinderen met psoriasis was beperkt en meestal van lage bewijskracht. Van de 
conventionele systemische behandelingen waren de meeste gegevens beschikbaar 
over methotrexaat, terwijl van de biologicals de meeste evidence beschikbaar was over 
etanercept. Met uitzondering van een publicatie naar de veiligheid en effectiviteit van 
etanercept gedurende 96 weken behandeling, waren er geen gegevens beschikbaar 
over de lange termijn veiligheid. (Hoofdstuk 2.2) 
• Behandeling met methotrexaat in 25 kinderen en adolescenten met plaque psoriasis in 
de dagelijkse praktijk had een positief effect op de ernst van de psoriasis, verbeterde de 
kwaliteit van leven en vertoonde een redelijk veiligheidsprofiel. (Hoofdstuk 2.3)
• Behandeling van 14 kinderen en adolescenten met psoriasis met fumaraten in de 
dagelijkse praktijk resulteerde in een verbetering van ziekte ernst en kwaliteit van leven 
in de meerderheid van de patiënten. Bijwerkingen kwamen frequent voor, maar waren 
meestal mild en tijdelijk van aard. (Hoofdstuk 2.4) 
• Een poliklinisch multidisciplinair trainingsprogramma voor kinderen en adolescenten 
met psoriasis en hun ouders werd goed geaccepteerd en positief beoordeeld. 
(Hoofdstuk 2.5) 
Uitkomstmaten (hoofdstuk 3)
• Een verfijnde PASI score voor patiënten met psoriasis bij wie een klein deel van het 
 lichaamsoppervlak is aangedaan (Low PASI) werd ontwikkeld. De Low PASI beschikt 
over meer potentiële scores dan de klassieke PASI indien een klein deel van het 
 lichaamsoppervlak is aangedaan. (Hoofdstuk 3.1)
• In patiënten met psoriasis in de leeftijd van 16-17 jaar correleerden de DLQI en CDLQI 
scores nauw. De gemiddelde DLQI score was lager dan de gemiddelde CDLQI score. 
(Hoofdstuk 3.2)
• Bij kinderen en adolescenten met psoriasis waren de voor kinderen gemodificeerde 
proSPI en saSPI valide en bruikbaar. (Hoofdstuk 3.3)
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bikkel! Heel veel succes met jouw eigen promotietraject. Lieve Len, wij kennen elkaar 
écht al ons hele leven; die band blijft heel speciaal! Lieve Marion, zeer veel dank voor 
je hartelijkheid, kopjes thee, fijne gesprekken en altijd luisterend oor. Ik ben heel blij jou 
als buuf te hebben!
503687-L-bw-van Geel
198
chapter 6
Lieve Laura (paranimf), wat ben ik blij dat jij op deze belangrijke dag naast mij staat! 
Wij leerden elkaar kennen als collega’s bij de Reumatologie. Sindsdien is er een hechte 
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